



KEMENTERIAN KESIHATAN MALAYSIA
PROGRAM PERKHIDMATAN FARMASI

LAPORAN TAHUNAN 2024



Annual Report

LAPORAN TAHUNAN 2024

Annual Report



PROGRAM PERKHIDMATAN FARMASI
PHARMACEUTICAL SERVICES PROGRAMME

LAPORAN TAHUNAN PROGRAM PERKHIDMATAN FARMASI 2024 PHARMACEUTICAL SERVICES PROGRAMME ANNUAL REPORT 2024

MOH/F/FAR/171.25(AR)-e
eISSN 2735-1254

Diterbitkan oleh:
Program Perkhidmatan Farmasi
Kementerian Kesihatan Malaysia
Lot 36, Jalan Profesor Diraja Ungku Aziz,
46200 Petaling Jaya, Selangor.
T 603 7841 3200

©Kementerian Kesihatan Malaysia

Hak Cipta Terpelihara. Tidak dibenarkan mengeluarkan ulang mana-mana bahagian artikel, ilustrasi, isi kandungan buku ini dalam apa-apa juga bentuk dan dengan cara apa jua sama ada secara elektronik, fotokopi, mekanik, rakaman atau cara lain sebelum mendapat izin bertulis daripada penulis dan penerbit.



ISI KANDUNGAN

INSIDE THIS REPORT

MENGENAI LAPORAN INI <i>ABOUT THIS REPORT</i>	02
PROGRAM PERKHIDMATAN FARMASI SEKILAS PANDANG <i>PHARMACEUTICAL SERVICES PROGRAMME AT A GLANCE</i>	03
PIAGAM PELANGGAN <i>CLIENT CHARTER</i>	04
VISI & MISI <i>VISION & MISSION</i>	06
OBJEKTIF BAHAGIAN <i>DIVISION OBJECTIVE</i>	07
PERUTUSAN TIMBALAN KETUA PENGARAH KESIHATAN (PERKHIDMATAN FARMASI) <i>MESSAGE FROM THE DEPUTY DIRECTOR GENERAL OF HEALTH (PHARMACEUTICAL SERVICES)</i>	08
CARTA ORGANISASI <i>ORGANISATIONAL CHART</i>	10
KEPIMPINAN KAMI <i>OUR LEADERS</i>	11
JAWATANKUASA EDITORIAL <i>EDITORIAL COMMITTEE</i>	14
BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI <i>PHARMACY POLICY AND STRATEGIC PLANNING DIVISION</i>	15
1.0 Pengenalan <i>Introduction</i>	17
2.0 Aktiviti dan Sorotan <i>Activities and Highlights</i>	19
3.0 Pencapaian dan Pengiktirafan <i>Achievement and Recognition</i>	37
4.0 Penerbitan dan Kajian <i>Publication and Research</i>	38
5.0 Kolaborasi dan Penglibatan Antarabangsa <i>International Collaboration and Participation</i>	43
BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI <i>PHARMACY PRACTICE AND DEVELOPMENT DIVISION</i>	45
1.0 Pengenalan <i>Introduction</i>	47
2.0 Aktiviti dan Sorotan <i>Activities and Highlights</i>	49
3.0 Pencapaian dan Pengiktirafan <i>Achievement and Recognition</i>	66
4.0 Penerbitan dan Kajian <i>Publication and Research</i>	67
5.0 Kolaborasi dan Penglibatan Antarabangsa <i>International Collaboration and Participation</i>	70
BAHAGIAN PENGUATKUASAAN FARMASI <i>PHARMACY ENFORCEMENT DIVISION</i>	72
1.0 Pengenalan <i>Introduction</i>	74
2.0 Aktiviti dan Sorotan <i>Activities and Highlights</i>	77
3.0 Pencapaian dan Pengiktirafan <i>Achievement and Recognition</i>	88
4.0 Penerbitan dan Kajian <i>Publication and Research</i>	89
5.0 Kolaborasi dan Penglibatan Antarabangsa <i>International Collaboration and Participation</i>	91
BAHAGIAN REGULATORI FARMASI NEGARA <i>NATIONAL PHARMACEUTICAL REGULATORY AGENCY</i>	96
1.0 Pengenalan <i>Introduction</i>	99
2.0 Aktiviti dan Sorotan <i>Activities and Highlights</i>	101
3.0 Pencapaian dan Pengiktirafan <i>Achievement and Recognition</i>	107
4.0 Penerbitan dan Kajian <i>Publication and Research</i>	109
5.0 Kolaborasi dan Penglibatan Antarabangsa <i>International Collaboration and Participation</i>	110
BAHAGIAN LEMBAGA FARMASI MALAYSIA <i>PHARMACY BOARD MALAYSIA DIVISION</i>	117
1.0 Pengenalan <i>Introduction</i>	118
2.0 Aktiviti dan Sorotan <i>Activities and Highlights</i>	125
3.0 Pencapaian dan Pengiktirafan <i>Achievement and Recognition</i>	128
4.0 Penerbitan dan Kajian <i>Publication and Research</i>	133
GLOSARI TERMA, SINGKATAN DAN AKRONIM <i>GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS</i>	134



MENGENAI LAPORAN INI

Laporan Tahunan Program Perkhidmatan Farmasi 2024 merekodkan tadbir urus dan pencapaian Program Farmasi serta aktiviti bagi perkhidmatan farmasi di bawah Kementerian Kesihatan Malaysia (KKM) sepanjang tahun 2024. Laporan ini menyediakan gambaran menyeluruh berkaitan strategi dan inisiatif yang dilaksanakan oleh Program ini dalam menyampaikan perkhidmatan farmasi terbaik kepada rakyat.

ABOUT THIS REPORT

Pharmaceutical Services Programme Annual Report 2024 reported on the governance and achievements of the Pharmacy Programme, and activities for pharmaceutical services under the Ministry of Health (MOH) throughout the year 2024. This report provides a holistic view of the strategies and initiatives implemented by the Programme in delivering the best pharmaceutical services to the nation.



PROGRAM PERKHIDMATAN FARMASI SEKILAS PANDANG

Program Perkhidmatan Farmasi (PPF) merupakan program di bawah KKM yang bertanggungjawab untuk memastikan orang awam mendapat keluaran farmaseutikal yang berkualiti, selamat dan berkesan, melindungi kepentingan mereka melalui penguatkuasaan undang-undang yang berkaitan, serta memastikan ubat-ubatan digunakan oleh penyedia perkhidmatan kesihatan dan juga pesakit secara wajar.

Sejak ditubuhkan pada tahun 1951, PPF telah melalui beberapa siri transformasi untuk memastikan perkhidmatan yang diberikan sejajar dengan hasrat kerajaan, setanding dengan perkembangan perkhidmatan farmasi sejagat serta kemajuan industri farmaseutikal.

PPF terdiri daripada lima (5) Bahagian utama yang diketuai oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi). Kelima-lima Bahagian ini mempunyai peranan yang penting dalam aspek yang berbeza dengan satu matlamat yang sama iaitu untuk menyediakan perkhidmatan farmasi yang terbaik kepada rakyat.

PHARMACEUTICAL SERVICES PROGRAMME AT A GLANCE

The Pharmaceutical Services Programme (PSP) is a programme under the MOH which is responsible for ensuring that the public gets access to safe, efficacious and quality pharmaceutical products, protecting their interest via enforcement of relevant legislations, and ensuring rational use of medicines by both healthcare providers and patients.

Since its establishment in 1951, PSP has gone through a series of transformations in order to ensure the services provided are in line with national transformation plans, on par with international standards and advancement of the pharmaceutical industry.

PSP consists of five (5) main divisions headed by the Deputy Director-General of Health (Pharmaceutical Services). These five (5) main divisions play important roles in different aspects and approaches towards the same objectives that are providing the best pharmacy services to the nation.

LIMA BAHAGIAN UTAMA PROGRAM PERKHIDMATAN FARMASI

BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI

PHARMACY POLICY AND STRATEGIC PLANNING DIVISION

BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI

PHARMACY PRACTICE AND DEVELOPMENT DIVISION

BAHAGIAN PENGUATKUASAAN FARMASI

PHARMACY ENFORCEMENT DIVISION

BAHAGIAN REGULATORI FARMASI NEGARA

NATIONAL PHARMACEUTICAL REGULATORY AGENCY

BAHAGIAN LEMBAGA FARMASI MALAYSIA

PHARMACY BOARD MALAYSIA DIVISION

5

**PIAGAM PELANGGAN PROGRAM
PERKHIDMATAN FARMASI 2024**
**CLIENTS' CHARTER OF THE PHARMACEUTICAL
SERVICES PROGRAMME 2024**

BIL	PIAGAM PELANGGAN CLIENT CHARTER	SASARAN TARGET	PENCAPAIAN ACHIEVEMENT
1	Keputusan penyenaian ubat ke dalam Formulari Ubat KKM (FUKKM) dimaklumkan kepada pemohon dalam masa tiga (3) hari bekerja dari tarikh Mesyuarat Panel FUKKM dijalankan <i>Notification to applicant on the result of the listing of medicine(s) into the Ministry of Health Medicine Formulary (MOHMF) done within three (3) working days from the MOHMF panel meeting date</i>	100%	96.36 (53/55)
2	Pengeluaran Kebenaran Import/ Eksport Dadah Berbahaya dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima <i>Issuance of Authorization for the Import/ Export of Psychotropic Substances within seven (7) working days upon receipt of complete application</i>	100%	100% (289/289)
3	Pengeluaran Kebenaran Import/ Eksport Bahan Psikotropik dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima <i>Issuance of Authorization for the Import/ Export of Psychotropic Substances within seven (7) working days upon receipt of complete application</i>	100%	100% (362/362)
4	Kelulusan e-Permit (Eksport) Bahan Kimia Prekursor dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima <i>Issuance of e-Permit (Export) Precursor Chemical within seven (7) working days upon receipt of complete application</i>	100%	100% (1,077/1,077)
5	Kelulusan e-Permit (Import) Bahan Terkawal dalam tempoh tiga (3) hari bekerja dari tarikh permohonan lengkap diterima <i>Issuance of e-Permit (Import) Controlled Substance within three (3) working days upon receipt of complete application</i>	100%	100% (897/897)
6	Keputusan bagi permohonan sijil iklan ubat dan iklan perkhidmatan kesihatan (selain iklan laman web) dibuat dalam tempoh lima (5) hari bekerja dari tarikh permohonan lengkap diterima <i>Decision for application of medicines advertisement certificate and healthcare services advertisement certificate (other than website advertisement) made within five (5) working days upon receipt of complete application</i>	90%	97.12% (3,574/3,680)
7	Keputusan bagi permohonan sijil iklan ubat dan iklan perkhidmatan kesihatan dalam laman web dibuat dalam tempoh 30 hari dari tarikh permohonan lengkap diterima <i>Decision for application of medicines advertisement certificate and healthcare services advertisement certificate for website advertisements made within 30 days upon receipt of complete application</i>	90%	97.26% (390/401)
8	Aduan berkaitan kesalahan di bawah undang-undang farmasi yang diterima diberi maklum balas tindakan dalam tempoh 14 hari bekerja dari tarikh aduan lengkap diterima <i>Complaint related to infringement of Pharmacy Laws responded within 14 working days upon receipt of complete complaint</i>	100%	100% (932/932)
9	Sampel aduan selesai dianalisis oleh Makmal Forensik Kimia Bahagian Penguatkuasaan Farmasi dalam tempoh 30 hari bekerja dari tarikh penerimaan sampel lengkap <i>Complaint sample completed analysis by Pharmacy Enforcement Division Chemical Forensic Laboratory within 30 working days from the sample receipt date</i>	90%	98.28% (171/174)
10	Laporan analisa peranti digital disiapkan dalam tempoh 120 hari dari tarikh penerimaan peranti <i>Digital device analysis report completed within 120 days upon receipt of the device</i>	75%	63.96% (126/197)
11	Pengeluaran Sijil Pendaftaran Ahli Farmasi dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Issuance of Full Registration of Pharmacist's Certificate within seven (7) working days upon receipt of complete application and in accordance with legislation</i>	100%	100% (1,071/1,071)
12	Pengeluaran Sijil Pendaftaran Pertubuhan Perbadanan dalam tempoh enam (6) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Issuance of Registration of Body Corporate's Certificate within six (6) working days upon receipt of complete application and in accordance with legislation</i>	100%	100% (99/99)
13	Pengeluaran Sijil Tahunan Ahli Farmasi dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Issuance of Annual Certificate of Pharmacist within seven (7) working days upon receipt of complete application and in accordance with legislation</i>	100%	100% (23,036/ 23,036)
14	Pengeluaran Sijil Pendaftaran Ahli Farmasi Provisional dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Issuance of Registration of Provisional Pharmacist's Certificate within seven (7) working days upon receipt of complete application and in accordance with legislation</i>	100%	100% (1,087/1,087)
15	Pengeluaran Sijil Tahunan Pertubuhan Perbadanan dalam tempoh enam (6) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Issuance of the Annual Certificate of Body Corporate within six (6) working days upon receipt of a complete application and in accordance with legislation</i>	100%	100% (1,586/1,586)

**PIAGAM PELANGGAN TERAS
KEMENTERIAN KESIHATAN MALAYSIA 2024**
**CLIENTS' CHARTER OF
THE MINISTRY OF HEALTH 2024**

BIL	PIAGAM PELANGGAN CLIENT CHARTER	SASARAN TARGET	PENCAPAIAN ACHIEVEMENT
1	Preskripsi didispen dalam tempoh 30 minit <i>Prescription dispensed in 30 minutes</i>	95%	93.22% (42,720,797/ 45,828,678)
2	Sijil Pendaftaran Ahli Farmasi diproses dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan <i>Pharmacist Registration Certificate processed within seven (7) working days upon receipt of a complete application and in accordance with legislation</i>	100%	100% (1,071/1,071)

ly dummy text of the
ting industry. Lorem
industry's standard
nce the 1500s, when an
ok a galley of type and
e a type specimen book

MEDICINE
HEALTH
TREATMENT
DOCTOR
SURVEY
RECIPE

MEDICINE

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. It was first recorded in Cicero's *De Finibus Bonorum et Malorum* in 120 BC. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and composed a specimen book.

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. It was first recorded in Cicero's *De Finibus Bonorum et Malorum* in 120 BC. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and composed a specimen book.

VISI VISION

Meningkatkan kesihatan rakyat menerusi kecemerlangan dalam amalan farmasi
Enhancing our nation's health through excellence in the practice of pharmacy

MISI MISSION



Menguatkuasakan undang-undang dan memperbaharui polisi untuk memastikan produk dan perkhidmatan farmaseutikal adalah berkualiti

Uphold legislation and improve policies to ensure the quality of pharmaceutical products and services



Memastikan sistem organisasi yang efektif dan responsif ke arah kelestarian perkhidmatan berkualiti

Ensure effective and responsive organisational system towards sustainable quality services



Membina keupayaan dan profesionalisme menerusi pembangunan bakat dan pemerkasaan tenaga kerja

Build capabilities and professionalism through talent development and workforce empowerment



Memperhebat kerjasama ke arah mencapai piawaian dan amalan terbaik

Intensify collaboration towards best practices and standards



Menjamin kesihatan rakyat melalui kawalan regulatori ubat-ubatan dan kosmetik berlandaskan kecemerlangan saintifik

To safeguard the nation's health through scientific excellence in the regulatory control of medicinal products and cosmetics

OBJEKTIF BAHAGIAN | DIVISION'S OBJECTIVES

BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI

PHARMACY POLICY AND STRATEGIC PLANNING DIVISION

- Membangunkan dasar untuk sektor farmaseutikal selaras dengan keperluan penjagaan kesihatan negara
- Memastikan pengurusan sumber yang efisien dan cemerlang
- *Develop policies for the pharmaceutical sector in line with the needs of national health care*
- *Ensure excellent and efficient resources management*

BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI

PHARMACY PRACTICE AND DEVELOPMENT DIVISION

- Memastikan kebolehcapaian berterusan terhadap ubat-ubatan yang berkualiti, selamat dan kos efektif
- Memperkukuh penggunaan ubat-ubatan secara berkualiti dan rasional ke arah kesihatan yang lebih baik
- Meningkatkan perkhidmatan penjagaan farmaseutikal selaras dengan piawaian dan amalan terbaik
- *Ensure continuous access to the quality, safe and cost-effective medicines*
- *Strengthen the quality and rational use of medicines towards the better health*
- *Enhance pharmaceutical care services in line with the good standards and best practices*

BAHAGIAN PENGUATKUASAAN FARMASI

PHARMACY ENFORCEMENT DIVISION

- Memastikan penjualan, pembekalan, pemilikan dan pengiklanan substans, produk dan kosmetik mematuhi peruntukan undang-undang
- *Ensure all sales, supply, possession and advertising of substances, products and cosmetics are in compliance with the legal provisions*

BAHAGIAN REGULATORI FARMASI NEGARA

NATIONAL PHARMACEUTICAL REGULATORY AGENCY

- Memastikan bahawa bahan-bahan terapeutik yang dibenarkan di pasaran tempatan adalah selamat, berkesan dan berkualiti serta kosmetik yang telah dinotifikasikan adalah selamat dan berkualiti
- *To ensure that therapeutic substances approved for the local market are safe, effective and of quality and to ensure that notified cosmetic products are safe and of quality*

BAHAGIAN LEMBAGA FARMASI MALAYSIA

PHARMACY BOARD MALAYSIA DIVISION

- Memastikan pendaftaran ahli farmasi dan pertubuhan perbadanan mematuhi Akta Pendaftaran Ahli Farmasi 1951 dan peraturan-peraturannya
- Menetapkan piawai untuk etika, tingkah laku, kemahiran, pendidikan dan latihan serta Pembangunan Profesional Berterusan (CPD)
- *Ensure the registration of pharmacists and bodies corporate complies with Registration of Pharmacists Act 1951 and its regulations*
- *Set the standard for conduct, ethics, proficiency, education and training and Continuous Professional Development (CPD)*



PERUTUSAN TIMBALAN KETUA PENGARAH KESIHATAN PERKHIDMATAN FARMASI

Assalamualaikum Warahmatullahi Wabarakatuh dan Salam Sejahtera,

Saya memanjatkan rasa kesyukuran ke hadrat Allah S.W.T. kerana atas keizinan dan kurniaNya, Program Perkhidmatan Farmasi telah menggalas tanggungjawab yang diamanahkan dan merealisasikan matlamatnya serta menempuhi pelbagai cabaran sepanjang tahun 2024. Segala yang diusahakan adalah demi kesinambungan dan kelestarian perkhidmatan farmasi di negara kita supaya kekal berada pada tahap yang paling unggul.

Sebagai sebahagian daripada sistem kesihatan, setiap tahun, kita menyaksikan peningkatan perbelanjaan ubat-ubatan, beban penyakit tidak berjangkit terutamanya di kalangan pesakit yang semakin muda, pertambahan bilangan preskripsi pesakit luar serta kos kesihatan yang semakin bertambah merupakan cabaran yang perlu dihadapi. Namun, usaha untuk membanteras isu-isu ini tetap dilaksanakan.

Salah satu daripada komitmen Kerajaan ialah memastikan akses kepada ubat-ubatan yang mampu milik oleh semua rakyat. Selaras dengan hak universal pengguna, inisiatif pemaparan harga ubat membolehkan pembeli mengetahui maklumat harga ubat, merancang perbelanjaan serta membuat perbandingan dan pilihan yang sesuai pada kadar yang berpatutan mengikut kemampuan. Kerjasama semua adalah amat penting bagi menjayakan inisiatif ini demi melindungi hak semua orang yang juga merupakan pengguna dalam sistem kesihatan negara ini.

Penyelidikan dan pembangunan merupakan pemandu utama sesuatu kejayaan. Tahun 2024 menyaksikan penganjuran Persidangan Penyelidikan dan Pembangunan Farmasi Kebangsaan Ke-12, bertemakan "*Unity for Medicine Security: Collaborative Solutions for a Safer Future*". Persidangan berprestij ini menghimpunkan lebih 400 peserta dari pelbagai bidang dalam sektor farmaseutikal dan menjadi pemangkin dalam memperkukuh daya saing industri farmaseutikal negara serta memperkasakan keterjaminan ubat-ubatan melalui pendekatan kolaboratif.

Kolaborasi antarabangsa memberikan manfaat dari segi perkongsian maklumat, teknologi dan pengalaman. Penganjuran *27th PIC/S Expert Circle Meeting on Human Blood, Tissues, Cells dan Advanced Therapy Medicinal Products (ATPMs)* telah menghimpunkan pihak berkuasa regulatori dan pemeriksa Amalan Perkilangan Baik (GMP) dari pelbagai negara ahli *Pharmaceutical Inspection Co-operation Scheme (PIC/S)*. Mesyuarat ini menekankan keperluan keselarasan pengawalseliaan dalam kalangan negara ahli PIC/S bagi mempertingkatkan perlindungan kesihatan awam dan memastikan produk darah, tisu, dan ATPM memenuhi piawaian keselamatan.

Pada tahun ini, hasil usaha Bahagian Penguatkuasaan Farmasi telah membawa kepada penghargaan daripada React, sebuah organisasi antarabangsa yang membanteras barangan palsu. Pengiktirafan ini diberikan atas kejayaan menangani produk farmaseutikal haram melalui siasatan, pemantauan e-dagang, serta program kesedaran. Salah satu usaha ketara ialah Kempen Tolak Ubat Tidak Sah (TOBaTS) yang telah dilancarkan bagi membanteras ubat tidak berdaftar, palsu dan susbtandard yang mengancam kesihatan awam. Pendekatan ini penting untuk memastikan pengguna memperoleh ubat daripada sumber yang sah serta mencegah pengiklanan ubatan tanpa kelulusan KKM. Kempen ini juga bertujuan untuk memperkasakan pengguna dalam membuat pilihan ubat yang selamat demi kesejahteraan rakyat dan negara.

Program ini sentiasa menitikberatkan kompetensi dan kepakaran anggota farmasi untuk memastikan penyampaian perkhidmatan farmasi yang bertahap tinggi. Dalam bidang pengkhususan klinikal dan teknikal, Bengkel Pembangunan Modul latihan *Malaysia Advanced Clinical Pharmacy Programme (MyACCP)* telah dilaksanakan. Bengkel ini berjaya menghasilkan lima modul latihan, merangkumi bidang Farmasi Kardiologi, *Antimicrobial Stewardship (AMS)*, Farmasi Diabetes, Farmasi Nuklear dan Farmasi Farmakokinetik Klinikal. Selain itu, 'Garis Panduan Credentialing Amalan Farmasi bagi Ahli Farmasi Berdaftar' telah dipersetujui sebagai piawaian kualiti dan pengiktirafan bagi ahli farmasi selaras dengan perkembangan semasa dalam perkhidmatan farmasi.

Seperti tahun-tahun sebelumnya, Hari Farmasi Sedunia 2024 Peringkat Kebangsaan dianjurkan dengan kehadiran pelbagai pemegang taruh sektor farmaseutikal sebagai satu pengiktirafan kepada peranan bidang farmasi dalam sistem kesihatan. Sambutan ini turut melancarkan inisiatif Pelupusan Ubat-Ubatan dalam Simpanan Pesakit Demi Kelestarian Alam Sekitar (MyMediSAFE) yang berperanan mendidik masyarakat tentang pelupusan ubat secara betul demi mencegah risiko kesihatan, mengelakkan kerintangan antimikrob, dan menjaga alam sekitar. Sejumlah 33 rakan strategik telah menyertai inisiatif ini, melibatkan 854 pusat pengumpulan ubat-ubatan telah dikenal pasti diseluruh negara.

Selama ini, kolaborasi bersama pelbagai pihak berkepentingan dalam bidang farmaseutikal telah membawa kepada persefahaman dan kebolehlaksanaan perkhidmatan farmaseutikal yang unggul di negara ini. Kita perlu mengamalkan *pharmaceutical resilience* dalam kesihatan ke inovasi teknologi, khususnya juga dalam pengurusan krisis supaya dapat memupuk kemampanan atau kelestarian sistem farmaseutikal negara.

Saya ingin mengucapkan ribuan terima kasih kepada seluruh warga Program Perkhidmatan Farmasi kerana telah menyumbang secara berdedikasi kepada kecemerlangan Program ini sepanjang tahun 2024. Laporan tahunan mengabadikan perjalanan dan pencapaian Program ini setiap tahun. Segala kejayaan ini tidak mungkin dicapai tanpa usaha, komitmen dan kerjasama semua anggota farmasi. Syabas juga kepada sidang redaksi atas kejayaan menerbitkan laporan ini.


Akhir kata, saya mengambil kesempatan ini merakamkan setinggi-tinggi penghargaan kepada seluruh warga Program Perkhidmatan Farmasi serta pemegang taruh yang telah memberikan sokongan padu dan sumbangan idea berterusan demi kecemerlangan bidang farmaseutikal. Semoga warga Program Perkhidmatan Farmasi akan mengekalkan interaksi, dinamik dan khidmat bakti ini serta menjadikan kejayaan yang lalu sebagai inspirasi untuk terus berusaha dalam menyampaikan perkhidmatan terbaik kepada rakyat.

Selamat maju jaya.

NORHALIZA BINTI A HALIM

Timbalan Ketua Pengarah Kesihatan
(Perkhidmatan Farmasi)
Kementerian Kesihatan Malaysia

**CARTA ORGANISASI
ORGANISATIONAL CHART**



KEPIMPINAN KAMI | *OUR LEADERS*

PIMPINAN PENGURUSAN ATASAN | *TOP MANAGEMENT*



**TIMBALAN KETUA
PENGARAH KESIHATAN**

**Puan Norhaliza
binti A Halim**

Timbalan Ketua Pengarah
Kesihatan (Perkhidmatan
Farmasi)

*Deputy Director-General
of Health (Pharmaceutical
Services)*



PENGARAH BAHAGIAN

Dr. Azuana binti Ramli

Pengarah Bahagian
Regulatori Farmasi Negara

*Director of National
Pharmaceutical Regulatory
Agency*



PENGARAH BAHAGIAN

**Encik Mohd Zawawi
bin Abdullah**

Pengarah Bahagian
Penguatkuasaan Farmasi

*Director of Pharmacy
Enforcement Division*



PENGARAH BAHAGIAN

**Puan Wan Noraimi
binti Wan Ibrahim**

Pengarah Bahagian
Amalan & Perkembangan
Farmasi

*Director of Pharmacy Practice
& Development Division*



PENGARAH BAHAGIAN

**Puan Siti Aisah
binti Bahari**

Pengarah Bahagian
Dasar & Perancangan
Strategik Farmasi

*Director of Pharmacy Policy &
Strategic Planning Division*



PENGARAH BAHAGIAN

**Puan Akmalyatun Kamal
binti Kamaruddin**

Pengarah Bahagian
Lembaga Farmasi Malaysia

*Director of Pharmacy Board
Malaysia Division*

BAHAGIAN DASAR & PERANCANGAN STRATEGIK FARMASI PHARMACY POLICY & STRATEGIC PLANNING DIVISION



Puan Nur'Ain Shuhaila binti Shohaimi
Timbalan Pengarah
Cawangan Dasar Farmasi
Deputy Director of Pharmacy Policy Branch



Puan Hazlinda Nazli binti Naem
Timbalan Pengarah
Cawangan Pembangunan Profesion Farmasi
Deputy Director of Pharmacy Professional Development Branch



Dr. Abdul Haniff bin Mohamad Yahaya
Timbalan Pengarah
Cawangan Penyelidikan dan Pembangunan Farmasi
Deputy Director of Pharmacy Research & Development Branch



Puan Nadzifah @ Rashidah binti Mohd Ariffin
Timbalan Pengarah
Cawangan Teknologi Maklumat dan Informatik Farmasi
Deputy Director of Pharmacy Information Technology and Informatics Branch



Puan Nurhairani binti Abdul Latif
Timbalan Pengarah
Cawangan Perkembangan Infrastruktur dan Kualiti Farmasi
Deputy Director of Pharmacy Infrastructure Development and Quality Branch



Encik Sabuting @ Sobiting bin Matanggal
Ketua Profesion
Cawangan Pembangunan Profesion Penolong Pegawai Farmasi
Head of Profession for the Pharmacist Assistants Professional Development Branch

BAHAGIAN AMALAN & PERKEMBANGAN FARMASI PHARMACY PRACTICE & DEVELOPMENT DIVISION



Puan Syahida binti Che Embi
Timbalan Pengarah
Cawangan Penjagaan Farmaseutikal
Deputy Director of Pharmaceutical Care Branch



Puan Nur Azibahwati binti Aziz
Timbalan Pengarah
Cawangan Pengurusan Farmasi Logistik
Deputy Director of Logistic Pharmacy Management Branch



Puan Fatkhiah binti Hj Khalil
Timbalan Pengarah
Cawangan Pengurusan Harga Ubat
Deputy Director of Medicines Pricing Branch



Dr. Nur Sufiza binti Ahmad
Timbalan Pengarah
Cawangan Pengurusan Formulari
Deputy Director of Formulary Management Branch



Puan Munira binti Muhammad
Timbalan Pengarah
Cawangan Penggunaan Ubat Berkualiti
Deputy Director of Quality Use of Medicines Branch

BAHAGIAN PENGUATKUASAAN FARMASI PHARMACY ENFORCEMENT DIVISION



Puan Nor Aza binti Hassan
Timbalan Pengarah
Cawangan Perundangan
Deputy Director of Legislation Branch



Puan Saleha binti Abdul Rahman @ Ngah
Timbalan Pengarah
Cawangan Forensik Farmasi
Deputy Director of Pharmacy Forensic Branch



Puan Asniza binti Alias
Timbalan Pengarah
Cawangan Kawalan Iklan
Deputy Director of Advertisement Control Branch




Puan Siti Mariaton binti Abd Moksni
Timbalan Pengarah
Cawangan Pelesenan
Deputy Director of Licensing Branch



Encik Mohd Azaruddin bin Azis
Timbalan Pengarah
Cawangan Perisikan dan Operasi
Deputy Director of Intelligence and Operation Branch

BAHAGIAN REGULATORI FARMASI NEGARA NATIONAL PHARMACEUTICAL REGULATORY AGENCY



Kosong
Timbalan Pengarah
Pusat Koordinasi dan
Perancangan Strategik
Regulatori
*Deputy Director for the
Centre of Regulatory
Coordination and Strategic
Planning*



Dr. Rosliza binti Lajis
Timbalan Pengarah
Pusat Penilaian Produk
dan Kosmetik
*Deputy Director for the
Centre of Product and
Cosmetic Evaluation*



**Dr. Noraida binti
Mohamad Zainoor**
Timbalan Pengarah
Pusat Komplians dan
Kawalan Kualiti
*Deputy Director for the
Centre of Compliance
and Quality Control*

BAHAGIAN LEMBAGA FARMASI MALAYSIA PHARMACY BOARD MALAYSIA DIVISION



**Puan Nurulfajar
binti Mohd Jamid**
Timbalan Pengarah
Cawangan Pengiktirafan
dan Etika
*Deputy Director of
Accreditation and Ethics
Branch*



**Puan Nurul Adha
binti Othman**
Timbalan Pengarah
Cawangan Pendaftaran
*Deputy Director of
Registration Branch*

PENTADBIRAN SOKONGAN MANAGEMENT SUPPORT



**Puan Azlin
binti Ahmad**
Ketua Unit
Pusat Pentadbiran
Bahagian Regulatori
Farmasi Negara
*Head of Administrative
Unit, National
Pharmaceutical
Regulatory Agency*



**Puan Saidatul
Fariana binti Che
Mori**
Ketua Unit Pentadbiran
Bahagian Dasar dan
Perancangan Strategik
Farmasi
*Head of Administrative
Unit, Pharmacy Policy
and Strategic Planning
Division*



**Puan Halipah
binti Hamdan**
Ketua Unit Kewangan
Bahagian Dasar dan
Perancangan Strategik
Farmasi
*Head of Finance Unit,
Pharmacy Policy and
Strategic Planning
Division*

JAWATANKUASA EDITORIAL

EDITORIAL COMMITTEE

PENAUNG | PATRON

YBRS. PUAN NORHALIZA BINTI A HALIM

Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi)
Deputy Director-General of Health (Pharmaceutical Services)

PENASIHAT | ADVISOR

YBRS. PUAN SITI AISAH BINTI BAHARI

Pengarah Bahagian Dasar dan Perancangan Strategik Farmasi
Director of the Pharmacy Policy and Strategic Planning Division

YBRS. PUAN WAN NORAIMI BINTI WAN IBRAHIM

Pengarah Bahagian Amalan dan Perkembangan Farmasi
Director of the Pharmacy Practice and Development Division

YBRS. ENCIK MOHD ZAWAWI BIN ABDULLAH

Pengarah Bahagian Penguatkuasaan Farmasi
Director of the Pharmacy Enforcement Division

YBRS. DR. AZUANA BINTI RAMLI

Pengarah Bahagian Regulatori Farmasi Negara
Director of the National Pharmaceutical Regulatory Agency

YBRS. PUAN AKMALYATUN KAMAL BINTI KAMARUDDIN

Pengarah Bahagian Lembaga Farmasi Malaysia
Director of the Pharmacy Board Malaysia Division

EDITOR | EDITORS

BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI PHARMACY POLICY AND STRATEGIC PLANNING DIVISION

PUAN NUR'AIN SHUHAILA BINTI SHOHAIMI

Timbalan Pengarah
Deputy Director

ENCIK MOHD AZUWAN BIN MOHD ZUBIR

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

CIK SITI NURUL FATHIHAH BINTI BAHARUDIN

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

PUAN LAU LING WEI

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

PUAN NURUZ ZAKIAH BINTI MD ZIN

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

CIK ERFI ERRISSA BINTI MD TARMIZI

Personel MySTEP
MySTEP Personnel

BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI PHARMACY PRACTICE AND DEVELOPMENT DIVISION

PUAN NUR SHAFIZA BINTI PINGI

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

PUAN SYAHIRAH IZZATY BINTI IKMAL HISHAM

Penolong Pengarah
Assistant Director

BAHAGIAN PENGUATKUASAAN FARMASI PHARMACY ENFORCEMENT DIVISION

PUAN TAM JIA JIA

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

ENCIK ASHRAF BIN ABDUL MUTALIB

Ketua Penolong Pengarah
Principal Assistant Director

BAHAGIAN REGULATORI FARMASI NEGARA NATIONAL PHARMACEUTICAL REGULATORY AGENCY

PUAN ATIKA BINTI CHE OMAR

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

PUAN SARAH AZLEENA BINTI ABDUL AZIZ

Penolong Pengarah Kanan
Principal Assistant Director

BAHAGIAN LEMBAGA FARMASI MALAYSIA PHARMACY BOARD MALAYSIA DIVISION

PUAN NURULBALKIS @ ZUBAIDAH ANUM BINTI HAMDAN

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director

PUAN NURUL AFIFAH BINTI OSMAN

Ketua Penolong Pengarah Kanan
Senior Principal Assistant Director





BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI

*PHARMACY POLICY AND
STRATEGIC PLANNING
DIVISION*



Jumlah Perjawatan Pegawai Farmasi
di KKM sehingga tahun 2024

*Total Number of Pharmacist Post in
the MOH up to the year 2024*

10,342

100%

Peratus **Pegawai Farmasi**
yang Mencapai 40 Mata
CPD Minimum, 2024

*Percentage of **Pharmacist**
Attaining Minimum 40 CPD
Points, 2024*



100%

Peratus **Penolong Pegawai
Farmasi** yang Mencapai 40
Mata CPD Minimum, 2024

*Percentage of **Pharmacist
Assistant** Attaining Minimum 40
CPD Points, 2024*

855

**PEGAWAI FARMASI KONTRAK
CONTRACT PHARMACIST**

Jumlah Graduan Farmasi Dilantik Sebagai
Pegawai Farmasi secara Kontrak

*Total of Pharmacy Graduates Appointed as
Contract Pharmacist*



Jumlah Fasilitas Farmasi KKM di Seluruh
Negara Melaksanakan PhIS dan CPS
(Go-Live)

*Total MOH Pharmacy Facilities Nationwide
Using PhIS and CPS (Go-Live)*

1,320

**FASILITI FARMASI KKM
MOH PHARMACY FACILITIES**



BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI
PHARMACY POLICY AND STRATEGIC PLANNING DIVISION

1.0 PENGENALAN | INTRODUCTION



Bahagian Dasar dan Perancangan Strategik Farmasi (BDPSF) terdiri daripada enam (6) cawangan seperti di atas. Fungsi keseluruhan Bahagian ini adalah:

1. Merancang dan menyelaraskan aktiviti farmasi supaya selari dengan Dasar Ubat Nasional (DUNas) dan hala tuju KKM serta penyelarasan isu-isu berkaitan dasar, aduan dan perhubungan intra agensi dan inter agensi
2. Merancang pengurusan keperluan sumber manusia dan kompetensi Pegawai Farmasi dan Penolong Pegawai Farmasi di seluruh negara supaya lebih efisien dan cemerlang
3. Menyelaraskan dan memantau pembangunan infrastruktur farmasi dan sistem kualiti perkhidmatan farmasi di fasiliti kesihatan KKM
4. Merancang dan menyelaraskan halatuju serta aktiviti-aktiviti penyelidikan dan pembangunan bagi PPF
5. Merancang, menyelaraskan dan melaksanakan keperluan prasarana ICT, keselamatan ICT, penyelenggaraan peralatan/ rangkaian/ bilik server dan perisian ICT jabatan
6. Menyelaraskan dan melaksanakan pengurusan perkhidmatan, pengurusan aset dan stor, pengurusan perolehan, pengurusan kenderaan serta pengurusan fail dan dokumen bagi anggota di PPF
7. Menyelaraskan dan memantau kedudukan perbelanjaan dan kewangan PPF supaya lebih efisien

Pharmacy Policy and Strategic Planning Division (BDPSF) consists of six (6) branches as above. The overall functions of the Division are:

1. *Planning and coordinating pharmacy activities to be in line with the National Medicines Policy (DUNas) and the way forward of the MOH as well as coordinating policy-related issues, complaints and intra-agency and inter-agency relations*
2. *Planning for the management of human resource needs and competency of Pharmacy Officers and Pharmacist Assistant throughout the country to be more efficient and excellent*
3. *Coordinating and monitoring the development of pharmacy infrastructures and quality system of the pharmacy services at MOH health facilities*
4. *Planning and coordinating research and development priorities and activities for the PSP*
5. *Planning, coordinating and implementing ICT infrastructure requirements, ICT security, maintenance of equipment/ network/ server room and departmental ICT software*
6. *Coordinating, performing and attending administrative matters, assets and store management, procurement management, transport/ fleet management as well as filing and document organization for PSP workforce*
7. *Coordinating and monitoring expenditure and financial status of the PSP to be more efficient*

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.

MEDICINE
HEALTH
TREATMENT
DOCTOR
SURVEY
RECIPE

MEDICINE

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.

MEDICINE
HEALTH
TREATMENT
DOCTOR
SURVEY
RECIPE

2.0 AKTIVITI DAN SOROTAN | ACTIVITIES AND HIGHLIGHTS

PERSIDANGAN PENYELIDIKAN DAN PEMBANGUNAN (R&D) FARMASI KEBANGSAAN KE-12, 2024

Persidangan Penyelidikan dan Pembangunan (R&D) Farmasi Kebangsaan Ke-12 yang bertema '*Unity for Medicine Security: Collaborative Solutions for a Safer Future*' telah berlangsung dari 19-21 Ogos 2024 di Hotel KSL Esplanade, Klang. Persidangan ini telah menghimpunkan pegawai farmasi, pemain industri farmaseutikal, para penyelidik dan ahli akademik di negara ini. Persidangan ini telah menjadi platform unggul untuk kerjasama strategik dan pencetus inovasi dalam memastikan keterjaminan ubat-ubatan yang mampan untuk masa depan. Upacara perasmian Persidangan R&D Farmasi Kebangsaan Ke-12 ini telah disempurnakan oleh Menteri Kesihatan.

Tarikan utama persidangan ini merupakan sesi forum bersama jemputan khas wakil sektor farmaseutikal dari Thailand dan Indonesia, yang berkongsi pencapaian serta pengalaman berkaitan isu keterjaminan ubat-ubatan dan vaksin di negara masing-masing. Perspektif antarabangsa ini memberikan dimensi baharu kepada peserta. Tidak ketinggalan, sesi perkongsian oleh Ketua Pegawai Eksekutif, Duopharma Biotech Berhad dan *Clinical Research Taskforce Chair, Pharmaceutical Association of Malaysia (PhAMA)* berjaya mencetuskan idea-idea inovatif bagi industri farmaseutikal.

Perspektif antarabangsa dan idea-idea inovatif yang dicetuskan dalam forum dan simposium ini turut dilengkapi dengan sesi pembentangan hasil penyelidikan yang merupakan tumpuan sebenar persidangan ini. Daripada sejumlah 413 abstrak penyertaan yang diterima, 73 kajian telah dipilih untuk pembentangan lisan, manakala 58 lagi dipersembahkan dalam bentuk poster. Kesemua abstrak ini diterbitkan dalam *Pharmacy Research Reports Volume 7, Supplement Issue, August 2024* yang boleh diakses secara dalam talian melalui portal rasmi PPF. Kehadiran peserta amat memberangsangkan dengan merekodkan kehadiran 500 peserta. Persidangan ini telah menjadi platform unggul untuk perbincangan mendalam, perkongsian ilmu dan kolaborasi strategik.

Secara keseluruhan, Persidangan R&D Farmasi Kebangsaan Ke-12 telah menzahirkan komitmen padu PPF dalam mengembeling tenaga pelbagai pihak demi memperkukuhkan keterjaminan ubat-ubatan di peringkat Malaysia dan ASEAN. Melalui kerjasama strategik, perbincangan mendalam, dan perkongsian ilmu, persidangan ini telah membuka jalan ke arah penyelesaian inovatif untuk mengatasi cabaran dalam rantaian farmaseutikal negara. Dengan kejayaan ini, ia bukan sahaja memperkukuhkan daya saing industri farmaseutikal tetapi juga menjadi inspirasi kepada usaha kolektif demi masa depan yang lebih selamat dan mampan dalam memastikan bekalan ubat terjamin.

12TH NATIONAL PHARMACY RESEARCH AND DEVELOPMENT (R&D) CONFERENCE, 2024

The 12th National Pharmacy Research and Development (R&D) Conference themed 'Unity for Medicine Security: Collaborative Solutions for a Safer Future' took place from 19-21 August 2024 at the KSL Esplanade Hotel in Klang. It brought together pharmacists, pharmaceutical industry players, researchers, and academics from across Malaysia, creating an excellent platform for strategic collaboration and innovation to ensure sustainable medicine security for the future. The event was officiated by the Minister of Health.

The main attraction of this conference was the forum session with the pharmaceutical sector representatives from Thailand and Indonesia who shared their experiences and achievements on issues related to medicines and vaccine security in their respective countries, bringing fresh international perspectives to the discussions. Additionally, two educational symposia by the CEO of Duopharma Biotech Berhad and the Clinical Research Taskforce Chair, Pharmaceutical Association of Malaysia (PhAMA) sparked innovative ideas for the pharmaceutical industry.

The international perspectives and innovative ideas shared in the forums and symposia were complemented by high-quality research presentations. Out of 413 submitted abstracts, 73 were selected for oral presentations, while 58 were presented as posters. All of these abstracts were published in the Pharmacy Research Reports Volume 7, Supplement Issue, August 2024 which is available online through the official PSP portal. This publication highlights the commitment to high-quality research with great potential to impact the pharmaceutical services. The conference also received strong support from 400 to 500 participants, making it a valuable platform for in-depth discussions, knowledge sharing, and strategic collaboration.

Overall, the 12th National Pharmacy R&D Conference demonstrated the strong commitment of the PSP in bringing together diverse stakeholders to strengthen medicine security at both national and regional levels. Through strategic cooperation, deep discussions, and knowledge sharing, the conference paved the way for innovative solutions to address challenges in the national pharmaceutical supply chain. This success not only strengthens the pharmaceutical industry's competitiveness but also serves as an inspiration for collective efforts toward a safer and more sustainable future, ensuring guaranteed access to medicines for all.



Persidangan R&D Farmasi Kebangsaan Ke-12
12th National Pharmacy R&D Conference

Pemenang Pembentangan Lisan Mengikut Bidang Penyelidikan
Winners of oral presentation by Research Area

Hadiah <i>Prize</i>	Nama <i>Name</i>	Tajuk Penyelidikan <i>Research Title</i>	Tempat bertugas <i>Facility/ Institution</i>
Track 1: Drug Development & Regulations (Oral Presentation)			
Pertama <i>First</i>	Hii Lu Yien	<i>Exploring the Issues and Challenges of Prosecution Faced by Pharmacy Enforcement Division in Malaysia</i>	Pharmacy Enforcement Division, JKN Sabah
Kedua <i>Second</i>	Julian Voong Cheng Liang	<i>FGS03 – Compound for Treating Neurodegenerative Diseases</i>	Sarawak Biodiversity Centre
Ketiga <i>Third</i>	Dr. Rema Panickar a/p Sugunan @ Vasanthan	<i>Development of a Strategic Plan to Enhance Medicines Risk Communication in Malaysia</i>	Pharmacovigilance Section, NPRA
Track 2: Consumer-centric Pharmacy Services (Oral Presentation)			
Pertama <i>First</i>	Kenny Tuang Ling Ee	<i>Knowledge, Confidence, and Information-Seeking Practices on Medicine Use in Pregnancy among Primary Care Pharmacists in Malaysia</i>	Hospital Kajang, Selangor
Kedua <i>Second</i>	Kho Boon Phiaw	<i>Virtual Counselling by Pharmacists using Mobile Devices: A Qualitative Exploration</i>	Hospital Umum Sarawak
Ketiga <i>Third</i>	Kong Lai San	<i>A Nationwide Study on Antibiotic Use Knowledge and Practice among General Public in Malaysia: Differences between Urban and Rural Areas, and Their Predictors</i>	Hospital Tuanku Ampuan Najihah, Negeri Sembilan
Track 3: Pharmacotherapy (Oral Presentation)			
Pertama <i>First</i>	Koh Hock Peng	<i>Clinically Significant Renal Function Decline among Non-Valvular Atrial Fibrillation Patients on Direct Oral Anticoagulant: A Retrospective, Multicenter Study in an Asian Population</i>	Hospital Kuala Lumpur
Kedua <i>Second</i>	Wan Mohd Akmal Bin Wan Sabri	<i>Evaluation of Chemotherapy Relative Drug Intensity Impact on Overall Survival of Breast, Colorectal and Lung Cancer Patients</i>	Hospital Seri Manjung, Perak
Ketiga <i>Third</i>	Nur Adilah binti A. Rahman	<i>Monitoring of Gentamicin Serum Concentration Among Newborns In the Neonatal Ward at Hospital Sultan Ismail Petra</i>	Hospital Sultan Ismail Petra, Kelantan

Hadiah Prize	Nama Name	Tajuk Penyelidikan Research Title	Tempat bertugas Facility/ Institution
Scholarly Best Oral Presentation Award			
Pertama First	Chow Ngah Kuan	<i>The Association Between Cigarette Smoking and Efavirenz Plasma Concentration Using the Population Pharmacokinetic Approach</i>	Hospital Sultanah Maliha, Langkawi
Saguhati Consolation	Chang Cheok Ee	<i>Development and Validation of STORIMAP - a Pharmaceutical Assessment Screening Tool for Prioritising Patient Care in a Tertiary Care Hospital</i>	Hospital Kuala Lumpur
Saguhati Consolation	Lukman Nul Hakim bin Md Khairi	<i>Trends and Determinants of Inhaled Corticosteroids Prescribing in Patients with Chronic Obstructive Pulmonary Disease</i>	Hospital Sultanah Nur Zahirah, Terengganu

Pemenang Pembentangan Poster
Winners of Poster Presentation

Hadiah Prize	Nama Name	Tajuk Penyelidikan Research Title	Tempat bertugas Facility/ Institution
Pertama First	Chong Yook Foong	<i>Patient's Own Medication (POM) Use in The Wards Using Enhanced-POM (En-POM) Process: A Costing Analysis</i>	Hospital Rehabilitasi Cheras, WPKL & Putrajaya
Saguhati Consolation	Dr. Ahmad Hafiz Murtadha bin Noor Din	<i>Phenotypic Characterisation of CD19 Chimeric Antigen Receptor T (CAR-T) Cells Manufactured using Automated CliniMACS Prodigy® System</i>	<i>Institute for Medical Research (IMR), National Institutes of Health (NIH)</i>
Saguhati Consolation	Yap Fei Ting	<i>Retrospective Study of Illegal Medicines Advertisements in Local E-Marketplace Platforms</i>	Bahagian Penguatkuasaan Farmasi, IPKKM
Saguhati Consolation	Lim Chiew Yee	<i>An Interventional Study on the Effectiveness of EAZiMED to Improve Hematinic Counselling among Pregnant Women in Health Clinics in Kota Tinggi</i>	PKD Kota Tinggi, Johor
Saguhati Consolation	See Yan Zhuang	<i>Comparison of effects between oral Deferiprone and combination iron chelation therapy on cardiac function in adult beta-thalassaemia patients: A Southern Malaysia study</i>	Hospital Pakar Sultanah Fatimah, Johor
Saguhati Consolation	Koay Hooi Hoon	<i>A Retrospective Study on the Use of Continuous Clonidine Infusion for Sedation in Critically Ill Paediatric Patients</i>	Hospital Kajang, Selangor

Piala Pusingan Anugerah Penyelidikan Farmasi Dato' Eisah A. Rahman

Piala Pusingan Anugerah Penyelidikan Farmasi Dato' Eisah A. Rahman dianugerahkan kepada negeri atau institusi di bawah KKM sebagai pengiktirafan kepada negeri atau institusi yang menunjukkan prestasi yang cemerlang di dalam bidang penyelidikan. Dalam Persidangan R&D Farmasi Kebangsaan ke-12, piala ini telah dianugerahkan kepada Hospital Kuala Lumpur di atas pencapaian yang cemerlang menjalankan aktiviti-aktiviti penyelidikan dari tahun 2021 sehingga 2024 serta pencapaian di persidangan tersebut.

Dato' Eisah A. Rahman Pharmacy Research Award Challenge Trophy

The Dato' Eisah A. Rahman Pharmacy Research Award Challenge Trophy is awarded to a state or an institution under the MOH as a recognition to its outstanding achievements in research activities. In conjunction with 12th National Pharmacy R&D Conference, this prestigious award goes to Hospital Kuala Lumpur for their outstanding achievements in research activities from 2021 to 2024 as well as during the conference.



Piala Pusingan Anugerah Penyelidikan Farmasi Dato' Eisah A. Rahman
Dato' Eisah A. Rahman Pharmacy Research Award Challenge Trophy

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE - PERSIDANGAN FARMASEUTIKAL ANTARABANGSA BORNEO (JoPPP-BIPC) 2024

Journal of Pharmaceutical Policy and Practice - Borneo International Pharmaceutical Conference (JoPPP-BIPC) 2024 telah diadakan pada 20-22 September 2024 di *Borneo Cultures Museum*, Kuching, Sarawak. Persidangan ini menghimpunkan 186 delegasi tempatan dan 70 delegasi antarabangsa dari 9 negara, mewujudkan platform pertukaran idea dan pandangan yang dinamik di bawah tema '*Delving into the Future of Medicine and Pharmaceutical Care*'.

Persidangan ini menampilkan penceramah ucapnama terkenal, termasuk Prof. Zaheer-Ud-Din Babar, Ketua Editor JoPPP, yang menyampaikan syarahan bertajuk '*Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy*'. Selain itu, Dr. Hwang Shiaw-Min dari Pusat Penyelidikan Genomik Taiwan turut berkongsi pandangan berharga mengenai penyelidikan sel stem dan aplikasinya dalam klinikal melalui tajuk '*Stem Cell Research and Clinical Application: Past, Present, and Future*' and '*Amniotic Fluid Stem Cells: A New Era in Regenerative Medicine*'. Persidangan ini turut merangkumi pelbagai topik seperti kesihatan awam farmaseutikal, aplikasi sel stem, dan inovasi dalam sistem penghantaran ubat. Para peserta berpeluang untuk membina rangkaian profesional dan berkongsi hasil penyelidikan melalui 128 pembentangan, termasuk kategori poster, sorotan penyelidikan, dan pembentangan lisan.

JoPPP-BIPC 2024 berjaya menarik 70 delegasi antarabangsa dari 9 negara, termasuk penceramah dan peserta, yang menyumbang kepada pertukaran ilmu dan kolaborasi global. Sebagai persidangan farmaseutikal antarabangsa pertama di Sarawak, acara ini menandakan pencapaian penting dalam usaha meletakkan negeri ini sebagai hab baharu bagi perbincangan farmaseutikal global. Para delegasi memberikan maklum balas yang amat positif, memuji kualiti perbincangan yang tinggi, kepakaran penceramah dan peluang rangkaian yang bernilai. Kejayaan acara ini turut diperkuat dengan sokongan padu daripada Kerajaan Sarawak melalui Biro Konvensyen Sarawak, menonjolkan komitmen kerajaan dalam memajukan sektor kesihatan dan amalan farmaseutikal di rantau ini.

1ST JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE - BORNEO INTERNATIONAL PHARMACEUTICAL CONFERENCE (JoPPP-BIPC) 2024

The inaugural Journal of Pharmaceutical Policy and Practice - Borneo International Pharmaceutical Conference (JoPPP-BIPC) 2024 was successfully held from 20-22 September 2024 at the *Borneo Cultures Museum*, Kuching, Sarawak. The conference brought together 186 local and 70 international delegates from 9 countries, fostering a dynamic exchange of ideas and insights under the theme '*Delving into the Future of Medicine and Pharmaceutical Care*'.

The event featured renowned keynote speakers, including Prof. Zaheer-Ud-Din Babar, Editor-in-Chief of JoPPP, who delivered a talk on "Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy." Additionally, Dr. Hwang Shiaw-Min from Taiwan's Genomic Research Centre shared valuable insights on stem cell research and clinical applications, covering topics such as 'Stem Cell Research and Clinical Application: Past, Present, and Future' and 'Amniotic Fluid Stem Cells: A New Era in Regenerative Medicine.' The conference covered topics such as pharmaceutical public health, stem cell applications, and innovations in drug delivery systems. Attendees had the opportunity to network and share research findings through 128 presentations, spanning poster, research highlight, and oral presentation categories.

The JoPPP-BIPC 2024 successfully attracted 70 international delegates from 9 countries, including distinguished speakers and participants, fostering a global exchange of knowledge and collaboration. As Sarawak's first international pharmaceutical conference, the event marked a significant milestone in positioning the state as an emerging hub for global pharmaceutical discussions. Delegates provided overwhelmingly positive feedback, praising the high quality of discussions, the calibre of speakers, and the valuable networking opportunities. The event's success was further strengthened by the strong support from the Sarawak Government through the Sarawak Convention Bureau, highlighting the government's commitment to advancing healthcare and pharmaceutical practices in the region.

JoPPP-BIPC 2024 telah mencapai kejayaan besar dengan menghimpunkan pakar dan profesional dalam bidang farmaseutikal bagi berkongsi ilmu, menggalakkan kolaborasi, dan meneroka kemajuan masa depan. Persidangan ini bukan sahaja menyumbang kepada pertumbuhan komuniti farmaseutikal tetapi juga mengukuhkan kedudukan Sarawak sebagai destinasi utama untuk persidangan farmaseutikal antarabangsa pada masa hadapan.

The JoPPP-BIPC 2024 was a resounding success, bringing together experts and professionals in the pharmaceutical field to share knowledge, foster collaboration, and explore future advancements. The event not only contributed to the growth of the pharmaceutical community but also positioned Sarawak as a key location for future international pharmaceutical conferences.

Senarai Pemenang
List of Winners

Kategori <i>Category</i>	Nama <i>Name</i>	Tajuk Penyelidikan <i>Research Title</i>
<i>Best Poster Presentation Award</i>	Laura Soon Cheau Ling (Malaysia)	<i>Impact of COVID-19 towards antibiotic consumption in a major specialist hospital: A non-COVID-19 hospital perspective</i>
<i>Best Healthcare and Pharmaceutical Policy Research Award</i>	Chaoncin Sooksriwong (Thailand)	<i>The price reduction pattern of innovators from the application of the reference pricing policy</i>
<i>Best Pharmacy Practice Research Award</i>	Dr. Nurolaini Kifli (Brunei Darussalam)	<i>The Prevalence of Unused Medicines Amongst Patients in Pengiran Anak Puteri Hajah Muta-Wakillah Hayatul Bolkiah Health Centre and Its Disposal Practices</i>
<i>Best Clinical Pharmacy Research Award</i>	Fiona Fong Pui Wun (Malaysia)	<i>Risk Factors of Central-line associated Bloodstream Infection among Adult Patients on Parenteral Nutrition</i>
<i>Best Pharmaceutical Sciences Research Award.</i>	Liandhajani (Indonesia)	<i>Review of Hair Growth and Weight of Hair Tonic Preparations from Several Herbs</i>
<i>Best Pharmaceutical Regulatory and Enforcement Research Award</i>	Tan Meng Hsiung (Malaysia)	<i>Acceptance of Electronic Prescription System among Community Pharmacists in Sarawak: A Preliminary Study</i>
<i>Best Medical Sciences Research Award</i>	Dr. Jesa Sabillano Madelo (Philippines)	<i>Health Seeking Behavior and Compliance of HIV Infected Individual to Anti-Retroviral Therapy</i>
<i>Outstanding Research Highlight Oral Presentation</i>	Ching Shan Lii (Malaysia)	<i>Prevalence and characteristic of drug-related problems (DRPs) amongst patients attending pharmacist-led Haemodialysis Medication Therapy Adherence Clinic (HD-MTAC): A longitudinal study</i>
	Kho Boon Phiaw (Malaysia)	<i>Conducting Follow-up with Patients Newly Discharged from Medical Wards using Mobile Devices: A Needs and Feasibility study</i>
	Chaoncin Sooksriwong (Thailand)	<i>The price reduction pattern of innovators from the application of the reference pricing policy</i>
<i>Research Highlight Commendation Award</i>	Fahmi bin Hassan (Malaysia)	<i>Exploring Patient Perceptions of the Diabetes Medication Therapy Adherence Clinic (DMTAC) in Malaysia: An Application of Andersen's Behavioral Model of Health Service Utilization</i>
	Farisa Luthfiana (Indonesia)	<i>The Relationship Between Linezolid Therapy and Hemoglobin (Hb) Levels in Patients with Drug-Resistant Tuberculosis (DR-TB)</i>
<i>Best Oral Presentation Award</i>	Josephine A/P Henry Basil (Malaysia)	<i>Machine Learning-Based Risk Prediction Model for Medication Administration Errors in Neonatal Intensive Care Units: A Prospective Direct Observational Study</i>



Barisan tetamu kehormat dan urusetia JoPPP-BIPC 2024
Distinguished guests and secretariat members of the JoPPP-BIPC 2024



Majlis Perasmian JoPPP-BIPC 2024
Opening ceremony of JoPPP-BIPC 2024

SESI LIBAT URUS BERSAMA PEMEGANG TARUH

Sebagai sebahagian daripada usaha berterusan untuk meningkatkan penyampaian perkhidmatan farmaseutikal dan memperkukuhkan keselamatan ubat-ubatan di Malaysia, PPF telah melaksanakan siri libat urus strategik dengan pemegang taruh utama. Libat urus ini bertujuan untuk memupuk kerjasama, memberikan maklumat terkini mengenai inisiatif utama seperti Keutamaan Penyelidikan Farmasi di Malaysia (Edisi Kedua) dan Inisiatif Keterjaminan Ubat-ubatan Malaysia, serta menyelaraskan pemegang taruh dengan matlamat nasional. Berikut adalah ringkasan mengenai libat urus yang telah dijalankan.

STAKEHOLDER ENGAGEMENTS

As part of the ongoing efforts to enhance the delivery of pharmaceutical services and strengthen medicine security in Malaysia, the PSP has undertaken a series of strategic engagements with key stakeholders. These engagements were aimed at fostering collaboration, providing updates on critical initiatives such as the Pharmacy Research Priorities in Malaysia (PRPM) 2nd Edition and the Malaysia Medicine Security initiative as well as aligning stakeholders with national goals. Below is a summary of the engagements conducted.

Sesi libat urus yang telah dijalankan pada tahun 2024
Engagement session conducted in 2024

Sesi Libat Urus <i>Engagement</i>	Tarikh <i>Date</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
Kunjungan Hormat kepada Majlis Dekan Farmasi <i>Courtesy Visit to the Council of Pharmacy Deans</i>	15 Mac 2024 <i>15 March 2024</i>	Lawatan ini bertujuan untuk mewujudkan kerjasama yang lebih erat dengan pihak akademik melalui libat urus bersama kepimpinan fakulti farmasi di seluruh Malaysia. Perbincangan memberi tumpuan kepada pengintegrasian garis panduan PRPM Edisi Kedua yang dikemas kini ke dalam kurikulum akademik, memupuk kolaborasi penyelidikan, dan melibatkan pihak akademik dalam merangka dasar bagi keterjaminan ubat-ubatan di Malaysia. <i>The visit aimed to establish a stronger partnership with academia by engaging the leadership of pharmacy faculties across Malaysia. Discussions focused on incorporating the updated PRPM 2nd Edition guidelines into academic curricular, fostering research collaborations, and involving academia in shaping policies for Malaysia's medicine security.</i>	Maklum balas positif diterima. Majlis Dekan Farmasi komited untuk menyokong Program dan mencadangkan kolaborasi penyelidikan serta peluang-peluang latihan. <i>Positive feedback received. The Council committed to supporting the programme and proposed research collaborations and training opportunities.</i>
Kunjungan Hormat kepada Pengarah-Pengarah Institut di Institut Penyelidikan Kebangsaan (NIH) <i>Courtesy Visit to the Directors of Institutes at the National Institutes of Health (NIH)</i>	24 April 2024 <i>24 April 2024</i>	Memberikan taklimat kepada pengarah NIH mengenai Inisiatif Keterjaminan Ubat-ubatan Malaysia, meneroka peluang kerjasama penyelidikan dan pembiayaan. <i>This engagement provided an opportunity to brief the NIH directors on the Malaysia Medicine Security Initiative and explore collaborative opportunities for research and development in the pharmaceutical sector.</i>	Pengarah-pengarah menyatakan minat untuk memanfaatkan sumber NIH bagi agenda reformasi kesihatan dan penggabalan dasar berasaskan data. <i>Directors expressed interest in leveraging NIH resources for healthcare reform agenda and data-driven policymaking.</i>

Sesi Libat Urus <i>Engagement</i>	Tarikh <i>Date</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
<p>Kunjungan Hormat kepada Timbalan Ketua Setiausaha (Pembangunan Teknologi) dan Pegawai Kanan Kementerian Sains, Teknologi & Inovasi (MOSTI)</p> <p><i>Courtesy Visit to the Deputy Secretary-General (Technology) and senior officials of Ministry of Science, Technology and Innovation (MOSTI)</i></p>	<p>8 Ogos 2024</p> <p><i>8 August 2024</i></p>	<p>Perbincangan peringkat tinggi telah diadakan bersama Timbalan Ketua Setiausaha (Teknologi) dan pegawai kanan MOSTI. Libat urus ini bertujuan untuk memastikan penyelarasan dengan keutamaan sains dan teknologi MOSTI serta meneroka peluang pembiayaan bagi inovasi farmaseutikal di bawah bidang kuasa mereka.</p> <p><i>A high-level discussion was held with the Deputy Secretary-General (Technology) and senior officials of MOSTI. The engagement aimed to secure alignment with MOSTI's science and technology priorities and explore funding opportunities for pharmaceutical innovation under their purview.</i></p>	<p>MOSTI menyatakan sokongan mereka dan menggalakkan permohonan pembiayaan untuk projek penemuan ubat, serta mencadangkan libat urus lanjut.</p> <p><i>MOSTI affirmed their support and encouraged funding applications for drug discovery projects, proposing further engagements.</i></p>



Sesi Libat Urus antara PPF bersama Majlis Dekan Farmasi
Engagement session between the PSP and the Deans of Pharmacy Council



Sesi Libat Urus antara PPF bersama MOSTI
Engagement session between the PSP and MOSTI



LAIN-LAIN AKTIVITI | OTHER ACTIVITIES

Bil. No.	Aktiviti Activity	Tarikh/ Tempat Date/ Venue	Peserta Participant	Objektif Objective	Hasil Outcome
1	Mesyuarat Panel Pakar Malaysian Statistics (MSOM) 2018-2022 Malaysian Statistics on Medicines (MSOM) 2018-2022 Expert Panel Meeting	11, 12 dan 14 Mac 2024, PPF 11, 12 and 14 March 2024, PSP	Pakar perubatan dari pelbagai disiplin Specialists from various disciplines	Mendapatkan maklum balas pakar mengenai pola penggunaan ubat-ubatan di Malaysia sepanjang tempoh 2018 hingga 2022 Obtain experts' feedback on the trends and patterns of medicines utilisation in Malaysia from 2018 to 2022	Hasil daripada mesyuarat ini telah memberikan input yang bernilai bagi memastikan ketepatan dan kualiti laporan MSOM 2018-2022. Maklum balas daripada pakar pelbagai bidang membantu memperkukuhkan pemahaman terhadap pola penggunaan ubat di Malaysia, sekali gus menyumbang kepada pembangunan dasar farmasi yang lebih berkesan pada masa hadapan. The outcomes of this meeting provided valuable insights to ensure the accuracy and quality of the MSOM 2018-2022 report. Feedback from experts across various fields has strengthened the understanding of medication utilisation trends in Malaysia, contributing to the development of more effective pharmaceutical policies in the future.
2	Bengkel Penulisan Manuskrip Kajian Farmasi 2024 Pharmacy Research Manuscript Writing Workshop 2024	5-7 November 2024, Hotel Impiana, Ipoh 5-7 November 2024, Impiana Hotel, Ipoh	25 Pegawai Farmasi IPKKM 25 Pharmacy Officers from the MOH HQ	Membantu pegawai di PPF agar dapat menghasilkan manuskrip yang boleh diterbitkan di jurnal tempatan atau antarabangsa Assist officers in the PSP in producing manuscripts that can be published in local or international journals	Para peserta diberi peluang untuk mendapatkan khidmat nasihat dan pandangan daripada penceramah, fasilitator, serta peserta lain bagi menghasilkan manuskrip yang berkualiti. Sebanyak lapan belas draf manuskrip telah dibincangkan sepanjang bengkel ini. Participants were given the opportunity to seek advice and feedback from the speaker, facilitators, and fellow participants to produce high-quality manuscripts. A total of eighteen manuscript drafts were discussed during the workshop.

Bil. No.	Aktiviti Activity	Tarikh/ Tempat Date/ Venue	Peserta Participant	Objektif Objective	Hasil Outcome
3	Bengkel Penyediaan dan Pemuktamadan Dokumen Projek Pembangunan Naik Taraf PhIS 3.0 <i>Workshop of Preparation and Finalization of Development Project Documents for the Upgrade of PhIS 3.0</i>	20 Mac hingga 6 Disember 2024 (73 sesi) <i>20 March till 6 December 2024 (73 sessions)</i>	83 pegawai PPF, 13 pegawai IPKIM dan 120 ahli farmasi dari 56 fasiliti <i>83 officers from the PSP, 13 officers from the MOH HQ and 120 pharmacists from 56 facilities</i>	<ul style="list-style-type: none"> • Memastikan pembangunan Pharmacy Information System (PhIS) 3.0 memenuhi keperluan pengguna dan selaras dengan hala tuju strategik KKM • Memperhalusi penambahbaikan modul sedia ada serta membangunkan modul baharu berdasarkan cadangan pengguna, dengan mematuhan kepada polisi dan garis panduan terkini • <i>Ensure that the development of the Pharmacy Information System (PhIS) 3.0 meets user requirements and aligns with the strategic direction of the MOH</i> • <i>Refine improvements to existing modules and develop new modules based on user recommendations while adhering to the latest policies and guidelines</i> 	<p>Hasil utama bengkel ini adalah penyediaan dokumen penting iaitu Dokumen Keperluan Pengguna (URS), Dokumen Keperluan Perniagaan (BRS), dan Dokumen Keperluan Sistem (SRS). Dokumen ini menjadi asas kukuh untuk pembangunan PhIS 3.0 yang lebih mantap, efisien, dan bersepadu, sekaligus mempertingkatkan kualiti pengurusan perkhidmatan farmasi di KKM serta memperkemas proses kerja secara keseluruhan.</p> <p><i>The key outcome of this workshop was the preparation of essential documents, including the User Requirement Specification (URS), Business Requirement Specification (BRS), and System Requirement Specification (SRS). These documents serve as a solid foundation for the development of PhIS 3.0, ensuring a more robust, efficient, and integrated system. Ultimately, this will enhance the quality of pharmacy service management within the MOH and streamline overall work processes.</i></p>

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participant</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
4	<p>Pembangunan Pelan Antirasuah Organisasi (OACP) Program Perkhidmatan Farmasi KKM</p> <ol style="list-style-type: none"> 1. Bengkel Penilaian Risiko Rasuah (CRA) dan Pelan Antirasuah Organisasi (OACP) 2. Bengkel Pelan Tindakan bagi Pembangunan Pelan Antirasuah Organisasi (OACP) 3. Bengkel Pemurnian bagi Pembangunan Pelan Antirasuah Organisasi (OACP) <p><i>Development of the Organizational Anti-Corruption Plan (OACP) for the Pharmaceutical Service Programme, MOH</i></p> <ol style="list-style-type: none"> 1. <i>Corruption Risk Assessment (CRA) and Organizational Anti-Corruption Plan (OACP) Workshop</i> 2. <i>Action Plan Workshop for the Development of the Organizational Anti-Corruption Plan (OACP)</i> 3. <i>Refinement Workshop for the Development of the Organizational Anti-Corruption Plan (OACP)</i> 	<p>6-8 Mei 2024, PPF</p> <p>4-5 Jun 2024, PPF</p> <p>22-23 Julai 2024, PPF</p> <p>6-8 May 2024, PSP</p> <p>4-5 June 2024, PSP</p> <p>22-23 July 2024, PSP</p>	<p>Anggota Farmasi dari PPF <i>Pharmacy Staff from the PSP</i></p>	<p>Bengkel-bengkel ini telah dirangka secara strategik dan diperkukuh melalui input dan bimbingan daripada Unit Integriti, IPKKM dan Institut Integriti Malaysia (IIM). Penglibatan entiti berautoriti ini memastikan setiap inisiatif yang dibangunkan selaras dengan dasar antirasuah yang ditetapkan, sekali gus mengukuhkan keberkesanan pelaksanaan langkah-langkah integriti dalam sektor farmasi. Tujuan bengkel adalah:</p> <ul style="list-style-type: none"> ● Mengenal pasti dan menilai risiko rasuah dalam organisasi sebagai asas kepada pembangunan pelan antirasuah ● Merangka strategi dan tindakan mitigasi yang sesuai bagi mengurangkan risiko rasuah yang telah dikenalpasti ● Menambah baik dan memperkembangkan pelan sebelum dimuktamadkan <p><i>These workshops were strategically designed and further strengthened with input and guidance from the Integrity Unit, IPKKM, and the Malaysian Integrity Institute (IIM). The involvement of these authoritative entities ensures that every initiative developed is aligned with established anti-corruption policies, thereby enhancing the effectiveness of integrity measures within the pharmaceutical sector. The aims of the workshops were to:</i></p> <ul style="list-style-type: none"> ● <i>Identify and assess corruption risks within the organization as a foundation for developing the anti-corruption plan</i> ● <i>Formulate appropriate strategies and mitigation measures to reduce the identified corruption risks</i> ● <i>Enhance and refine the plan before its finalization</i> 	<p>Hasil daripada bengkel ini menjadi landasan utama dalam merangka strategi intervensi yang lebih berkesan bagi memastikan persekitaran kerja yang berintegriti dan bebas daripada sebarang unsur rasuah. <i>The outcomes of this workshop serve as a fundamental basis for formulating more effective intervention strategies to ensure a work environment that upholds integrity and is safeguarded against any form of corruption.</i></p>

Bil. No.	Aktiviti Activity	Tarikh/ Tempat Date/ Venue	Peserta Participant	Objektif Objective	Hasil Outcome
5	Kursus Penyelidikan Berkesan Pegawai Farmasi Tahun 2024 <i>Effective Supervision Course for Pharmacist Year 2024</i>	2-4 Julai 2024, Hotel KSL Esplanade, Klang <i>2-4 July 2024, KSL Esplanade Hotel, Klang</i>	40 Pegawai Farmasi yang memegang jawatan strategik di fasiliti KKM <i>40 pharmacists holding strategic positions in MOH facilities</i>	Memberi pendedahan dan mempersiapkan pegawai dengan kemahiran dalam bidang kepimpinan serta penyediaan secara berkesan di tempat kerja <i>Provide insights and equip the pharmacists with leadership and effective supervisory skills in the workplace</i>	
6	Bengkel Pembangunan Training Road Map (TRM) bagi Bahagian di Ibu Pejabat Program Perkhidmatan Farmasi <i>Workshop on the Development of the Training Road Map (TRM) for Divisions at the Pharmaceutical Services Programme Headquarters</i>	7-8 Oktober 2024, PPF <i>7-8 October 2024, PSP</i>	38 Pegawai Farmasi dan 3 Penolong Pegawai Farmasi daripada 5 bahagian di ibu pejabat <i>38 pharmacists and 3 pharmacist assistant from 5 divisions at the headquarters</i>	Membangunkan modul TRM yang selaras dengan hala tuju Program/ Bahagian serta bidang tugas pegawai agar latihan yang dirancang lebih sistematik, berstruktur dan komprehensif <i>Develop a TRM module aligned with the strategic direction of the Programme/ Division and the officers' job scope, ensuring a more structured, systematic, and comprehensive training framework</i>	
7	Kursus Pemanapan Kepimpinan dan Penambahbaikan Kualiti bagi Pegawai Farmasi di KKM <i>Workshop on Leadership Enhancement and Quality Improvement for Pharmacists In the MOH</i>	1-4 Oktober 2024, Hotel Premiere, Klang <i>1-4 October 2024, Premiere Hotel, Klang</i>	37 peserta <i>37 participants</i>	<ul style="list-style-type: none"> ● Memantapkan kepimpinan serta mengenal pasti Pegawai Farmasi yang berpotensi menjadi pemimpin di Bahagian/ Pusat masing-masing ● Memperkukuh kepimpinan dalam inisiatif penambahbaikan kualiti (QIIs) dalam memastikan hasil yang dicapai selaras dengan visi, misi, dan objektif jabatan/ fasiliti/ institusi ● <i>To strengthen leadership competencies and identify Pharmacists with high potential to become future leaders within their respective Divisions/ Centres</i> ● <i>To reinforce leadership capabilities in implementing Quality Improvement Initiatives (QIIs), ensuring that the outcomes achieved are aligned with the vision, mission, and objectives of the department/ facility/ institution</i> 	

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participant</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
8	Sambutan Hari Farmasi Sedunia 2024 <i>Celebration of the World Pharmacists Day 2024</i>	25 September 2024, Marina Putrajaya <i>25 September 2024, Marina Putrajaya</i>	Timbalan Menteri Kesihatan, wakil dari KKM, Kementerian Sumber Asli dan Kelestarian Alam, industri dan persatuan farmaseutikal, farmasi komuniti, hospital swasta, ahli akademik serta pihak berkepentingan <i>Deputy Minister of Health, representatives from the MOH, the Ministry of Natural Resources and Environmental Sustainability, pharmaceutical industry and associations, community pharmacies, private hospitals, academics and stakeholders</i>	Meningkatkan kesedaran awam tentang profesion ahli farmasi serta mengiktiraf kepentingan bidang farmasi dalam perkhidmatan kesihatan <i>Raise public awareness about the pharmacist profession and recognize the importance of the pharmacy field in health services</i>	
9	Bengkel Pembangunan Kapasiti: <i>Forecasting Methods Using Artificial Intelligence Capacity Building Workshop: Forecasting Methods Using Artificial Intelligence</i>	5-7 Jun 2024, UNU-IIGH, Hospital Canselor Tuanku Muhriz UKM (HCTM), Kuala Lumpur <i>5-7 June 2024, UNU-IIGH, Chancellor Tuanku Muhriz Hospital, UKM, Kuala Lumpur</i>	Pegawai-pegawai daripada Bahagian Amalan dan Perkembangan Farmasi, Bahagian Dasar dan Perancangan Strategik Farmasi, Institut Penyelidikan Sistem Kesihatan, dan Institut Penyelidikan Klinikal (NIH) <i>Pharmacists from the Pharmacy Practice and Development division, Pharmacy Policy and Strategic Planning division, Institute for Health Systems Research, and Institute for Clinical Research (NIH)</i>	Mendedahkan peserta kepada konsep <i>machine learning</i> dan algoritma yang berkaitan untuk membina model yang bersesuaian untuk analisa data <i>Expose participants on the concepts of machine learning and relevant models and algorithms for data analysis</i>	Hasil kursus ini ialah untuk mengenalpasti model yang tepat untuk meramal kuantiti penggunaan dan perolehan ubat-ubatan secara kontrak berpusat untuk penambahbaikan sistem inventori farmasi. <i>The outcome of the workshop was to enhance the pharmacy inventory system by exploring suitable predictive models to forecast the utilisation of medicines for central contract procurements.</i>

Bil. No.	Aktiviti Activity	Tarikh/ Tempat Date/ Venue	Peserta Participant	Objektif Objective	Hasil Outcome
10	Mesyuarat Saintifik Farmasi Pediatrik Kebangsaan Ke-4 (NPPSM) 2024 <i>4th National Paediatric Pharmacy Scientific Meeting (NPPSM) 2024</i>	2-3 Oktober 2024, Pusat Konvensyen Bangi Avenue <i>2-3 October 2024, Bangi Avenue Convention Centre</i>	114 pegawai farmasi dari fasiliti KKM, institusi pengajian tinggi dan institusi swasta <i>114 pharmacists from MOH facilities, higher education institutions and private institutions</i>	Bertemakan 'The Greatest Wealth is the Health of our Children', topik-topik ceramah yang dipilih untuk edisi ini adalah memfokuskan kepada rawatan bagi penyakit endokrin dan respiratori kanak-kanak. Objektif program adalah untuk meningkatkan kompetensi dengan maklumat dan perkembangan terkini bidang farmasi pediatrik serta mempromosikan perkongsian ilmu dalam bidang farmasi pediatrik. <i>With the theme of 'The Greatest Wealth is the Health of Our Children', this program aimed to improve the competencies of pharmacists with the latest in the field of paediatric pharmacy, especially in paediatric respiratory and endocrine while at the same time promoting knowledge sharing among the participants.</i>	Ceramah yang diberikan sepanjang program dapat meningkatkan kemahiran anggota farmasi dalam perkhidmatan farmasi (pediatrik) justeru menambah kualiti perkhidmatan kepada pesakit. <i>The lectures given throughout the programme can enhance the skills of pharmacists in pharmaceutical services (pediatrics), thereby improving the quality of service to patients.</i>
11	Bengkel Pemandapan Penggunaan Aplikasi IQVIA Analysis Manager (IAM) <i>Refresher Course on IQVIA Analysis Manager (IAM) Application</i>	25 Julai 2024, Ibu Pejabat IQVIA, Damansara Utama, Selangor <i>25 July 2024, IQVIA Malaysia headquarters in Damansara Utama, Selangor</i>	10 pengguna aplikasi IAM yang terdiri daripada pegawai-pegawai daripada Cawangan Pengurusan Harga Ubat, Cawangan Pengurusan Farmasi Logistik, Cawangan Pengurusan Formulari, dan Cawangan Penjagaan Farmaseutikal <i>10 IAM users consisting of pharmacists from the Medicines Price Management Branch, Logistic Pharmacy Management Branch, Formulary Management Branch, and the Pharmaceutical Care Branch</i>	Memantap dan memperkasakan penggunaan aplikasi IAM di kalangan pegawai farmasi untuk memperoleh dan menganalisa maklumat pasaran ubat-ubatan dan produk farmaseutikal di Malaysia untuk membantu dalam kajian dan pembentukan dasar berasaskan data <i>Provide updates on the system and strengthen the use of IAM features among pharmacists to aid in acquiring and analysing information related to the sales and marketing of local medicines and pharmaceutical products in Malaysia, and consequently to drive data-driven research and policy-making</i>	Para peserta memperoleh pengetahuan dan kemahiran terkini mengenai ciri-ciri baharu sistem, membolehkan mereka menavigasi dan menggunakan fungsi IAM dengan berkesan untuk mengakses data pasaran ubat-ubatan dan produk farmaseutikal di Malaysia. <i>Participants gained updated knowledge and skills on the latest system features, enabling them to effectively navigate and utilize IAM functionalities for accessing sales and market data on local medicines and pharmaceutical products in Malaysia.</i>

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participant</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
12	Bengkel Research Framework: How to Construct Research Framework: How to Construct Workshop	2 Ogos 2024, PPF 2 August 2024, PSP	20 pegawai farmasi dari KKM 20 MOH pharmacists	<ul style="list-style-type: none"> Memberikan pemahaman mendalam tentang konsep <i>research framework</i> dan <i>Pharmacy Research Priorities in Malaysia (PRPM)</i>, seterusnya membantu peserta merangka kertas cadangan penyelidikan yang berkualiti Membangunkan kemahiran praktikal kepada peserta dalam membina dan menggunakan <i>research framework</i> bagi mengenal pasti <i>research question</i> yang relevan Merupakan platform kepada peserta untuk menerima maklum balas terhadap kerangka yang telah dihasilkan dan membuat penambahbaikan berdasarkan saranan yang diterima <i>Provide participants with an in-depth understanding of the research framework concept and the PRPM, thus assisting them in drafting high-quality research proposals.</i> <i>Develop participants' practical skills in constructing and utilising a research framework to identify relevant research questions</i> <i>Serve as a platform for participants to receive feedback on their frameworks and make improvements based on the suggestions provided</i> 	<p>Timbalan Pengarah Cawangan R&D Farmasi, bersama-sama pegawai dari cawangan yang sama, turut memberikan pandangan dan bimbingan kepada peserta mengenai <i>research framework</i> dan kertas cadangan penyelidikan yang telah dihasilkan.</p> <p><i>The Deputy Director of the Pharmacy R&D Branch, along with officers from the same branch, provided valuable insights and guidance to participants on their research frameworks and the research proposals they had developed.</i></p>

Bil. No.	Aktiviti Activity	Tarikh/ Tempat Date/ Venue	Peserta Participant	Objektif Objective	Hasil Outcome
13	<p>Mesyuarat Penilaian Pengesyoran Hala Tuju bagi Projek Quality Improvement Initiatives (QIIS) Farmasi Diiktiraf di Peringkat Kebangsaan Tahun 2023 Bil. 1/2024 dan Bil. 2/2024</p> <p><i>Mesyuarat Penilaian Pengesyoran Hala Tuju bagi Projek Quality Improvement Initiatives (QIIS) Farmasi Diiktiraf di Peringkat Kebangsaan Tahun 2023 Bil. 1/2024 dan Bil. 2/2024</i></p>	<p>Bil. 1/2024: 22-24 Januari 2024, PPF</p> <p>Bil. 2/2024: 26 Ogos 2024, Google Meet</p> <p>No. 1/2024: 22-24 January 2024, PSP</p> <p>No. 2/2024: 26 August 2024, Google Meet</p>		<ul style="list-style-type: none"> Menilai projek-projek Quality Improvement Initiatives (QIIs) farmasi yang telah menerima pengiktirafan di peringkat kebangsaan Mencadangkan pengesyoran hala tuju projek <i>Quality Improvement Initiatives (QIIs)</i> farmasi untuk diangkat kelulusan bagi menambah baik dasar/ polisi perkhidmatan farmasi Memaklumkan hasil penilaian berkaitan hala tuju projek QIIs Farmasi kepada pengurusan tertinggi di peringkat program dan negeri <i>Evaluating Pharmacy Quality Improvement Initiatives (PharmQIIs) projects that have received national-level recognition</i> <i>Recommending the direction of pharmacy QIIs projects for approval to enhance pharmacy service policies</i> <i>Informing top management at the program and state levels about the evaluation results and future direction of pharmacy QIIs projects</i> 	<p>Jumlah projek dinilai: Bil. 1/2024: 21 projek Bil. 2/2024: 1 projek <i>Total projects evaluated: No. 1/2024: 21 projects No. 2/2024: 1 project</i></p>

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participant</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
14	Seminar Perkongsian Inisiatif Kualiti Farmasi 2024 <i>Pharmacy Quality Initiatives Sharing Seminar 2024</i>	29 Oktober 2024, PPF dan Google Meet (Live) 29 October 2024, PSP and Google Meet (Live)	585 peserta <i>585 participants</i>	<ul style="list-style-type: none"> Mengembangkan projek-projek inovasi farmasi yang telah menerima pengiktirafan di peringkat kebangsaan/ antarabangsa Berkongsi amalan praktis terbaik (<i>best practice</i>) dan pengalaman kepada fasilititi farmasi KKM seluruh negara Dijadikan rujukan dalam pelaksanaan projek-projek farmasi KKM di lapangan Meningkatkan usahasama antara fasilititi farmasi KKM seluruh negara melalui kaedah replikasi sama ada diadaptasi secara terus atau diubah suai mengikut keperluan Menggalakkan seluruh anggota Farmasi KKM membudayakan kualiti <i>Expand nationally/ internationally recognized pharmacy innovation projects</i> <i>Share best practices and experiences among pharmacy facilities throughout the MOH</i> <i>Use as a reference for the implementation of pharmaceutical innovation projects in the facilities</i> <i>Enhance collaboration among MOH's Pharmacy facilities nationwide through replication methods, whether adapted directly or modified to meet specific needs</i> <i>Promote a quality culture among all members of the MOH Pharmacy</i> 	
15	Bengkel Inisiatif Penambahbaikan Kualiti (Training of Trainer): Lean Quality Improvement Initiatives (Training of Trainer): Lean Workshop	5-7 Ogos 2024, Dewan Serai Wangi, Bahagian Regulatori Farmasi Negara 5-7 August 2024, Dewan Serai Wangi, National Pharmaceutical Regulatory Agency	30 peserta <i>30 participants</i>	<ul style="list-style-type: none"> Memberi pendedahan dan pengetahuan mengenai Lean bagi tujuan meningkatkan kualiti perkhidmatan Memperkukuh pelaksanaan dan pemantauan projek Lean Menghasilkan pelatih/ fasilitator lean sebagai pakar rujuk <i>Provide exposure and knowledge on Lean concept to improve service quality</i> <i>Strengthen the implementation and monitoring of Lean projects</i> <i>Produce Lean trainers/ facilitators as reference experts</i> 	

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participant</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
16	Bengkel Pendaftaran dan Kepentingan Perlindungan Hakcipta <i>Registration and the Importance of Copyright Protection Workshop</i>	15 Oktober 2024, Akademi Harta Intelek (IPA), Menara MyIPO, Selangor <i>15 October 2024, Intellectual Property Academy (IPA), Menara MyIPO, Selangor</i>	8 peserta <i>8 participants</i>	<ul style="list-style-type: none"> • Memberi pendedahan mengenai operasi, prosedur, perundangan dan lain-lain • Memfokuskan kepada hak-hak pencipta, pemilik dan pengguna karya berhak cipta dan penguatkuasaan ke atas isu pelanggaran • Mewujudkan ruang perkongsian maklumat berkaitan perkembangan semasa persekitaran hak cipta di Malaysia dan dunia • <i>Provide exposure to operations, procedures, legislation, and other relevant aspects</i> • <i>Focus on the rights of creators, owners, and users of copyrighted works, as well as enforcement on infringement issues</i> • <i>Create a platform for sharing information on current developments in the copyright landscape in Malaysia and globally</i> 	
17	Penceramah dan Fasilitator bagi Bengkel Penulisan Manuskrip Projek Kualiti Farmasi JKWP/KLP 2024 <i>Speakers and Facilitators for the JKWP/KLP Pharmacy Quality Project Manuscript Writing Workshop 2024</i>	6-7 November 2024, Hospital Rehabilitasi Cheras, Kuala Lumpur <i>6-7 November 2024, Cheras Rehabilitation Hospital, Kuala Lumpur</i>	14 peserta <i>14 participants</i>	<ul style="list-style-type: none"> • Melatih kemahiran penulis untuk menyediakan manuskrip inisiatif penambahbaikan kualiti mengikut format dan standard penerbitan jurnal secara <i>peer-review</i> • Menggalakkan inovator/ ahli kumpulan untuk menulis laporan saintifik (<i>scientific report</i>) bagi berkongsi amalan praktis terbaik (<i>best practice</i>) dan pengalaman melaksanakan QIIs • <i>Provide Training authors to prepare manuscripts for quality improvement initiatives according to journal publication format and peer-review standards</i> • <i>Encourage innovators/ team members to write scientific reports to share best practices and experiences in implementing QIIs</i> 	

Bil. No.	Aktiviti <i>Activity</i>	Tarikh/ Tempat <i>Date/ Venue</i>	Peserta <i>Participants</i>	Objektif <i>Objective</i>	Hasil <i>Outcome</i>
18	Kursus Profesionalisme Diri Unggul Kumpulan Pelaksana Program Perkhidmatan Farmasi <i>Kursus Profesionalisme Diri Unggul Kumpulan Pelaksana Program Perkhidmatan Farmasi</i>	2-4 Ogos 2024, Swan Garden Resort Hotel, Melaka <i>2-4 August 2024, Swan Garden Resort Hotel, Malacca</i>	48 peserta <i>48 participants</i>	<ul style="list-style-type: none"> ● Mengaplikasikan cara bekerja yang lebih baik untuk meningkatkan hasil kerja berkualiti ● Mengaplikasikan tugas secara profesional, beretika dan berintegriti dalam pasukan dan organisasi ● Menambah nilai yang positif dalam mengurus emosi untuk meningkatkan tahap profesionalisme diri yang unggul ● <i>Apply better working methods to improve quality work outcomes</i> ● <i>Apply tasks professionally, ethically and with integrity within the team and the organization</i> ● <i>Add positive value in managing emotions to increase the level of superior self-professionalism</i> 	



3.0 PENCAPAIAN DAN PENGIKTIRAFAN | ACHIEVEMENT AND RECOGNITION

PENGURUSAN ISO | ISO MANAGEMENT

Pelaksanaan Sistem Pengurusan Kualiti MS ISO 9001:2015

Implementation of MS ISO 9001: 2015 Quality Management System



CERTIFIED TO ISO 9001:2015
CERT. NO. : QMS 01408

PPF telah mendapat pensijilan Sistem Pengurusan Kualiti MS ISO 9001:2015 sejak tahun 2018. Pelbagai aktiviti telah dilaksanakan dan diselarasakan oleh Jawatankuasa Kerja ISO PPF IPKKM sepanjang tahun 2024.

Pada 28 dan 29 Februari 2024, audit pemantauan MS ISO 9001:2015 PPF telah dilaksanakan oleh pihak SIRIM QAS Sdn. Bhd. secara fizikal. Barisan juruaudit terdiri daripada Puan Kho Yeck Lan dan Encik Izzat Izwan bin Othman. Secara keseluruhan, PPF telah melaksanakan Sistem Pengurusan Kualiti (SPK) mengikut keperluan standard MS ISO 9001:2015, serta mampu mencapai sasaran yang dirancang. Hasil audit pemantauan juga mendapati tiada ketidakakuran.

The PSP has been certified with MS ISO 9001: 2015 Quality Management System since 2018. Various activities have been implemented and coordinated by the ISO Working Committee of the Pharmaceutical Services Program Headquarters throughout year 2024.

The PSP has engaged in recertification audit of MS ISO 9001:2015 with SIRIM QAS Sdn Bhd on February 28 and 29, 2024. The auditors involved were Mrs. Kho Yeck Lan dan Mr. Izzat Izwan bin Othman. The PSP has carried out the Quality Management System based on the MS ISO 9001:2015 standard and been able to achieve planned objectives. Surveillance audits show no findings for non-conformity reports (NCR).



Audit pemantauan MS ISO 9001:2015 PPF IPKKM
PSP, MOH HQ MS ISO 9001:2015 Monitoring Audit

Penggabungan Skop Pensijilan MS ISO 9001:2015 Program Perkhidmatan Farmasi dan Bahagian Regulatori Farmasi Negara

Merging the Scope of MS ISO 9001:2015 Certification of the Pharmaceutical Services Programme and the National Pharmaceutical Regulatory Agency

Pada 22 Februari 2024, Mesyuarat Polisi PPF Bil. 1/2024 telah memutuskan penggabungan skop pensijilan MS ISO 9001:2015 bagi PPF dan NPRA untuk menyelaraskan sistem pengurusan kualiti di kedua-dua bahagian.

Susulan keputusan tersebut, beberapa aktiviti penggabungan telah dijalankan, termasuk sesi perbincangan oleh urus setia, pelantikan Jawatankuasa ISO PPF bagi tahun 2024-2025, penyesuaian dan perubahan prosedur kualiti, penyelarasan skop dan dasar kualiti, serta sesi taklimat berkala kepada semua anggota. Usaha ini bertujuan memperkemaskan operasi serta meningkatkan keberkesanan perkhidmatan farmasi secara keseluruhan. Penggabungan ini dijangka dapat memperkukuh sistem pengurusan kualiti, menyelaraskan pelaksanaan proses kerja, serta meningkatkan kecekapan penyampaian perkhidmatan kepada pelanggan.

On 22 February 2024, the PSP Policy Meeting No. 1/2024 decided to merge the MS ISO 9001:2015 certification scope of the PSP and NPRA to streamline the quality management system in both divisions.

Following this decision, several integration activities have been carried out, including discussions by the secretariat, the appointment of the PSP ISO Committee for 2024-2025, adaptation and modification of quality procedures, alignment of scope and quality policy, as well as periodic briefing sessions for all staff. This effort aims to enhance operational efficiency and improve the overall effectiveness of pharmacy services. This integration is expected to strengthen the quality management system, standardize the implementation of work processes, and improve service delivery efficiency for customers.



DASAR KUALITI

Program Perkhidmatan Farmasi KKM komited memberi perkhidmatan yang berkualiti ke arah meningkatkan kesihatan rakyat berdasarkan keperluan undang-undang dan keperluan MS ISO 9001 bagi;

1. Memenuhi keperluan dan jangkaan pelanggan dan pihak berkepentingan
2. Usaha penambahbaikan kualiti secara berterusan
3. Pewujudan sistem kawal selia yang cekap, telus dan berwibawa
4. Kebolehcapaian kepada produk dan perkhidmatan farmaseutikal yang berkualiti*
5. Mengurus sumber secara cekap dan optimum
6. Melaksanakan pengurusan tenaga yang berkesan dan mampan

Perubahan kenyataan Dasar Kualiti di atas telah diluluskan dalam Mesyuarat Kajian Semula Pengurusan (MKSP) Bil.1/2024 pada 25 April 2024. Hebahan kenyataan Dasar Kualiti ini telah dilaksanakan melalui memo dengan rujukan KKM.100-14/1/34 Jld 5 (51) bertarikh 22 Ogos 2024.

JKK Latihan & Promosi ISO

Hebahan Dasar Kualiti yang baru
Announcement of new Quality Policy

4.0 PENERBITAN DAN KAJIAN | PUBLICATION AND RESEARCH

KEUTAMAAN PENYELIDIKAN FARMASI DI MALAYSIA (EDISI KEDUA)


Dokumen Keutamaan Penyelidikan Farmasi di Malaysia (PRPM) diterbitkan untuk memberi panduan kepada aktiviti penyelidikan farmasi ke arah penjana bukti yang relevan dengan keutamaan kesihatan negara. Penetapan bidang-bidang keutamaan bagi penyelidikan farmasi adalah amat penting untuk penyelarasan aktiviti penyelidikan, merapatkan jurang pengetahuan, memaksimumkan penggunaan sumber dan menyokong pembangunan polisi kesihatan yang baru. Dokumen PRPM Edisi Kedua telah diterbitkan pada April 2024 dan dilancarkan oleh Menteri Kesihatan pada 16 Ogos 2024 sempena majlis perasmian Persidangan R&D Farmasi Kebangsaan ke-12 2024 di Hotel KSL Esplanade, Selangor. Sebanyak lapan domain keutamaan penyelidikan telah dikenal pasti dalam dokumen PRPM Edisi Kedua, iaitu:

1. *Medicine Development*
2. *Access to Medicines*
3. *Impact of Pharmacotherapy Optimisation*
4. *Impact of pharmacy Services*
5. *Medicine Consumerism*
6. *Digital-in-health*
7. *Governance*
8. *Capacity and Capability Building*


PHARMACY RESEARCH PRIORITIES IN MALAYSIA (SECOND EDITION)

The Pharmacy Research Priorities in Malaysia (PRPM) aims to provide guidance to pharmacy research activities towards the generation of evidence relevant to the national health priorities. The setting of priority areas for pharmacy research is crucial for the coordination of research activities, bridging the knowledge gaps, maximising the resources and supporting the development of new health policies. The second edition of PRPM was published in April 2024 and was officially launched by the Minister of Health on 16 August 2024 during the Opening Ceremony of the 12th National Pharmacy R&D Conference 2024 at KSL Esplanade Hotel, Selangor. Eight research priority domains have been identified in the Second Edition of PRPM, namely:

1. *Medicine Development*
2. *Access to Medicines*
3. *Impact of Pharmacotherapy Optimisation*
4. *Impact of Pharmacy Services*
5. *Medicine Consumerism*
6. *Digital-in-health*
7. *Governance*
8. *Capacity and Capability Building*



Penerbitan PRPM (Edisi Kedua) dan pelancarannya sempena majlis perasmian
 Persidangan R&D Farmasi Kebangsaan ke-12 2024
*Publication of the PRPM (Second Edition) and its official launch during the opening
 ceremony of the 12th National Pharmacy R&D Conference 2024*



Statistik Penggunaan Ubat di Malaysia 2018-2022
Malaysian Statistics on Medicines 2018-2022

STATISTIK PENGGUNAAN UBAT DI MALAYSIA 2018-2022


Laporan Statistik Penggunaan Ubat di Malaysia (MSOM) 2018-2022 telah berjaya diterbitkan pada November 2024. Laporan ini menyediakan maklumat mengenai jumlah dan corak penggunaan ubat-ubatan di Malaysia bagi menyokong pemantauan pelaksanaan DUNas.

Projek MSOM merupakan usaha berskala nasional yang melibatkan pengumpulan data daripada pelbagai sumber dan memerlukan kerjasama pelbagai pihak. Laporan ini mula diterbitkan pada tahun 2006 dengan nama *National Medicines Use Survey (NMUS)* yang menggunakan kaedah tinjauan dalam mengumpul data. Sejak itu, metodologi pengumpulan data telah ditambah baik untuk menghasilkan laporan yang lebih tepat dan menyeluruh. Dalam laporan MSOM 2018-2022 yang terkini, kaedah pengumpulan serta penyemakan data telah diperbaharui melalui kerjasama dengan entiti swasta bagi meningkatkan ketepatan maklumat.

MALAYSIAN STATISTICS ON MEDICINES 2018-2022

Malaysian Statistics on Medicines (MSOM) 2018-2022 report was successfully published in November 2024. This report provides information on the total medicine used in the country as well as the pattern and trends of utilisation in Malaysia to support the monitoring and implementation of DUNas.

The MSOM project is a nationwide initiative that involves data collection from various sources and requires collaboration from multiple stakeholders. The report was first published in 2006 under the name National Medicines Use Survey (NMUS), utilizing survey methods for data collection. Since then, data collection methodologies have been continuously improved to enhance the accuracy and comprehensiveness of the report. In the latest MSOM 2018-2022 report, data collection and verification methods have been further refined by means of a smart partnership with a private entity.



Towards Covid-19 Endemic in Malaysia: The Journey Continues
Towards Covid-19 Endemic in Malaysia: The Journey Continues Report

TOWARDS COVID-19 ENDEMIC IN MALAYSIA: THE JOURNEY CONTINUES REPORT

Program Imunisasi COVID-19 Kebangsaan (PICK) dilancarkan pada awal tahun 2021 berikutan kelulusan regulatori bagi vaksin COVID-19. Usaha ini merupakan langkah penting dan bertujuan untuk memvaksinkan seluruh rakyat dan mempercepatkan peralihan Malaysia ke status endemik COVID-19. Sebagai salah satu komponen penting dalam sistem penjagaan kesihatan negara, anggota farmasi meneruskan kerjasama dengan profesional kesihatan lain untuk menjayakan program PICK. Laporan khas ini telah diterbitkan pada Julai 2024 untuk mendokumentasikan aktiviti, peranan dan sumbangan anggota farmasi KKM dalam pelaksanaan dan kejayaan program PICK, sama ada di barisan hadapan atau di belakang tabir.

TOWARDS COVID-19 ENDEMIC IN MALAYSIA: THE JOURNEY CONTINUES REPORT

Following the regulatory approval of the COVID-19 vaccines, the National COVID-19 Immunisation Programme (Program Imunisasi COVID-19 Kebangsaan - PICK) was launched in early 2021. This monumental effort aimed to vaccinate the entire population and accelerate Malaysia's transition to an endemic phase of COVID-19. As an integral part of the healthcare system, pharmacy personnel collaborated closely with other healthcare professional to ensure the success of the PICK programme. This special report, published in July 2024, documented the activities, roles and contributions of MOH pharmacy personnel in the implementation and success of the PICK programme, either at the front lines or behind the scenes.

PENERBITAN PENYELIDIKAN OLEH PEGAWAI FARMASI PADA TAHUN 2024

RESEARCH PUBLICATIONS BY PHARMACISTS IN YEAR 2024

Pada tahun 2024, Pegawai Farmasi KKM dari seluruh negara berjaya menerbitkan sebanyak 117 artikel penyelidikan di jurnal tempatan dan antarabangsa. Selain itu, sasaran penerbitan dan pembentangan penyelidikan oleh PPF turut berjaya dicapai, dengan tujuh artikel penyelidikan dan laporan teknikal berjaya diterbitkan serta 11 pembentangan telah dibentangkan sepanjang tahun tersebut.

In 2024, pharmacists from the MOH across the country successfully published a total of 117 research articles in local and international journals. Additionally, the publication and presentation targets set by the PSP were achieved, with seven research articles and technical reports published, as well as 11 presentations delivered throughout the year.

Penerbitan artikel penyelidikan dan laporan teknikal yang dihasilkan oleh pegawai dari Ibu Pejabat PPF
The publication of research articles and technical reports published by officers from the PSP Headquarters

Bil. No.	Institusi Institution	Laporan artikel Report Title	Maklumat penerbitan Publication Information	Pengarang Authors
1.	BDPSF & NPRA	<i>Determining the Willingness to Pay for Innovative Oncology Medicines in Malaysia</i>	<i>Dzulkipli, M. R., Shafie, A. A., Maon, S. N., Ramli, A., Yahaya, A. H. M., Ho, S. W., Muhsin, N. I. A., & Ahmat, A. N. M. F. (2024). Determining the Willingness to Pay for Innovative Oncology Medicines in Malaysia. Value in Health Regional Issues, 40, 19-26</i>	Mohd Redhuan Dzulkipli, Asrul Akmal Shafie, Siti Noorsuriani Maon, Azuana Ramli, Abdul Haniff Mohamad Yahaya, Ho See Wan, Nor Ilham Ainaa Mushin, Azmi Nor Mohd Fareez Ahmat

Bil. No.	Institusi Institution	Laporan artikel Report Title	Maklumat penerbitan Publication Information	Pengarang Authors
2.	BDPSF & ICR	<i>A comparison between antibiotic utilization in public and private community healthcare in Malaysia</i>	<i>Lim, A. H., Ab Rahman, N., Nasarudin, S. N. S., Velvanathan, T., Fong, M. C. C., Mohamad Yahaya, A. H., & Sivasampu, S. (2024). A comparison between antibiotic utilisation in public and private community healthcare in Malaysia. BMC Public Health, 24(1), 79</i>	Audrey Lim Huili, Norazida Ab Rahman, Siti Nur Su'aidah Nasarudin, Tineshwaran Velvanathan, Mary Chok Chiew Fong, Abdul Haniff Mohamad Yahaya, Sheamini Sivasampu
3.	BDPSF	<i>Investigating pharmacists views on implementing pharmacy research priorities in Malaysia Insights from FGD</i>	<i>Muhsin, N.I.A., Ho, S. W., Nordin, N., Chan, P. L., Mohamad Yahaya, A. H. (2024). Investigating pharmacists views on implementing pharmacy research priorities in Malaysia Insights from FGD. Pharmacy Research Report, Vol. 7(1), 10-16.</i>	Nur Ilham Ainaa Muhsin, Ho See Wan, Noraini Nordin, Chan Pui Lim, Abdul Haniff Mohamad Yahaya
4.	BDPSF & ICR	<i>Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018-2022</i>	<i>Ab Rahman, N., Low, E. V., Lim, A. H., Ahmad Shanizza, A. I., Ho, S. W., Kamal, M., Mohamad Yahaya, A. H., & Sivasampu, S. (2024). Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018-2022. Journal of Pharmaceutical Policy and Practice, 17(1), 2401468</i>	Norazida Ab Rahman, Low Ee Vien, Audrey Lim Huili, Azzy Ilyzati Ahmad Shanizza, Ho See Wan, Mardhiyah Kamal, Abdul Haniff Mohamad Yahaya, Sheamini Sivasampu
5.	BDPSF	<i>Malaysian Statistic on Medicines (MSOM) 2018-2022</i>	<i>Technical Report: Pharmaceutical Services Programme, Ministry of Health Malaysia. (2024). Malaysian Statistic on Medicines (MSOM) 2018 - 2022</i>	Norhaliza A Halim, Siti Aisah Bahari, Abdul Haniff Mohamad Yahaya, Mohd Azli Fakri Abdul Aziz, Azzy Ilyzaty Ahmad Shanizza, Nur Fasihah Ashari, Siti Nur Su'aidah Nasarudin, Mary Chok Chiew Fong
6.	BAPF	<i>Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia - a multiple HTA approach</i>	<i>Choo, C. S. B., Yong, Y. V., Chandriah, H., & Ahmad, N. S. (2024). Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia - a multiple HTA approach. International Journal of Technology Assessment in Health Care, 40(1), e69</i>	Coleen Choo Siew Bee, Yong Yee Vern, Haarathi Chandriah, Nur Sufiza Ahmad
7.	BAPF	<i>Medicine Prices Monitoring Survey in Malaysia 2022</i>	<i>Technical Report: Pharmaceutical Services Programme, Ministry of Health Malaysia. (2024). Medicine Prices Monitoring Survey in Malaysia 2022</i>	Norhaliza A Halim, Wan Noraimi Wan Ibrahim, Fatkhiah Khalil, Saliza Ibrahim, Wan Nor Ashikin Wan Ibrahim, Nurul Hanani Mohamad Nordin, Akrimi Najihah Mohd Khamil, Nurliyana Najwa Md Razip

Senarai pembentangan yang telah dibentangkan oleh Pegawai di Ibu Pejabat PPF

The list of presentations presented by officers from the PSP Headquarters

Bil. No.	Tajuk Pembentangan <i>Title of Presentation</i>	Nama Persidangan, Lokasi & Tarikh <i>Conference Name, Location & Date</i>	Nama Pembentang <i>Presenter's Name</i>
1.	<i>Prevalence and Determinants of Unregistered and Falsified Medicinal Products in Malaysia: A Cross-Sectional Study</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Khairul Annuar Abdul Karim, BPF
2.	<i>Insights into Diphenhydramine Cough Syrup Supply in Malaysian Private Healthcare: Compliance and Offences 2020-2022</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Wong Hui Shean, BPF
3.	<i>Retrospective Study of Illegal Medicines Advertisements in Local E-Marketplace Platforms</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Yap Fei Ting, BPF
4.	<i>A Cross-Sectional Study on Non-compliance to Pharmacy Legislations among Retail Pharmacies in Malaysia</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Fauziah Mohamad Ismail, BPF
5.	<i>Pharmacist's Perspectives on Access to New Medicines Listed in the Ministry of Health Medicines Formulary (MOHMF): A Qualitative Study</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Azlina Ismail, BAPF
6.	<i>An Overview Medicines Pooled Procurement in The Public Sector: How Much We Save?</i>	<i>National Pharmacy R&D Conference 2024</i> KSL Esplanade Hotel, Selangor 19-21 Ogos 2024	Saliza Ibrahim, BAPF
7.	<i>Determining the cost elements for reimbursement of pharmaceutical services provided by community pharmacies: A scoping review</i>	<i>1st Journal of Pharmaceutical Policy and Practice – Borneo International Pharmaceutical Conference</i> Borneo Cultures Museum, Sarawak 20-22 September 2024	Nor Ilham Ainaa Muhsin, BDPSF
8.	<i>A Longitudinal Study on the Factors Associated with the Number of Research Publications among Pharmacists in the Ministry of Health Malaysia</i>	<i>1st Journal of Pharmaceutical Policy and Practice – Borneo International Pharmaceutical Conference</i> Borneo Cultures Museum, Sarawak 20-22 September 2024	Tan Yi Huan, BDPSF
9.	<i>Identifying Key Research Gaps in Malaysian Pharmaceutical Services: A Qualitative Thematic Analysis of Stakeholder Insights</i>	<i>1st Journal of Pharmaceutical Policy and Practice – Borneo International Pharmaceutical Conference</i> Borneo Cultures Museum, Sarawak 20-22 September 2024	Ho See Wan, BDPSF
10.	<i>Evaluating the Belt Conveyor Utilization Policy on Waiting Time and Productivity in Outpatient Pharmacies</i>	<i>1st Journal of Pharmaceutical Policy and Practice – Borneo International Pharmaceutical Conference</i> Borneo Cultures Museum, Sarawak 20-22 September 2024	Siti Nur Su'aidah Nasarudin, BDPSF
11.	<i>Impact of Live Data Registry on Diabetes Medication Therapy Adherence Clinic Services in MOH Facilities</i>	<i>Diabetes Asia 2024 Conference</i> Royale Chulan Kuala Lumpur 17-19 October 2024	Nurish Ezzantie Mishan, BAPF

5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA INTERNATIONAL COLLABORATION AND PARTICIPATION

MESYUARAT ASEAN MENGENAI ASEAN VACCINE SECURITY AND SELF-RELIANCE (AVSSR): MEMPERKUKUH KESELAMATAN VAKSIN MELALUI KOLABORASI DAN PEMBENTUKAN JAWATANKUASA PEMANDU AVSSR

Mesyuarat ini merupakan kesinambungan daripada Mesyuarat ASEAN Consultative Meeting on AVSSR tahun lalu. Mesyuarat yang diadakan pada 25 September 2024 di Bangkok, Thailand ini telah membincangkan dengan lebih mendalam dan terperinci mengenai pembentukan Jawatankuasa Pemandu AVSSR (AVSSR Steering Committee) dan tadbir urus berkaitan.

Mesyuarat ini telah dihadiri bersama oleh wakil dari PPF dan Pejabat Projek Vaksin Malaysia (MVPO), Kementerian Sains, Teknologi dan Inovasi (MOSTI). Wakil MVPO telah membentangkan bagi pihak *Malaysia Advancing Vaccine Security in ASEAN: Strategies, Capabilities, and Challenges in Malaysia* manakala wakil PPF telah diberi mandat untuk menjadi Pengerusi Bersama Session 2 and 3: *Advancing Vaccine Security in ASEAN: Strategies, Capabilities, and Challenges*.

Antara faedah yang diperolehi daripada mesyuarat ini adalah kita dapat mengetahui jurang dan kekuatan negara ASEAN bagi membantu dalam pembangunan vaksin negara. Di samping itu, ianya juga menjadi platform jalinan jaringan dengan agensi luar negara bagi memberi peluang belajar dan berkongsi pengalaman untuk menghasilkan vaksin dan perkara berkaitan.



Perwakilan daripada Malaysia bersama wakil-wakil antarabangsa
Representative from Malaysia together with international representatives

ASEAN MEETING ON THE ASEAN VACCINE SECURITY AND SELF-RELIANCE (AVSSR): STRENGTHENING VACCINE SECURITY THROUGH COLLABORATION AND ESTABLISHING THE AVSSR STEERING COMMITTEE

This meeting is a continuation of the ASEAN Consultative Meeting on AVSSR last year. The meeting held on 25 September 2024 in Bangkok, Thailand discussed the establishment and governance of the AVSSR Steering Committee. It also served as a platform for information sharing between ASEAN regional countries with regards to vaccines related issues.

This meeting was attended by the representatives from the PSP and the Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology and Innovation (MOSTI). MVPO presented on Malaysia Advancing Vaccine Security in ASEAN: Strategies, Capabilities, and Challenges in Malaysia while the PSP has been mandated to be the co-Chair of Session 2 and 3: Advancing Vaccine Security in ASEAN: Strategies, Capabilities, and Challenges.

Among the benefits obtained from this meeting is that we were able to identify the gaps and strengths of ASEAN countries to help in the development of national vaccines. In addition, it is also a networking platform with foreign agencies to provide opportunities to learn and share experience to produce vaccines and related matters.



LATIHAN AVSSR: PROGRAM PEMBANGUNAN SUMBER MANUSIA VAKSIN UNTUK MENINGKATKAN KAPASITI PEMBANGUNAN DAN PENYEBARAN VAKSIN DI NEGARA-NEGARA ASEAN

AVSSR TRAINING: VACCINE HUMAN RESOURCES DEVELOPMENT PROGRAMME FOR ENHANCING VACCINE DEVELOPMENT AND DEPLOYMENT CAPACITIES IN ASEAN COUNTRIES

Latihan ini telah dianjurkan bersama oleh *National Vaccine Institute (NVI)* Thailand dengan kerjasama *International Vaccine Institute (IVI)*, *World Bank*, dan Sekretariat ASEAN pada 26 hingga 27 September 2024 di Bangkok Thailand. Ianya bertujuan untuk memperkukuhkan keupayaan negara-negara ASEAN melalui perkongsian pengetahuan mengenai pemindahan teknologi dan amalan terbaik, menganalisis cabaran regulatori untuk memastikan akses yang saksama, memahami penolakan terhadap vaksin dan keyakinan rakyat serta membina kerjasama dan kolaborasi yang mapan antara negara ASEAN.

Latihan ini telah dihadiri oleh wakil daripada PPF, NPRA dan 2 wakil industri farmaseutikal Malaysia. Ianya terdiri daripada kuliah, kajian kes praktikal, dan aktiviti interaktif yang menengahkan topik-topik merangkumi pemindahan teknologi vaksin, daripada proses pembangunan sehingga implikasi perniagaan dan undang-undang; amalan regulatori global, termasuk pengalaman daripada inisiatif perolehan pukal vaksin; komunikasi risiko; dan koordinasi sekuriti kesihatan global. Penceramah dan pemudah cara sesi-sesi ini adalah penceramah daripada IVI dan NVI serta pengeluar vaksin utama di rantau ini seperti PT Bio Farma dan SK Bioscience; gabungan global seperti *CEPI-hosted Regionalized Vaccine Manufacturing Collaborative*; agensi kerajaan termasuk *Korea Disease Control and Prevention Agency*, dan *Duke-NUS Centre of Regulatory Excellence*.

Latihan selama dua hari ini memberikan peluang unik kepada peserta untuk belajar daripada pakar-pakar terkemuka, memupuk dan memperkukuhkan kerjasama sedia ada, yang seterusnya akan membantu memastikan kelestarian pembangunan dan penggunaan vaksin di rantau ASEAN.

This training was jointly organized by the National Vaccine Institute (NVI) Thailand in collaboration with the International Vaccine Institute (IVI), the World Bank, and the ASEAN Secretariat from 26 to 27 September 2024 in Bangkok, Thailand. It aimed to strengthen the capacity of ASEAN countries through knowledge sharing on technology transfer and best practices, analyze regulatory challenges to ensure equitable access, understand vaccine hesitancy and public confidence, and build sustainable cooperation and collaboration among ASEAN countries.

The training consists of lectures, practical case studies, and interactive activities highlighting topics across vaccine technology transfer, from process development to business and legal implications; global regulatory practices, including experiences from pooled procurement initiatives; risk communication; and global health security coordination. Facilitating these sessions are speakers from IVI and NVI as well as key vaccine manufacturers in the region such as PT Bio Farma and SK bioscience; global coalitions such as the CEPI-hosted Regionalized Vaccine Manufacturing Collaborative; government agencies including the Korea Disease Control and Prevention Agency, and the Duke-NUS Centre of Regulatory Excellence.

This two-day training offers participants a unique opportunity to learn from leading experts, fostering future collaboration while strengthening existing partnerships, which will help ensure the sustainability of vaccine development and deployment in the ASEAN region.



Program Pembangunan Sumber Manusia Vaksin untuk Meningkatkan Kapasiti
Pembangunan dan Penyebaran Vaksin di Negara-negara ASEAN
*Vaccine Human Resource Development Program for Enhancing Vaccine
Development and Deployment Capacities in ASEAN Countries*



BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI

***PHARMACY PRACTICE AND
DEVELOPMENT DIVISION***


**BILANGAN PERKHIDMATAN FARMASI
PENILAIAN UBAT-UBATAN DI RUMAH**

 NUMBER OF HOME MEDICATION
REVIEW (HMR)

15,428
3,108,390
**BILANGAN PRESKRIPSI SUSULAN YANG
DIDISPENS MELALUI PERKHIDMATAN NILAI
TAMBAH FARMASI**

 NUMBERS OF FOLLOW-UP PRESCRIPTIONS
DISPENSED THROUGH VALUE-ADDED SERVICES

2,095,863
**BILANGAN KAUNSELING
UBAT-UBATAN YANG
DIJALANKAN**

 NUMBER OF MEDICATION
COUNSELLING SESSIONS
CONDUCTED

317,737
**BILANGAN PHARMACOTHERAPY REVIEW YANG
DIJALANKAN BAGI PERKHIDMATAN KLINIK KEPATUHAN
TERHADAP UBAT-UBATAN**

 NUMBER OF PHARMACOTHERAPY REVIEW CONDUCTED IN
MEDICATION THERAPY ADHERENCE CLINIC (MTAC) SERVICES

227
**BILANGAN SESI
WAWANCARA TV
DAN RADIO**

 NUMBER OF TV AND RADIO
INTERVIEW SESSIONS

55
**BILANGAN
ARTIKEL
KESIHATAN**

 NUMBER OF HEALTH
ARTICLES

56
**BILANGAN
INFOGRAFIK
KESIHATAN**

 NUMBER OF HEALTH
INFOGRAPHICS

1,001,585
BILANGAN INTERVENSI PRESKRIPSI PESAKIT LUAR

 NUMBERS OF INTERVENTIONS OF OUT-PATIENT
PRESCRIPTIONS

754,697
BILANGAN INTERVENSI PRESKRIPSI PESAKIT DALAM

 NUMBERS OF INTERVENTIONS OF IN-PATIENT
PRESCRIPTIONS

61,7955,746
BILANGAN PRESKRIPSI PESAKIT LUAR DITERIMA

NUMBER OF OUTPATIENT PRESCRIPTIONS RECEIVED


14,670,664
BILANGAN PRESKRIPSI PESAKIT DALAM DITERIMA

NUMBER OF INPATIENT PRESCRIPTIONS RECEIVED


RM3,455.40 JUTA
PEROLEHAN UBAT-UBATAN KKM (RM)

MOH MEDICINES PROCURED (RM)

RM1,368.80 JUTA
PEROLEHAN BUKAN UBAT KKM (RM)

MOH NON-MEDICINES PROCURED (RM)

16

 entiti kimia baru
new chemical entities

**PENYENARAIAH UBAT BARU KE
DALAM FORMULARI UBAT KKM**

 NEW MEDICINES LISTED
IN THE MOH MEDICINE FORMULARY

RM241.18 JUTA

Fasiliti KKM MOH Facilities

RM269.34 JUTA

 Fasiliti Bukan KKM / Institusi Swasta
Non-MOH Facilities / Private Institution

**KOS PERMOHONAN UBAT
KELULUSAN KHAS YANG
DILULUSKAN**

 COST OF APPROVED
APPLICATIONS FOR
SPECIAL APPROVAL
MEDICINES

26,353
PROGRAM KENALI UBAT ANDA

 KNOW YOUR MEDICINES
PROGRAMME

2,300
**BILANGAN DUTA
KENALI UBAT ANDA**

 NUMBER OF 'KNOW YOUR
MEDICINES' AMBASSADOR

236,382
**BILANGAN
PERTANYAAN UBAT**

 NUMBERS OF DRUG
INFORMATION ENQUIRIES




BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI **PHARMACY PRACTICE AND DEVELOPMENT DIVISION**

1.0 PENGENALAN | INTRODUCTION

Bahagian Amalan dan Perkembangan Farmasi (BAPF) bertanggungjawab memastikan keperolehan dan kepenggunaan ubat-ubatan yang berkualiti melalui amalan farmasi yang berkesan bagi mempertingkatkan Perkhidmatan Farmasi di Malaysia supaya setanding dengan kemajuan perkembangan perkhidmatan farmasi di negara-negara maju. Lima cawangan telah ditubuhkan di bawah pengawasan BAPF, iaitu Penjagaan Farmaseutikal, Pengurusan Harga Ubat, Pengurusan Farmasi Logistik, Pengurusan Ubat Berkualiti dan Pengurusan Formulari.

The Pharmacy Practice and Development Division (BAPF) is responsible for ensuring the quality of drug procurement and usage through effective pharmacy practice in order to improve pharmacy services in Malaysia to be on par with other developed countries. Five branches under the management of BAPF are Pharmaceutical Care, Medicine Pricing Management, Logistic Pharmacy Management, Quality Use of Medicines, and Formulary Management.

Berikut merupakan fungsi utama bagi cawangan dan seksyen di bawah Bahagian A&P Farmasi:

Below are the main functions of branches and section under Pharmacy Practice and Development Division:

CAWANGAN PENGURUSAN FARMASI LOGISTIK
LOGISTIC PHARMACY
MANAGEMENT BRANCH

Menyelaras dan memantau keperluan dan perbelanjaan peruntukan, kontrak, pembekalan ubat-ubatan, aktiviti kesiapsiagaan dan pengurusan stor di fasiliti KKM dengan memastikan pekeliling, tatacara serta peraturan berkuat kuasa dipatuhi.

Coordinate and monitor allocation requirements and expenses, contracts, medicine supply, preparedness activities and store management at MOH facilities by ensuring that circulars, procedures and regulations in force are complied with.

CAWANGAN PENJAGAAN FARMASEUTIKAL
PHARMACEUTICAL CARE
BRANCH

Merancang, menyelaras, memantau dan memperkasakan aktiviti amalan penjagaan farmaseutikal yang menyeluruh di fasiliti KKM bagi memastikan penggunaan ubat-ubat secara optimum agar dapat meningkatkan kualiti penyampaian perkhidmatan kepada pesakit.

Plan, coordinate, monitor and empower comprehensive pharmaceutical care practice activities at MOH facilities to ensure the optimal use of medicines in order to improve the quality of service delivery to patients.

CAWANGAN PENGURUSAN FORMULARI
FORMULARY MANAGEMENT
BRANCH

Merancang polisi dan pelan tindakan berkaitan Formulari Ubat Kementerian Kesihatan Malaysia (FUKKM) dan Ubat Kelulusan Khas (UKK) dalam usaha untuk meningkatkan akses terhadap ubat-ubatan bagi rakyat Malaysia.

Plan policies and action plans related to the Ministry of Health Medicines Formulary (MOHMF) and Special Approval Medicines (SAM) in an effort to increase access to medicines for Malaysians.

CAWANGAN PENGGUNAAN UBAT BERKUALITI
QUALITY USE OF MEDICINES
BRANCH

Memberikan pendidikan kepada orang awam berkaitan penggunaan ubat secara berkualiti serta memastikan kesinambungan penjagaan kesihatan dan kepatuhan pesakit kepada rawatan di dalam komuniti.

Provision of education to the public on quality use of medicines as well as ensuring continuity of care and patient compliance to treatment in the community.

CAWANGAN PENGURUSAN HARGA UBAT
MEDICINES PRICE
MANAGEMENT BRANCH

Mengurus aktiviti pemantauan, analisis dan penetapan harga ubat-ubatan untuk mendapatkan harga patut bagi meningkatkan ketelusan harga ubat di sektor swasta serta perolehan ubat yang menguntungkan kerajaan.

Manage the activities of monitoring, analyzing and setting the price of medicines to get the reasonable price to increase the transparency of medicine prices in the private sector as well as the procurement of medicines that benefit the government.

SEKSYEN KOORDINASI
COORDINATION SECTION

Mengurus, memantau dan menyelaras perihal keperluan peruntukan dan perbelanjaan, latihan, pelaksanaan aktiviti kualiti, pengurusan mesyuarat dan pelan tindakan serta aduan, pertanyaan atau pelaporan yang berkaitan dengan BAPF. Selain menyelaras dan memantau aktiviti Audit Dalam Amalan Farmasi (ADAF).

Manage, monitor, and coordinate matters related to the allocation and expenditure requirements, training, implementation of quality activities, meeting management, action plans, as well as complaints, inquiries, or reports related to the BAPF. In addition to coordinating and monitoring the activities of the Audit Dalam Amalan Farmasi (ADAF).

2.0 AKTIVITI DAN SOROTAN | ACTIVITIES AND HIGHLIGHTS

BENKEL PEMBANGUNAN MODUL LATIHAN MALAYSIA ADVANCED CLINICAL PHARMACY PROGRAMME (MYACPP)

Malaysia Advanced Clinical Pharmacy Programme (MyACPP) adalah program latihan kompetensi lanjutan yang bertujuan untuk mempertingkatkan kepakaran pegawai farmasi dalam bidang pengkhususan farmasi klinikal dan teknikal. Program ini diperkenalkan pada tahun 2024 sebagai langkah ke arah peningkatan profesionalisma dan kualiti penjagaan kesihatan di Malaysia.

Sebagai langkah awal, beberapa siri bengkel pembangunan modul latihan telah dilaksanakan pada Februari, April, dan November 2024 di Institut Kesihatan Negara (NIH), yang dihadiri oleh pegawai farmasi lepasan sarjana kedokteran dan pegawai farmasi berpengalaman dalam bidang pengkhususan. Bengkel-bengkel ini telah berjaya menghasilkan modul latihan yang berstruktur serta mendapat pengiktirafan antarabangsa.

Melalui bengkel-bengkel ini, lima (5) modul latihan telah dihasilkan yang meliputi bidang pengkhususan Farmasi Kardiologi, *Antimicrobial Stewardship (AMS)*, Farmasi Diabetes, Farmasi Nuklear, dan Farmasi Farmakokinetik Klinikal. Selain itu, lima (5) modul latihan lagi yang masih dalam pembangunan merangkumi bidang Farmasi Pediatrik, Farmasi Respiratori, Farmasi Geriatrik, Farmasi Hemofilia, dan Farmasi Onkologi yang dijangka akan selesai pada Februari 2025.

MALAYSIA ADVANCED CLINICAL PHARMACY PROGRAMME (MYACPP) TRAINING MODULES DEVELOPMENT WORKSHOP

The Malaysia Advanced Clinical Pharmacy Programme (MyACPP) is an advanced competency training program aimed at enhancing the expertise of pharmacists in clinical and technical pharmacy specializations. The program was introduced in 2024 as a step towards improving professionalism and the quality of healthcare in Malaysia.

As an initial step, a series of training module development workshops were held in February, April, and November 2024 at National Institute of Health (NIH), attended by pharmacists with doctoral qualifications and experienced pharmacists in the relevant clinical fields. These workshops successfully produced structured training modules that have received international recognition.

These workshops have resulted in five (5) training modules covering the specializations of Cardiology Pharmacy, Antimicrobial Stewardship (AMS), Diabetes Pharmacy, Nuclear Pharmacy, and Clinical Pharmacokinetics. Additionally, five (5) more training modules are still under development, covering the fields of Pediatric Pharmacy, Respiratory Pharmacy, Geriatric Pharmacy, Hemophilia Pharmacy, and Oncology Pharmacy, which are expected to be completed by February 2025.



Bengkel Pembangunan Modul Latihan *Malaysia Advanced Clinical Pharmacy Programme (MyACPP)* *Malaysia Advanced Clinical Pharmacy Programme (MyACPP) Training Modules Development Workshop*

BENGKEL INSIGHTS INTO NEW GUIDELINES 2024

Bengkel *Insights into New Guidelines* telah diadakan pada 5 November 2024 di Hotel Sheraton, Petaling Jaya. Bengkel ini telah dianjurkan oleh Cawangan Pengurusan Formulari dengan kerjasama *Pharmaceutical Association of Malaysia* (PhAMA) dan dihadiri oleh seramai 200 ahli PhAMA.

Tujuan utama bengkel ini adalah untuk memberikan pendedahan kepada ahli PhAMA berhubung perubahan dan prosedur terkini berkaitan permohonan *dossier*, Ubat Kelulusan Khas dan *Medicines Access Schemes* (MASc). Bengkel ini berjaya mencapai matlamatnya dengan memperkukuhkan pemahaman peserta terhadap garis panduan terkini dan proses berkaitan.

INSIGHTS INTO NEW GUIDELINES WORKSHOP 2024

The Insights into New Guidelines workshop was held on 5 November 2024 at the Sheraton Hotel, Petaling Jaya. The workshop was organised by the Formulary Management Branch in collaboration with the Pharmaceutical Association of Malaysia (PhAMA), and was attended by 200 PhAMA members.

The primary objective of the workshop was to provide PhAMA members with insights into recent updates and procedures related to dossier submissions, Special Approval Medicines and Medicines Access Schemes (MASc). The workshop successfully achieved its objectives by enhancing participants' understanding of the latest guidelines and related processes.



Bengkel *Insights into New Guidelines 2024*
Insights into New Guidelines Workshop 2024

BENGKEL LATIHAN SIMULASI TABLE TOP BENCANA: PENGURUSAN BEKALAN UBAT 2024 (PHARMDEX)

PharmDEX 2024 yang telah berlangsung pada 13-15 Ogos 2024 di Hotel KSL Esplanade Klang, merupakan sesi latihan dengan pendekatan simulasi *tabletop* bertujuan bagi mengasah kemahiran anggota farmasi untuk berfikir secara kritikal serta membuat keputusan dalam keadaan tekanan sebagai persediaan untuk berhadapan dengan situasi bencana yang sebenar. Bengkel ini adalah sebahagian daripada kolaborasi antara BAPF dan Fakulti Farmasi, Universiti Kebangsaan Malaysia (UKM) untuk membangunkan rangka kerja pengurusan bekalan farmaseutikal semasa bencana. Aktiviti termasuk latihan simulasi pelbagai ancaman seperti banjir, kemalangan

kimia, dan wabak, bertujuan menilai respons, memperbaiki koordinasi, dan mengenal pasti kelemahan dalam pelan tindakan. Hasilnya, ia berjaya meningkatkan kesedaran, kemahiran, dan keberkesanan pengurusan bencana dalam sektor farmasi.

WORKSHOP ON DISASTER TABLETOP SIMULATION TRAINING: MEDICINE SUPPLY MANAGEMENT 2024 (PHARMDEX)

PharmDEX 2024 held from 13-15 August 2024, at Hotel KSL Esplanade Klang, is a training session with a tabletop simulation approach aiming to hone critical thinking and decision-making skills under duress as preparedness for response during real disaster situations. This workshop is part of a collaboration between the BAPF and the Faculty of Pharmacy, Universiti Kebangsaan Malaysia (UKM), to develop a pharmaceutical supply management framework during disasters. Activities included simulation exercises for various threats, such as floods, chemical accidents, and outbreaks, designed to assess responses, improve coordination, and identify weaknesses in action plans. As a result, it successfully increased awareness, skills, and the effectiveness of disaster management in the pharmaceutical sector.



Bengkel Latihan Simulasi Table Top Bencana:
Pengurusan Bekalan Ubat 2024 (PharmDEX)
*Workshop on Disaster Tabletop Simulation Training:
Medicine Supply Management 2024 (PharmDEX)*

CADANGAN PELAKSANAAN INISIATIF PEMAPARAN HARGA UBAT DI KEMUDAHAN JAGAAN KESIHATAN SWASTA DAN FARMASI KOMUNITI DI BAWAH AKTA KAWALAN HARGA DAN ANTIPENCATUTAN 2011 [AKTA 723]

Mekanisme Ketelusan Harga Ubat (MKHU) telah dibentangkan dalam Mesyuarat Majlis Tindakan Sara Hidup Negara pada 3 Oktober 2023 yang dipengerusikan oleh YAB Perdana Menteri. Beliau mengumumkan komitmen kerajaan untuk meningkatkan ketelusan harga melalui mekanisme paparan harga bagi membolehkan rakyat mengetahui harga yang perlu dibayar, membuat perbandingan dan pilihan terbaik dalam mendapatkan ubat-ubatan pada harga munasabah dan mampu milik.

Konsultasi awam telah diadakan pada 15 Julai 2024 sehingga 20 Ogos 2024 melalui platform *Unified Public*

Consultation (UPC) untuk meluaskan capaian maklumat kepada pihak berkepentingan serta mendapatkan maklum balas menerusi soal selidik yang dijalankan. UPC ini telah mencapai 6,999 views dan seramai 459 responden memberikan maklum balas. Secara keseluruhan, 76.25% (350/459) bersetuju dengan inisiatif ini yang majoritinya terdiri daripada pengguna/ orang awam dan agensi awam.

Satu sesi libat urus diadakan pada 13 Ogos 2024 di Auditorium JAKIM, Putrajaya melibatkan beberapa pihak berkepentingan seperti pengguna/ pesakit, penyedia insurans, industri farmaseutikal, farmasi komuniti, penyedia perkhidmatan bagi klinik perubatan swasta, klinik pergigian swasta, hospital swasta dan lain-lain yang telah dihadiri oleh seramai 472 peserta secara fizikal dan dalam talian. Berdasarkan maklum balas yang diterima, 63.80% (67/105) peserta bersetuju dengan cadangan inisiatif ini.

Selaras dengan kerjasama strategik antara Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup (KPDN) dan KKM bagi pelaksanaan Inisiatif Pemaparan Harga Ubat, satu mesyuarat dasar telah dijalankan pada 11 hingga 13 September 2024 di SCAPES Hotel, Genting Highlands. Mesyuarat ini telah dihadiri 30 wakil daripada Bahagian Undang-undang, Bahagian Dasar dan Bahagian Penguatkuasa daripada kedua-dua kementerian, dan dipengerusikan bersama oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi), KKM dan Ketua Pengarah Penguat Kuasa, KPDN untuk menyelaraskan pelaksanaan dan penguatkuasaan. Pelaksanaan inisiatif ini dijangka dapat dilaksanakan pada tahun 2025.

PROPOSAL FOR THE IMPLEMENTATION OF MEDICINE PRICE DISPLAY INITIATIVES IN PRIVATE HEALTHCARE FACILITIES AND COMMUNITY PHARMACIES UNDER THE PRICE CONTROL AND ANTI-PROFITEERING ACT 2011 [ACT 723]

The Medicine Price Transparency Mechanism (MKHU) was presented at the National Action Council on Cost of Living meeting, chaired by the Prime Minister on 3 October 2023. The Prime Minister announced the government's commitment to ensuring greater transparency in the sale of medicines through a price display mechanism to enable the public to know the prices they need to pay, compare prices, and make informed decisions to obtain medicines at reasonable and affordable prices.

A public consultation was held from 15 July 2024 to 20 August 2024 via the Unified Public Consultation (UPC) platform to gather broader feedback to the stakeholders through a survey conducted. The UPC received a total of 6,999 views, and 459 respondents provided feedback. Overall, 76.25% of respondents (350/459) agreed with the proposed this initiative, with the majority of those in favour being consumers and public agencies.

An engagement session was held on 13 August 2024 at JAKIM Auditorium, Putrajaya involved various stakeholders, including consumers/ patients, insurance providers, the pharmaceutical industry, community pharmacies, service providers for private medical clinics, private dental clinics, private hospitals, and others which has been attended by 472 participants, both in person and online. Based on the feedback received, 63.80% (67/105) agreed with the implementation of this initiative.

In line with the strategic collaboration between Ministry of Domestic Trade and Cost of Living of Malaysia (KPDN) and MOH for the implementation of the Medicine Price Display Initiative, a policy meeting was held from 11 to 13 September 2024 at SCAPES Hotel, Genting Highlands. The meeting was attended by 30 representatives from the Legal Division, Policy Division, and Enforcement Division of both ministries and was co-chaired by the Deputy Director-General of Health (Pharmaceutical Services), MOH and the Director-General of Enforcement, KPDN to coordinate implementation and enforcement. The implementation of this initiative is expected to be implemented in 2025.



Mesyuarat di antara KPDN dan KKM
Meeting between KPDN and MOH

INISIATIF PELUPUSAN UBAT-UBATAN DALAM SIMPANAN PESAKIT DEMI KELESTARIAN ALAM SEKITAR (MYMEDISAFE)

Inisiatif MyMediSAFE yang diperkenalkan oleh Program Perkhidmatan Farmasi (PPF) adalah usaha strategik untuk mendidik masyarakat tentang pelupusan ubat-ubatan dalam simpanan pesakit secara betul dan selamat. Pelaksanaan MyMediSAFE bertujuan untuk mencegah risiko kesihatan yang berpunca daripada sisa farmaseutikal kepada manusia, memerangi isu kerintangan antimikrob dan seterusnya memastikan kelestarian alam sekitar. MyMediSAFE telah dilancarkan secara rasmi oleh YB Timbalan Menteri Kesihatan pada 25 September 2024 di Putrajaya.

MyMediSAFE merupakan sinergi awam swasta yang melibatkan pelbagai organisasi. MyMediSAFE telah disertai oleh 33 rakan strategik yang merangkumi persatuan berkaitan bidang farmaseutikal, hospital swasta, farmasi komuniti, hospital universiti, syarikat farmaseutikal, syarikat penyedia perkhidmatan pelupusan ubat serta syarikat berkaitan pengiklanan kesihatan. Usaha kolektif ini dapat mengoptimumkan sumber dan meluaskan kesedaran masyarakat tentang pelupusan ubat yang betul.

Sehingga Disember 2024, sebanyak 854 pusat pengumpulan ubat-ubatan yang terdiri daripada 149 hospital KKM dan 705 fasiliti bukan KKM telah dikenal pasti di seluruh negara. Lokasi pusat pengumpulan ubat boleh disemak melalui laman web rasmi <https://www.mymedisafe.org.my>.

INITIATIVE FOR THE DISPOSAL OF UNUSED PATIENT MEDICINES FOR ENVIRONMENTAL SUSTAINABILITY (MYMEDISAFE)

The MyMediSAFE initiative introduced by the Pharmaceutical Services Programme (PSP) is a strategic effort to educate the public on the proper and safe disposal of unused medicines. The implementation of MyMediSAFE aims to prevent health risks to humans arising from pharmaceutical waste, mitigate antimicrobial resistance issues and subsequently ensure environmental sustainability. MyMediSAFE was officially launched by the YB Deputy Minister of Health on 25 September 2024 in Putrajaya.

MyMediSAFE is a public-private synergy involving various organizations. MyMediSAFE has been joined by 33 strategic partners which include pharmaceutical-related associations, private hospitals, community pharmacies, university hospitals, pharmaceutical companies, medicines disposal service providers and companies involved in health advertising. This collective effort can optimize resources and expand public awareness about the proper disposal of medicines.

As of December 2024, a total of 854 medicines collection centers consisting of 149 MOH hospitals and 705 non-MOH facilities have been identified nationwide. The location of the medicines collection center can be checked via the official website <https://www.mymedisafe.org.my>.



Inisiatif Pelupusan Ubat-Ubatan dalam Simpanan Pesakit Demi Kelestarian Alam Sekitar (MyMediSAFE)
Initiative for the Disposal of Unused Patient Medicines for Environmental Sustainability (MyMediSAFE)

MESYUARAT PEMURNIAN SENARAI SEMAK ADAF

Mesyuarat dihadiri oleh wakil pengurusan tertinggi dari seluruh negara, bertujuan untuk menyemak dan menambah baik senarai semak Audit Dalam Amalan Farmasi (ADAF) agar selaras dengan prosedur, garis panduan dan amalan terkini.

Perbincangan tertumpu kepada meningkatkan keberkesanan senarai semak, menangani cabaran semasa serta mengemas kini elemen yang perlu berdasarkan perubahan dasar dan garis panduan terkini. Selain itu, peserta turut berkongsi pandangan dan pengalaman, bagi memastikan pelaksanaan ADAF yang lebih menyeluruh dan seragam di seluruh negara.

ADAF CHECKLIST REFINEMENT MEETING

This meeting, attended by senior management representatives from across the country, aimed to review and enhance the Audit Dalam Amalan Farmasi (ADAF) checklist to ensure its alignment with current policies, guidelines, and best practices.

Discussions focused on enhancing the checklist's effectiveness, addressing current challenges, and updating necessary elements based on the latest policy and guideline changes. Additionally, participants shared insights and experiences, contributing to a more comprehensive and standardized approach in ADAF implementation nationwide.



Mesyuarat Pemurnian Senarai Semak ADAF di Hotel Lexis, Port Dickson | 5-7 Ogos 2024
ADAF Checklist Refinement Meeting held at Lexis Hotel, Port Dickson | 5-7 August 2024

LAIN-LAIN AKTIVITI OTHER ACTIVITIES

TAJUK TITLE	Mesyuarat Saintifik Farmasi Renal Kebangsaan Ke-4 (NRPSM) 2024 <i>4th National Renal Pharmacy Scientific Meeting (NRPSM) 2024</i>
TARIKH/ TEMPAT DATE/ VENUE	20-21 September 2024, Hotel KSL Esplanade, Klang <i>20-21 September 2024, KSL Esplanade Hotel, Klang</i>
PESERTA PARTICIPANT	167 pegawai farmasi terdiri daripada fasiliti KKM, institusi pengajian tinggi dan institusi swasta <i>167 pharmacists from MOH facilities, higher education institutions, and private institutions</i>
OBJEKTIF OBJECTIVE	Program yang bertemakan "Breaking Barriers: Diversifying Renal Pharmacy Practice" ini bertujuan untuk meningkatkan kompetensi dengan maklumat dan perkembangan terkini bidang farmasi nefrologi di samping mempromosikan perkongsian ilmu dalam bidang Farmasi Nefrologi. <i>The program themed "Breaking Barriers: Diversifying Renal Pharmacy Practice" aimed to enhance competencies with the latest information and developments in the field of nephrology pharmacy while promoting knowledge sharing in nephrology pharmacy.</i>
HASIL OUTCOME	Forum, ceramah dan pembentangan poster saintifik telah mengukuhkan rangkaian profesional dan menggalakkan pendekatan inovatif, bertujuan untuk meningkatkan amalan penjagaan renal dan hasil pesakit di seluruh sektor kesihatan. <i>Forums, lectures and scientific poster presentations strengthened professional networks and encouraged innovative approaches, aiming to improve renal care practices and patient outcomes across healthcare sectors.</i>



TAJUK TITLE	Mesyuarat Saintifik Farmasi Pediatrik Kebangsaan Ke-4 (NPPSM) 2024 <i>4th National Paediatric Pharmacy Scientific Meeting (NPPSM) 2024</i>
TARIKH/ TEMPAT DATE/ VENUE	2-3 Oktober 2024, Pusat Konvensyen Bangi Avenue <i>2-3 October 2024, Bangi Avenue Convention Centre</i>
PESERTA PARTICIPANT	114 pegawai farmasi terdiri daripada fasiliti KKM, institusi pengajian tinggi dan institusi swasta <i>114 pharmacists from MOH facilities, higher education institutions, and private institutions</i>
OBJEKTIF OBJECTIVE	Bertemakan "The Greatest Wealth is the Health of our Children", topik-topik ceramah yang dipilih untuk edisi ini adalah memfokuskan kepada rawatan bagi penyakit endokrin dan respiratori kanak-kanak. Objektif program adalah untuk meningkatkan kompetensi dengan maklumat dan perkembangan terkini bidang farmasi pediatrik serta mempromosikan perkongsian ilmu dalam bidang farmasi pediatrik. <i>With the theme of "The Greatest Health is the Wealth of Our Children", this program aimed to improve the competencies of pharmacists with the latest in the field of paediatric pharmacy, especially in paediatric respiratory and endocrine while at the same time promoting knowledge sharing among the participants.</i>
HASIL OUTCOME	Ceramah yang diberikan sepanjang program dapat meningkatkan kemahiran anggota farmasi dalam perkhidmatan farmasi (pediatrik) justeru menambah kualiti perkhidmatan kepada pesakit. <i>The lectures given throughout the programme can enhance the skills of pharmacists in pharmaceutical services (pediatrics), thereby improving the quality of service to patients.</i>



TAJUK <i>TITLE</i>	Bengkel Persediaan Pemeriksaan Stok di Level 3 Tahun 2024 <i>Bengkel Persediaan Pemeriksaan Stok di Level 3 Tahun 2024</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	22-23 Februari 2024, Institut Kesihatan Negara (NIH) <i>22-23 February 2024, National Institute of Health (NIH)</i>
PESERTA <i>PARTICIPANT</i>	65 pegawai farmasi KKM <i>65 MOH pharmacists</i>
OBJEKTIF <i>OBJECTIVE</i>	<ul style="list-style-type: none"> • Memastikan rekod fizikal stok dan stok dalam sistem adalah selaras • Menyelaraskan stok yang rosak, tidak bergerak atau hampir luput tempoh penggunaan • Menyediakan tindakan penambahbaikan berdasarkan laporan hasil pemeriksaan • <i>To ensure the physical stock records and stock in the system are aligned</i> • <i>To manage stock that is damaged, inactive, or approaching its expiration date</i> • <i>To develop corrective actions based on the findings from the inspections</i>
HASIL <i>OUTCOME</i>	Panduan Pemeriksaan Stok Level 3 di Fasiliti KKM telah diedarkan pada 27 Mei 2024 untuk menjadi rujukan kepada fasiliti semasa pengendalian stok di level 3. <i>Panduan Pemeriksaan Stok Level 3 di Fasiliti KKM was issued on 27 May 2024 to provide guidance for facilities in managing stock at level 3.</i>



TAJUK <i>TITLE</i>	Bengkel Master TOT Modul Pemantapan Soft Skills Anggota di Kaunter Farmasi <i>Bengkel Master TOT Modul Pemantapan Soft Skills Anggota di Kaunter Farmasi</i>
TARIKH <i>DATE</i>	<ul style="list-style-type: none"> • 23-25 April 2024 (Zon Utara dan Zon Timur) • 13-15 Mei 2024 (Zon Tengah dan Zon Selatan) • 3-5 Julai 2024 (Zon Sabah, Sarawak dan Wilayah Persekutuan Labuan) • <i>23-25 April 2024 (North Zone and East Zone)</i> • <i>13-15 May 2024 (Central Zone and South Zone)</i> • <i>3-5 July 2024 (Sabah Zone, Sarawak Zone and Federal Territory of Labuan)</i>
TEMPAT <i>VENUE</i>	Institut Kesihatan Negara (NIH) <i>National Institute of Health (NIH)</i>
PESERTA <i>PARTICIPANT</i>	92 Pegawai Farmasi KKM (termasuk 8 pegawai farmasi IPKKM) <i>92 MOH pharmacists (including 8 pharmacists from IPKKM)</i>
OBJEKTIF <i>OBJECTIVE</i>	<ul style="list-style-type: none"> • Memberikan pendedahan kaedah dan kemahiran <i>soft skills</i> dalam perkhidmatan kaunter farmasi • Menyediakan solusi kepada senario/ isu yang biasa ditemui di kaunter perkhidmatan farmasi • Menerapkan budaya <i>soft skills</i> dalam perkhidmatan kaunter farmasi bagi meningkatkan kecekapan anggota farmasi dalam memenuhi ekspektasi pelanggan • <i>Provide exposure to soft skills techniques applicable for pharmacy counter services</i> • <i>Provide remedial solutions to commonly encountered scenarios/ issues at pharmacy counter services</i> • <i>Inculcate soft skills culture in pharmacy counter services to improve the pharmacy staff efficiency to fulfil customer expectations</i>

HASIL OUTCOME	<p>Seramai 84 pegawai farmasi KKM telah dilahirkan sebagai penggerak dan <i>Master Trainer Modul Pemantapan Soft Skills</i> Anggota di Kaunter Farmasi bagi melatih lebih ramai anggota di negeri masing-masing agar aspek <i>soft skills</i> seperti kaedah <i>motivational interviewing</i>, komunikasi berkesan dan ekspektasi pelanggan dapat dibudayakan sebagai amalan kita.</p> <p><i>A total of 84 MOH pharmacists were trained as Master Trainers for the Pharmacy Counter Soft Skills Enhancement Module who are the main driving force to upskill more members in their respective states on the soft skills aspects such as motivational interviewing tools, effective communication and customer expectations can be instilled as part of our practice.</i></p>
--------------------------	--



TAJUK TITLE	<p>Bengkel Pengukuhan Farmasi Rawatan Rapi 2024 <i>Bengkel Pengukuhan Farmasi Rawatan Rapi 2024</i></p>
TARIKH/ TEMPAT DATE/ VENUE	<p>23-24 Mei 2024, Institut Kesihatan Negara (NIH) <i>23-24 May 2024, National Institute of Health (NIH)</i></p>
PESERTA PARTICIPANT	<p>80 Pegawai Farmasi KKM <i>80 MOH pharmacists</i></p>
OBJEKTIF OBJECTIVE	<p>Bertemakan "<i>Mastering Critical Care from the Ground Up</i>", objektif utama bengkel ini dianjurkan adalah untuk mengukuhkan pengetahuan pegawai-pegawai farmasi yang berkhidmat di Unit Rawatan Rapi di samping memberi pendedahan terhadap rawatan terkini bagi pesakit kritikal.</p> <p><i>With the theme of "Mastering Critical Care from the Ground Up", the main objective of this workshop is to strengthen the knowledge of critical care pharmacists while highlighting the latest treatment recommendation for critically ill patients.</i></p>
HASIL OUTCOME	<p>Topik-topik ceramah yang disampaikan semasa bengkel ini merangkumi pengetahuan asas yang perlu dikuasai oleh semua pegawai farmasi yang berkhidmat di Unit Rawatan Rapi. Bengkel ini meningkatkan kemahiran dan pengetahuan pegawai farmasi, seterusnya meningkatkan kualiti perkhidmatan kepada pesakit, khususnya pesakit di Unit Rawatan Rapi.</p> <p><i>The lectures delivered during this workshop encompassed the basic knowledge that all pharmacists working in the Intensive Care Unit (ICU) are required to master. This workshop enhances the skills and knowledge of pharmacists, thereby improving the quality of services provided to patients, particularly those in the ICU.</i></p>



TAJUK <i>TITLE</i>	Mesyuarat Teknikal Farmakoekonomi 2024 <i>Pharmacoeconomic Technical Meeting 2024</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	11-13 September 2024, Hotel Lexis, Port Dickson, Negeri Sembilan <i>11-13 September 2024, Lexis Hotel, Port Dickson, Negeri Sembilan</i>
PESERTA <i>PARTICIPANT</i>	16 Pegawai Farmasi dari pelbagai negeri/ institusi di bawah KKM <i>16 pharmacists from various states/ institutions under the MOH</i>
OBJEKTIF <i>OBJECTIVE</i>	Mengenal pasti serta merancang aktiviti farmakoekonomi termasuk penyelidikan dan latihan bagi mengembangkan dan memantapkan aplikasi prinsip farmakoekonomi dalam perkhidmatan farmasi. <i>Identify and plan pharmacoeconomic activities, including research and training, to expand and strengthen the application of pharmacoeconomic principles in pharmacy services.</i>
HASIL <i>OUTCOME</i>	Mesyuarat telah berjaya menggariskan perancangan aktiviti farmakoekonomi bagi tahun 2025. Antara aktiviti yang telah dicadangkan adalah penganjuran sesi coffee talk berkaitan bidang farmakoekonomi serta pelaksanaan bengkel pengukuhan penyelidikan farmakoekonomi. <i>The meeting successfully outlined the pharmacoeconomic activity plans for 2025, including proposed initiatives such as coffee talk sessions on pharmacoeconomics and a workshop to enhance pharmacoeconomic research.</i>



TAJUK <i>TITLE</i>	Bengkel Echo Training Evidence-Based Medicine (EBM) <i>Evidence-Based Medicine (EBM) Echo Training Workshop</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	Bermula Mei 2024 sehingga Oktober 2024, Fasiliti-fasiliti Kesihatan KKM <i>From May 2024 to October 2024, MOH Healthcare facilities</i>
PESERTA <i>PARTICIPANT</i>	461 Pegawai Farmasi KKM <i>461 MOH pharmacists</i>
OBJEKTIF <i>OBJECTIVE</i>	<ul style="list-style-type: none"> • Melatih dan mengukuhkan kemahiran mengaplikasikan konsep EBM oleh pegawai farmasi di fasiliti KKM supaya pelaksanaan polisi dan keputusan berkaitan ubat-ubatan adalah secara <i>evidence-based</i>. • Membina kapasiti dan kapabiliti pelatih-pelatih bagi pelaksanaan program latihan EBM di peringkat negeri/ institusi. • <i>To train and enhance the skills of pharmacists in applying EBM concepts at MOH facilities to ensure evidence-based implementation of policies and decisions related to medicines.</i> • <i>To build the capacity and capability of trainers for implementing EBM training programs at state/ institution levels.</i>
HASIL <i>OUTCOME</i>	Pegawai farmasi lebih mahir dalam mengaplikasi EBM untuk menyokong keputusan klinikal dan polisi. <i>Pharmacists are more proficient in applying EBM concepts to support clinical and policy decisions.</i>



Bengkel pertama diadakan di Kedah pada 14-16 Mei 2024
First workshop conducted in Kedah on 14-16 May 2024



Bengkel terakhir diadakan di Melaka pada 7-8 Oktober 2024
Last workshop conducted in Melaka on 7-8 October 2024

TAJUK TITLE	e-JERAYAWARA bagi Garis Panduan Pengendalian Medicines Access Scheme (MASc) di Fasilitas KKM Edisi Kedua 2024, Tatacara Pengendalian Mesyuarat Jawatankuasa Ubat & Terapeutik (JKUT) Di Fasilitas KKM dan Garis Panduan <i>Submission of Dossier for Listing into the Ministry of Health Medicines Formulary</i> (Edisi ke-3) <i>e-JERAYAWARA for Garis Panduan Pengendalian Medicines Access Scheme (MASc) di Fasilitas KKM Edisi Kedua 2024, Tatacara Pengendalian Mesyuarat Jawatankuasa Ubat & Terapeutik (JKUT) di Fasilitas KKM dan Garis Panduan Submission of Dossier for Listing into the Ministry of Health Medicines Formulary (Edisi ke-3)</i>
TARIKH/ TEMPAT DATE/ VENUE	27 Mac 2024 dan 24 April 2024, Secara dalam talian (Google Meet) <i>27 March 2024 and 24 April 2024, Virtual platform (Google Meet)</i>
PESERTA PARTICIPANT	Seramai lebih kurang 900 Pegawai Farmasi daripada pelbagai fasiliti, institusi dan Jabatan Kesihatan Negeri telah menghadiri sesi e-jerayawara ini. <i>Approximately 900 pharmacists from various facilities, institutions, and State Health Departments attended this e-roadshow session.</i>
OBJEKTIF OBJECTIVE	<ul style="list-style-type: none"> • Memberikan penerangan berhubung garis-garis panduan yang telah dikemas kini • Memastikan tadbir urus ubat-ubatan dapat dilakukan dengan baik • <i>Provide clarification regarding the updated guidelines</i> • <i>Ensure the proper governance of medications</i>
HASIL OUTCOME	Sesi e-jerayawara yang dijalankan telah memberikan pendedahan kepada pegawai Farmasi terlibat berhubung tatacara dan prosedur terkini dalam tadbir urus ubat-ubatan di fasiliti susulan penerbitan garis-garis panduan yang baharu. <i>The e-roadshow sessions conducted have provided exposure to the pharmacists regarding the latest procedures and protocols in the governance of medicines at healthcare facilities, following the publication of new guidelines.</i>

e-JERAYAWARA



CAWANGAN PENGURUSAN FORMULARI
BAHAGIAN AMALAN & PERKEMBANGAN FARMASI

TAJUK <i>TITLE</i>	Perbincangan Perolehan Ubat Oral Antiviral oleh Fasiliti Kesihatan KKM bersama Syarikat Pfizer (Malaysia) Sdn. Bhd. <i>Discussion on The Procurement of Oral Antiviral Drugs by MOH Health Facilities with Pfizer (Malaysia) Sdn. Bhd.</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	2 Februari 2024, PPF <i>2 February 2024, PSP</i>
PESERTA <i>PARTICIPANT</i>	Perbincangan ini dijalankan secara fizikal dan juga secara maya dengan penyertaan seramai 15 pegawai daripada kedua-dua pihak. <i>The discussion was conducted physically and also virtually with the participation of 15 officers from both parties.</i>
OBJEKTIF <i>OBJECTIVE</i>	Menyelaras perancangan perolehan ubat antiviral Paxlovid® dengan pemegang pendaftaran produk tersebut bagi memastikan kesinambungan bekalan antiviral untuk rawatan COVID-19 di fasiliti kesihatan KKM. <i>Coordinating the procurement planning of the antiviral drug Paxlovid® with the product registration holder to ensure the continuity of the antiviral supply for COVID-19 treatment at MOH healthcare facilities.</i>
HASIL <i>OUTCOME</i>	Memastikan bekalan Paxlovid® sentiasa tersedia di fasiliti kesihatan KKM melalui penyelarasan dengan pemegang pendaftaran, untuk memastikan rawatan COVID-19 yang berterusan dan efisien. <i>Ensure a continuous supply of Paxlovid® in MOH healthcare facilities through coordination with the product registrant, to ensure ongoing and efficient COVID-19 treatment.</i>



TAJUK <i>TITLE</i>	Mesyuarat Jawatankuasa Farmasi Logistik Tahun 2024 <i>Logistics Pharmacy Committee Meeting Year 2024</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	Sesi Bil. 01/2024: 26-28 Februari 2024, Hotel KSL Esplanade, Klang <i>Session No. 01/2024: 26-28 February 2024, KSL Esplanade Hotel, Klang</i> Sesi Bil. 02/2024: 21 November 2024, PPF <i>Session No. 02/2024: 21 November 2024, PSP</i>
PESERTA <i>PARTICIPANT</i>	Mesyuarat ini dipengerusikan oleh Pengarah BAPF, dengan penyertaan seramai 45 ahli jawatankuasa, termasuk wakil daripada setiap negeri. <i>The meeting was chaired by the Director of the BAPF, with the participation of 45 committee members, including representatives from each state.</i>
OBJEKTIF <i>OBJECTIVE</i>	Membincangkan isu-isu berkaitan pengurusan farmasi logistik dengan tujuan untuk menambah baik amalan sedia ada. <i>To discuss issues related to the management of logistics pharmacy, with the aim of improving existing practices.</i>
HASIL <i>OUTCOME</i>	Penyampaian maklumat terkini berkenaan pengurusan farmasi logistik kepada wakil negeri serta penyelesaian isu-isu berbangkit bagi memastikan tadbir urus serta tatakelola pengurusan peruntukan dan perolehan bekalan perubatan dilaksanakan dengan baik. <i>The delivery of logistics management information has been presented to the state representatives, and the issues raised have been resolved.</i>



TAJUK TITLE	Majlis Pelancaran Modul Latihan Farmasi Logistik: Pengenalan Asas Pengurusan Farmasi Logistik <i>Launching Ceremony of the Logistic Pharmacy Training Module: Introduction to Basic Management of Logistic Pharmacy</i>
TARIKH/ TEMPAT DATE/ VENUE	14 Mei 2024, Hotel KSL Esplanade, Klang <i>14 May 2024, KSL Esplanade Hotel, Klang</i>
PESERTA PARTICIPANT	Timbalan Pengarah (Farmasi) dan Timbalan Pengarah Kesihatan Negeri (Farmasi) dari pelbagai negeri dan hospital di bawah Kementerian Kesihatan Malaysia Ahli Jawatankuasa Farmasi Logistik sesi 2020/2023 serta sesi 2024/2027 <i>Deputy Director (Pharmacy) and Deputy State Health Director (Pharmacy) from various states and hospitals under the Ministry of Health Malaysia. Committee Members of the Pharmacy Logistics for the 2020/2023 and 2024/2027 sessions.</i>
OBJEKTIF OBJECTIVE	Melancarkan satu modul latihan piawai yang boleh digunakan dalam pelaksanaan aktiviti latihan bagi meningkatkan kompetensi anggota di lapangan ke arah melicinkan operasi pengurusan farmasi logistik. <i>Unveil a standardized training module designed to enhance the competency of field personnel, ensuring smoother operations in the management of logistic pharmacy.</i>
HASIL OUTCOME	Penyampaian maklumat yang konsisten kepada anggota serta memudahkan pelaksanaan latihan di lapangan. <i>Ensured consistent information delivery and facilitated training implementation in the logistic pharmacy facilities.</i>



TAJUK TITLE	Mesyuarat Jawatankuasa Penerbitan Hasil Kajian Pemantauan Harga Ubat (KPHU) <i>Meeting on The Publication Committee of Medicine Prices Monitoring Survey (KPHU)</i>
TARIKH/ TEMPAT DATE/ VENUE	10-12 Jun 2024, Hotel Colmar Tropicale, Bukit Tinggi Pahang <i>10-12 June 2024, Colmar Tropicale Hotel, Bukit Tinggi Pahang</i>
PESERTA PARTICIPANT	14 Pegawai Farmasi daripada Kementerian Kesihatan Malaysia 1 Pegawai Farmasi daripada Kementerian Pertahanan Malaysia (MINDEF) 2 Pegawai Farmasi daripada 2 Hospital Pengajar Universiti, Kementerian Pengajian Tinggi <i>14 pharmacists from the Ministry of Health Malaysia 1 pharmacist from the Ministry of Defence Malaysia (MINDEF) 2 pharmacists from the 2 University Teaching Hospital, Ministry of Higher Education</i>
OBJEKTIF OBJECTIVE	Membincangkan hasil dan meneliti laporan Kajian Pemantauan Harga Ubat 2022 untuk tujuan penerbitan. <i>Discuss the results and review the report of the Medicine Prices Monitoring Survey 2022 for the publication.</i>
HASIL OUTCOME	Hasil perbincangan mesyuarat, laporan kajian telah ditambahbaik dan dimurnikan sebelum penerbitan kajian. <i>As a result of the discussion of the meeting, the study report was improved and refined before publication of the study.</i>



TAJUK TITLE	Mesyuarat Jawatankuasa Kerja Penerbitan Kajian Penilaian Impak Harga Ubat-Ubatan yang Dibeli Secara Perolehan Bersama (Pooled Procurement) di Sektor Awam 2024 <i>Working Committee Meeting on The Publication Study of The Impact of Pooled Procurement on Medicines Pricing in The Public Sector 2024</i>
TARIKH/ TEMPAT DATE/ VENUE	23-25 Oktober 2024, Hotel Avillion, Port Dickson, Negeri Sembilan <i>23-25 October 2024, Avillion Hotel, Port Dickson, Negeri Sembilan</i>
PESERTA PARTICIPANT	9 Pegawai Farmasi daripada BAPF 2 Pegawai Farmasi daripada Kementerian Pertahanan Malaysia (MINDEF) 10 Pegawai Farmasi daripada 6 Hospital Pengajar Universiti, Kementerian Pengajian Tinggi <i>9 pharmacists from the BAPF 2 pharmacists from the Ministry of Defence Malaysia (MINDEF) 10 pharmacists from the 6 University Teaching Hospital, Ministry of Higher Education</i>
OBJEKTIF OBJECTIVE	Membincangkan hasil analisis data kajian Fasa 2, penyediaan laporan dan perbincangan hala tuju dan isu-isu perolehan secara bersama antara Kementerian Kesihatan Malaysia, Kementerian Pengajian Tinggi dan Kementerian Pertahanan Malaysia. <i>Discuss the results of the Phase 2 study data analysis, report preparation and discussion of direction and procurement issues among the Ministry of Health Malaysia, the Ministry of Higher Education and the Ministry of Defense Malaysia.</i>
HASIL OUTCOME	Hasil perbincangan mesyuarat, laporan kajian telah ditambahbaik dan dimurnikan sebelum penerbitan kajian. <i>As a result of the discussion of the meeting, the study report was improved and refined before publication of the study.</i>



TAJUK TITLE	Bengkel Senarai Ubat-Ubatan Bagi Skim Perubatan Madani (SPM) Sesi 1, 2, & 3 Bagi Tahun 2024 <i>Workshop on The List of Medicines for Skim Perubatan Madani (SPM) Sessions 1, 2, & 3 for the Year 2024</i>
TARIKH/ TEMPAT DATE/ VENUE	10 Oktober 2024, 7 November 2024 & 20 Disember 2024 <i>10 October 2024, 7 November 2024 & 20 December 2024 ProtectHealth Corporation Sdn. Bhd. Cyberjaya, Selangor ProtectHealth Corporation Sdn. Bhd. Cyberjaya, Selangor</i>
PESERTA PARTICIPANT	3 peserta dari BAPF 4 peserta dari ProtectHealth Corporation Sdn. Bhd. <i>3 participants from the BAPF 4 participants from ProtectHealth Corporation Sdn. Bhd.</i>
OBJEKTIF OBJECTIVE	Perbincangan status terkini pelaksanaan Skim Perubatan MADANI (SPM) dan pencapaian semasa. Perbincangan mengenai semakan harga ubat di bawah SPM supaya selaras dengan harga pasaran semasa dan isu-isu berkaitan dengan penambahbaikan senarai ubat SPM. <i>Current status of the Skim Perubatan MADANI (SPM) implementation and its achievements. Review of medicine pricing under SPM to ensure alignment with current market prices and also addressing issues related to improving the SPM medicines list.</i>
HASIL OUTCOME	Cadangan semakan semula harga ubat SPM telah dikongsikan kepada ProtectHealth Corporation pada 3 Januari 2025. <i>Newly proposed SPM medicines prices was shared with ProtectHealth Corporation on 3 January 2025.</i>



TAJUK TITLE	Perbincangan Jabatan Perangkaan Malaysia (DOSM) bersama Pihak Kementerian Kesihatan Malaysia (KKM) berkenaan Indeks Kesihatan <i>Discussion Between the Department of Statistics Malaysia (DOSM) And the Ministry of Health Malaysia (MOH) Regarding the Health Index</i>
TARIKH/ TEMPAT DATE/ VENUE	23 Ogos 2024, Jabatan Perangkaan Malaysia, Putrajaya <i>23 August 2024, Department of Statistics Malaysia, Putrajaya</i>
PESERTA PARTICIPANT	5 peserta daripada BAPF 3 peserta daripada National Health Financing 8 peserta daripada DOSM <i>5 participants from BAPF 3 participants from National Health Financing 8 participants from DOSM</i>
OBJEKTIF OBJECTIVE	Susulan cadangan pembangunan Indeks Kesihatan merangkumi tiga kategori iaitu Farmaseutikal, Peralatan Kesihatan dan Perkhidmatan Kesihatan, mesyuarat ini diadakan untuk membincangkan senarai item ubat yang sesuai untuk dicadangkan ke dalam kategori Farmaseutikal. <i>Following the proposal to develop a Health Index encompassing three categories, namely Pharmaceuticals, Medical Equipment, and Health Services, this meeting is held to discuss the list of suitable drug items to be proposed under the Pharmaceuticals category.</i>
HASIL OUTCOME	Daripada perkongsian kriteria-kriteria harga ubat yang digunakan dalam membangun Indeks Harga Pengguna, kedua-dua pihak bersetuju pembangunan Indeks Harga Ubat perlu melihat semula pengelasan ubat yang diambil kira, wajaran yang akan digunakan dan mengharmonikan senarai sedia ada, sebelum membangun Indeks Kesihatan dan Indeks Harga Ubat. <i>From the sharing of drug price criteria used in developing the current Consumer Price Index, both parties agreed that the development of the Drug Price Index should revisit the classification of drugs considered, the weighted to be used, and the harmonization of the existing list before proceeding with the development of the Health Index and the Medicine Price Index.</i>

TAJUK TITLE	Mesyuarat Bersama Globaldata [Pembekal Pangkalan Data Harga Rujukan Antarabangsa, Pharmonline International (POLI)] <i>Meeting with Globaldata [Provider of The International Reference Price Database, Pharmonline International (POLI)]</i>
TARIKH/ TEMPAT DATE/ VENUE	18 November 2024, Ibu Pejabat PPF & Atas Talian <i>18 November 2024, PSP Office & Online</i>
PESERTA PARTICIPANT	19 peserta daripada BAPF 4 peserta daripada NPRA 2 peserta daripada BDPSF 2 wakil GlobalData <i>19 participants from the BAPF 4 participants from the NPRA 2 participants from the BDPSF 2 representatives of GlobalData</i>
OBJEKTIF OBJECTIVE	Memberikan taklimat mengenai ciri platform Pharmaceutical Global Data, yang menyediakan data farmaseutikal mengikut negara, termasuk harga, strategi komersial, pangkalan data khusus, serta alat untuk kecerdasan persaingan pasaran dan analisis pasaran farmaseutikal. <i>Provide a briefing on the Pharmaceutical Global Data platform's feature, which offers comprehensive, country-specific pharmaceutical data, including pricing, commercial strategies, specialized databases, and tools for competitive intelligence and market analytic.</i>

HASIL OUTCOME	Langganan POLI telah diperbaharui untuk tempoh setahun dan akan mempertimbangkan tambahan modul lain untuk langganan bagi tahun yang akan data. Pihak GlobalData bersetuju untuk memberikan akses cubaan (trial) kepada 3 modul tambahan bagi tempoh sebulan termasuk modul <ul style="list-style-type: none"> ● Drugs database ● World Market Healthcare ● Patent database ● AI Hub <i>The POLI subscription has been renewed for one year, and additional modules will be considered for the subscription in the upcoming year. GlobalData has agreed to provide a trial access to 3 additional modules for a one-month period, including:</i> <ul style="list-style-type: none"> ● Drugs database ● World Market Healthcare ● Patent database ● AI Hub
-------------------------	---



TAJUK <i>TITLE</i>	Sesi Advokasi Penggunaan Ubat Berkualiti Fokus kepada Orang Kurang Upaya (OKU) Pendengaran dan Pertuturan 2024 <i>Advocacy Session on The Quality Use of Medicines, Focusing on Individuals with Hearing and Speech Disabilities 2024</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	25-27 Jun 2024, Hotel Lexis, Port-Dickson, Negeri Sembilan <i>25-27 June 2024, Lexis Hotel, Port-Dickson, Negeri Sembilan</i>
PESERTA <i>PARTICIPANT</i>	66 pegawai farmasi KKM <i>66 pharmacists from MOH facilities</i>
OBJEKTIF <i>OBJECTIVE</i>	Objektif utama sesi ini adalah untuk memberi pendedahan asas bahasa isyarat kepada pegawai farmasi bagi memudahkan komunikasi dengan pesakit daripada golongan OKU Pendengaran dan Pertuturan. Selain itu, sesi advokasi ini turut bertujuan meningkatkan kefahaman pegawai farmasi mengenai keperluan khusus pesakit OKU Pendengaran dan Pertuturan, sekali gus memastikan penyampaian perkhidmatan farmasi yang lebih inklusif dan berkesan di fasiliti kesihatan kerajaan. <i>The primary objective of this session was to provide pharmacists with basic exposure to sign language to facilitate communication with patients from the hearing and speech-impaired community. Additionally, the session aimed to enhance pharmacists' understanding of the specific needs of these patients, thereby ensuring a more inclusive and effective pharmacy service delivery at government healthcare facilities.</i>
HASIL <i>OUTCOME</i>	Seramai 66 pegawai farmasi dari seluruh negara telah menyertai sesi ini yang memberi pendedahan kepada asas bahasa isyarat. Sebanyak 12 video pendidikan Kenali Ubat Anda dalam Bahasa Isyarat Malaysia (BIM) turut dihasilkan semasa sesi advokasi ini. Video-video ini diharap dapat menjadi panduan berguna bagi meningkatkan kefahaman golongan OKU Pendengaran dan Pertuturan berkaitan penggunaan ubat yang betul. <i>A total of 66 pharmacists from across the country participated in this session which provided exposure to the basics of sign language. As part of this initiative, a total of 12 educational Know Your Medicines videos in Malaysian Sign Language were also produced during the session. These videos are expected to serve as valuable resources in improving the understanding of hearing and speech-impaired individuals regarding proper medication use.</i>



Seramai 66 peserta sesi advokasi yang terdiri daripada pegawai farmasi dari seluruh negara bergambar sambil menunjukkan bahasa isyarat.

A total of 66 advocacy session participants, consisting of pharmacists from across the country, posed for a photo while showcasing sign language.

TAJUK <i>TITLE</i>	Bengkel Duta Kenali Ubat Anda Orang Kurang Upaya (OKU) Penglihatan, Pendengaran dan Pertuturan 2024 <i>Know Your Medicines Ambassador Workshop: Persons with Disabilities (PWD) In Visual, Hearing, and Speech Impairments 2024</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	22 Oktober 2024, Institut Latihan DBKL (ID) Cheras, Kuala Lumpur <i>22 October 2024, Institut Latihan DBKL (ID) Cheras, Kuala Lumpur</i>
PESERTA <i>PARTICIPANT</i>	22 peserta <i>22 participants</i>
OBJEKTIF <i>OBJECTIVE</i>	Bengkel Duta Kenali Ubat Anda untuk golongan Orang Kurang Upaya (OKU) Penglihatan, Pendengaran, dan Pertuturan 2024 telah berjaya dilaksanakan pada 22 Oktober 2024. Bengkel ini merupakan program rintis bagi memperkasa komuniti yang melibatkan golongan OKU. Melalui modul-modul yang komprehensif, sejumlah 22 peserta telah dilatih tentang Penggunaan Ubat Berkualiti bagi memastikan mereka mendapat informasi yang tepat dan sahih tentang ubat-ubatan dalam usaha membudayakan literasi kesihatan. <i>The Know Your Medicines Ambassador Workshop for Persons with Disabilities (PWD) with Visual, Hearing, and Speech Impairments 2024 was successfully held on October 22, 2024. This workshop served as a pilot program aimed at empowering the PWD community. Through comprehensive modules, a total of 22 participants were trained on the Rational Use of Medicines to ensure they received accurate and reliable information about medications, promoting health literacy.</i>
HASIL <i>OUTCOME</i>	Menerusi bengkel ini, wakil masyarakat dalam golongan OKU dilatih untuk bertindak sebagai ejen kesihatan komuniti agar turut membantu KKM dalam memberi maklumat asas tentang ubat-ubatan kepada komuniti OKU masing-masing. <i>In addition, representatives from the PWD community were trained to act as community health agents, assisting the Ministry of Health (KKM) in providing basic information about medicines to their respective PWD communities.</i>



Duta Kenali Ubat Anda OKU Penglihatan, Pendengaran dan Pertuturan bergambar kenang-kenangan bersama-sama para fasilitator
The Know Your Medicine Ambassadors for the visually, hearing, and speech impaired posed for a memorable photo together with the facilitators

TAJUK TITLE	Mesyuarat Pemurnian Senarai Semak ADAF <i>ADAF Checklist Refinement Meeting</i>
TARIKH/ TEMPAT DATE/ VENUE	5-7 Ogos 2024, Hotel Lexis, Port Dickson <i>5-7 August 2024, Lexis Hotel, Port Dickson</i>
PESERTA PARTICIPANT	45 pegawai farmasi KKM dari wakil pengurusan tertinggi dari seluruh negeri. <i>45 MOH senior management pharmacists' representatives from across the country.</i>
OBJEKTIF OBJECTIVE	Menyemak dan menambah baik senarai semak Audit Dalam Amalan Farmasi (ADAF) agar selaras dengan prosedur, garis panduan dan amalan terkini. <i>To review and enhance the Audit Dalam Amalan Farmasi (ADAF) checklist to ensure its alignment with current procedures, guidelines, and best practices.</i>
HASIL OUTCOME	Meningkatkan keberkesanan senarai semak, menangani cabaran semasa, dengan mengemas kini elemen yang perlu berdasarkan perubahan dasar dan garis panduan terkini. Selain itu, peserta turut berkongsi pandangan dan pengalaman, bagi memastikan pelaksanaan ADAF yang lebih menyeluruh dan seragam di seluruh negeri. <i>Enhance the checklist's effectiveness, addressing current challenges, by updating necessary elements based on the latest policy and guideline changes. Additionally, participants shared insights and experiences, contributing to a more comprehensive and standardized approach in ADAF implementation nationwide.</i>



TAJUK TITLE	Taklimat Pemurnian Senarai Semak ADAF <i>ADAF Checklist Refinement Briefing</i>
TARIKH/ TEMPAT DATE/ VENUE	9 Disember 2024, Secara atas talian (Google meet) <i>9 December 2024, Online (Google Meet)</i>
PESERTA PARTICIPANT	42 pegawai farmasi KKM dari seluruh negara <i>42 MOH pharmacists from across the country</i>
OBJEKTIF OBJECTIVE	Objektif taklimat ini adalah untuk memastikan senarai semak baharu digunakan di semua fasiliti yang menjalankan ADAF/ audit sendiri mulai Januari 2025 tanpa mengganggu perancangan audit di negeri/ institusi. Taklimat ini adalah berikutan pindaan senarai semak ADAF hasil Bengkel Pemurnian Senarai Semak ADAF pada 5-7 Ogos 2024 yang dihadiri oleh wakil pengurusan tertinggi negeri/institusi. <i>The objective of this briefing is to ensure that the new checklist is used in all facilities conducting ADAF/ self-audits starting January 2025 without disrupting audit planning at the state/ institution level. This briefing follows the amendments to the ADAF checklist from the ADAF Checklist Refinement Workshop, held on 5-7 August 2024, attended by senior management representatives from states/institutions.</i>
HASIL OUTCOME	Taklimat ini memastikan pemahaman yang jelas mengenai penggunaan senarai semak ADAF baharu dan membolehkan penyelarasan di peringkat negeri/ institusi serta memastikan pelaksanaan yang lebih efektif dan sistematik. <i>This briefing ensures a clear understanding of the use of the new ADAF checklist, facilitates coordination at the state/ institution level, and ensures more effective and systematic implementation.</i>



AKTIVITI LAIN (SENARAI)**OTHER ACTIVITIES (LIST)**

Lawatan Penilaian Bagi Tujuan Pengiktirafan Pusat Latihan Sangkutan Jangka Pendek Perkhidmatan Farmasi Klinikal dan Teknikal

Assessment Visit for the Appointment of Clinical Pharmacy Attachment Training Centre

PENGLIBATAN SEBAGAI PENCERAMAH:**INVOLVEMENT AS SPEAKER:**

Senarai penglibatan sebagai penceramah jemputan bagi beberapa bengkel/ persidangan yang diadakan seperti berikut:

List of involvement as a guest speaker for several workshops/ conferences held as below:

1. Forum Ekonomi Kesihatan ke-7, 2024 anjuran Universiti Teknologi Mara dan PhAMA (17 Oktober 2024)

7th Health Economics Forum 2024 organised by Universiti Teknologi Mara and PhAMA (17 October 2024)

2. Kursus Pengenalan Kepada Kelulusan Khas Yang Dikeluarkan Oleh Program Perkhidmatan Farmasi KKM anjuran Bahagian Penguatkuasaan Farmasi

Introduction Course on Special Approvals Issued by the Pharmaceutical Services Programme, Ministry of Health organised by Pharmacy Enforcement Division (15 May 2024)

3. Seminar *Monitoring of Registered and Special Approval Medicine* anjuran Bahagian Regulatori Farmasi Negara

Monitoring of Registered and Special Approval Medicine, NPRA (22 April 2024)

4. Bengkel Health Economics for Cancer Treatment anjuran Taylor's University dan Malaysian Oncological Society (20 Januari 2024)

Health Economics Workshop for Cancer Treatment organised by Taylor's University and Malaysian Oncological Society (20 January 2024)

5. Liver Cancer Awareness Programme sempena World Cancer Day 2024 anjuran Universiti Kebangsaan Malaysia (4 Februari 2024)

Liver Cancer Awareness Programme in conjunction with World Cancer Day 2024 organised by the National University of Malaysia (4 February 2024)



3.0 PENCAPAIAN DAN PENGIKTIRAFAN | ACHIEVEMENT AND RECOGNITION

PENYERTAAN PERSIDANGAN PENYELIDIKAN DAN PEMBANGUNAN (R&D) FARMASI KEBANGSAAN KE-12 TAHUN 2024

Persidangan Penyelidikan dan Pembangunan (R&D) Farmasi Kebangsaan Ke-12 Tahun 2024 diadakan pada 19-21 Ogos 2024 bertempat di KSL Esplanade Hotel, Klang Selangor anjuran PPF. Cawangan Pengurusan Harga Ubat telah menyertai pembentangan oral dengan tajuk "An Overview of Medicines Pooled Procurement in the Public Sector: How Much We Save?"



PARTICIPATION IN THE 12TH NATIONAL PHARMACY RESEARCH AND DEVELOPMENT (R&D) CONFERENCE 2024

The 12th National Pharmaceutical Research and Development (R&D) Conference 2024 was held from 19-21 August 2024 at the KSL Esplanade Hotel, Klang, Selangor, organized by the PSP. The Medicines Price Management Branch participated in an oral presentation titled "An Overview of Medicines Pooled Procurement in the Public Sector: How Much We Save?"



Penyertaan Persidangan Penyelidikan dan Pembangunan (R&D) Farmasi Kebangsaan Ke-12 Tahun 2024
Participation in the 12th National Pharmaceutical Research and Development (R&D) Conference 2024


PENYERTAAN PERSIDANGAN DIABETES ASIA 2024

Persidangan Diabetes Asia 2024 telah diadakan pada 17 hingga 19 Oktober di Royal Chulan, Kuala Lumpur anjuran National Diabetes Institute (NADI). Cawangan Pengurusan Harga Ubat telah menyertai pembentangan poster dengan tajuk "Access to Non-communicable diseases (NCDs) Medicines in Malaysia Healthcare System: A Nationwide Cross-Sectional Study".




PARTICIPATION IN THE DIABETES ASIA CONFERENCE 2024

The Diabetes Asia Conference 2024 was held from 17 to 19 October at Royale Chulan, Kuala Lumpur, organized by the National Diabetes Institute (NADI). The Medicines Price Management Branch participated in a poster presentation titled "Access to Non-Communicable Diseases (NCDs) Medicines in Malaysia Healthcare System: A Nationwide Cross-Sectional Study".



Penyertaan Persidangan Diabetes Asia 2024
Diabetes Asia Conference 2024 participation

4.0 PENERBITAN DAN KAJIAN | PUBLICATION AND RESEARCH



Guidelines on Submission of Dossier for Listing into the Ministry of Health Medicines Formulary (2024)
Guidelines on Submission of Dossier for Listing into the Ministry of Health Medicines Formulary (2024)




Garis Panduan Pengendalian Medicine Access Schemes (MASc) di Fasilitas KKM (Edisi Kedua) 2024
Garis Panduan Pengendalian Medicine Access Schemes (MASc) di Fasilitas KKM (Edisi Kedua) 2024



Modul Latihan Farmasi Logistik - Pengenalan Asas Pengurusan Farmasi Logistik
Modul Latihan Farmasi Logistik - Pengenalan Asas Pengurusan Farmasi Logistik



Dilution Guide for Fluid Restricted Critically Ill Adults 2024
Dilution Guide for Fluid Restricted Critically Ill Adults 2024




Neurology Medication Therapy Adherence Clinic (MTAC) Protocol (Second Edition)
Neurology Medication Therapy Adherence Clinic (MTAC) Protocol (Second Edition)




Oncology Pharmacy Service Guide
Oncology Pharmacy Service Guide




Geriatric Pharmacy Protocol: MTAC, Ward Pharmacy & HMR (Second Edition) 2024
Geriatric Pharmacy Protocol: MTAC, Ward Pharmacy & HMR (Second Edition) 2024



Garis Panduan Antimikrobal Kebangsaan (National Antimicrobial Guideline, NAG) Edisi Keempat
Garis Panduan Antimikrobal Kebangsaan (National Antimicrobial Guideline, NAG) Edisi Keempat



Heart Failure Medication Therapy Adherence Clinic (MTAC) Protocol (Second Edition)
Heart Failure Medication Therapy Adherence Clinic (MTAC) Protocol (Second Edition)



Rheumatoid Arthritis Medication Therapy Adherence Clinic (RaMTAC) Protocol (Second Edition)
Rheumatoid Arthritis Medication Therapy Adherence Clinic (RaMTAC) Protocol (Second Edition)



Laporan Kajian Pemantauan Harga Ubat di Malaysia 2022
Medicine Prices Monitoring in Malaysia Survey Report 2022



Penerbitan manuskrip bertajuk '*Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia – a multiple HTA approach*' dalam *International Journal of Technology Assessment in Health Care*, 40(1), e69, 1–9
Publication of manuscript entitled 'Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia - a multiple HTA approach' in the International Journal of Technology Assessment in Health Care, 40(1), e69, 1–9

5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA INTERNATIONAL COLLABORATION AND PARTICIPATION

KONSULTASI TEKNIKAL PANDUAN OPERASI WHO BAGI NEGARA YANG BERSEDIA MEMPERKENALKAN ANTIBIOTIK BAHARU (25-26 JUN 2024)

Konsultasi Teknikal Panduan Operasi WHO bagi Negara yang Bersedia Memperkenalkan Antibiotik Baharu telah diadakan di Ibu Pejabat Pertubuhan Kesihatan Sedunia (WHO) di Geneva dan dihadiri oleh Dr. Nur Sufiza binti Ahmad, Timbalan Pengarah Cawangan Pengurusan Formulari. Konsultasi ini bertujuan untuk menambah baik panduan WHO dalam pengenalan antibiotik baharu, dengan memberi tumpuan kepada laluan peraturan, pengurusan rantai bekalan, dan penjagaan antimikrob serta menekankan kepentingan perancangan nasional yang kukuh bagi memastikan akses yang mampan dan mengurangkan rintangan antimikrob (AMR). Pakar-pakar turut membincangkan amalan terbaik, khususnya untuk negara berpendapatan rendah dan sederhana (LMICs), serta meneroka strategi bagi mengimbangkan ketersediaan antibiotik dengan penggunaan yang bertanggungjawab. Antara topik utama yang dibincangkan termasuk rangka kerja analisa kos, senarai semak perancangan, strategi perolehan, model harga, serta pembentangan kajian kes mengenai kejayaan pengenalan antibiotik baharu. Hasil daripada konsultasi ini akan membantu memperkukuh panduan WHO dan membantu sesebuah negara dalam mengurus pengenalan antibiotik baharu dengan lebih berkesan dalam sistem penjagaan kesihatan negara-negara tersebut.

TECHNICAL CONSULTATION ON WHO OPERATIONAL GUIDANCE FOR COUNTRIES PREPARING TO INTRODUCE NEW ANTIBIOTICS (25-26 JUNE 2024)

The Technical Consultation on WHO Operational Guidance for Countries Preparing to Introduce New Antibiotics was held at WHO Headquarters in Geneva and attended by Deputy Director of Formulary Management Branch. The consultation aimed to refine WHO's guidance on antibiotic introduction, focusing on regulatory pathways, supply chain management, and antimicrobial stewardship while emphasizing strong national planning to ensure sustainable access and minimize antimicrobial resistance (AMR). Experts discussed best practices, particularly for low- and middle-income countries (LMICs), and explored strategies to balance availability with responsible use. Key topics included cost analysis frameworks, planning checklists, procurement strategies, and pricing models, along with case studies on successful antibiotic introduction. The outcomes will help enhance WHO's guidance and support countries in effectively managing new antibiotics in their healthcare systems.

MESYUARAT PERANCANGAN OPERASI SECURE (27 JUN 2024)

Mesyuarat Perancangan Operasi SECURE, yang diketuai oleh WHO, memberi tumpuan kepada pembangunan aktiviti teras bagi meningkatkan akses global kepada antibiotik. Mesyuarat ini mengenal pasti keutamaan operasi, termasuk pemilihan senarai pendek antibiotik bagi fasa *proof-to-concept* serta menangani kegagalan pasaran yang menjejaskan ketersediaan, terutamanya di negara berpendapatan rendah dan sederhana (LMICs). Perbincangan memberi tumpuan kepada strategi pembentukan pasaran, seperti penyelarasan polisi regulatori, mekanisme perolehan berpusat, dan model kewangan seperti jaminan volum bagi menstabilkan rantai bekalan. Mesyuarat ini menyediakan asas bagi pelaksanaan SECURE, memastikan usaha global yang terkoordinasi dalam meningkatkan akses kepada antibiotik sambil memelihara keberkesannya melalui penggunaan yang bertanggungjawab.

SECURE OPERATIONAL PLANNING MEETING (27 JUNE 2024)

The SECURE Operational Planning Meeting, led by WHO, focused on developing core activities to enhance global antibiotic access. The meeting identified key priorities, including selecting a shortlist of antibiotics for the proof-of-concept phase and addressing market failures that limit availability, particularly in low- and middle-income countries (LMICs). Discussions centered on market shaping strategies, such as regulatory streamlining, pooled procurement, and financial models like volume guarantees to stabilize supply chains. The meeting laid the groundwork for operationalizing SECURE, ensuring a coordinated global effort to improve antibiotic access while promoting responsible use.



Mesyuarat Perancangan Operasi SECURE
SECURE Operational Planning Meeting

THE EIGHTH MEETING OF THE ASIA-PACIFIC NETWORK ON ACCESS TO MEDICINES UNDER UNIVERSAL HEALTH COVERAGE

Mesyuarat yang diadakan pada 25 hingga 26 September 2024 bertempat di Seoul, Korea Selatan telah dianjurkan oleh WHO Regional Offices for the Western Pacific and South-East Asia, dengan kolaborasi OECD dan Seoul National University. Mesyuarat ini memfokuskan pada mekanisme untuk pembiayaan ubat-ubatan secara mampan, perkongsian maklumat harga dan peraturan, kecekapan dalam sistem perolehan dan pengurusan bekalan, serta pemantauan dan penilaian dasar farmaseutikal dan intervensi untuk meningkatkan akses kepada ubat-ubatan penting.

THE EIGHTH MEETING OF THE ASIA-PACIFIC NETWORK ON ACCESS TO MEDICINES UNDER UNIVERSAL HEALTH COVERAGE

The meeting held from 25 to 26 September 2024 in Seoul, South Korea, was organized by the WHO Regional Offices for the Western Pacific and South-East Asia, in collaboration with the OECD and Seoul National University. This meeting focused on mechanisms for sustainable medicines financing, price information sharing and regulation, efficiencies in procurement and supply management systems, as well as monitoring and evaluation of pharmaceutical policies and interventions to improve access to essential medicines.



The Eighth Meeting of The Asia-Pacific Network on Access to Medicines under Universal Health Coverage

The Eighth Meeting of The Asia-Pacific Network on Access to Medicines under Universal Health Coverage



Wakil KKM dari BAPF dan Bahagian Perolehan dan Penswastaaan

Representatives of the MOH from the BAPF and Procurement and Privatisation Division

LAWATAN SAMBIL BELAJAR KE THAILAND BERKAITAN MEDICINES PRICING, REIMBURSEMENT POLICY, AND BENEFIT PACKAGE FOR MEDICINES

Pertubuhan Kesihatan Sedunia (WHO) Pejabat Wilayah Pasifik Barat (WPRO) telah bekerjasama dengan Health Intervention and Technology Assessment Program (HITAP) Kementerian Kesihatan, Thailand untuk menganjurkan lawatan sambil belajar ke Thailand. Lawatan ini diadakan pada 4 hingga 8 Mac 2024 di Nonthaburi, Thailand, bertujuan untuk berkongsi pendekatan Thailand terhadap penetapan harga ubat dan memudahkan pembelajaran antara negara. Peserta dari lima negara iaitu Mongolia, Filipina, Brunei, Bhutan dan Malaysia terlibat dalam perbincangan dan pembentangan yang meliputi pelbagai aspek dasar harga ubat, mekanisme perolehan dan Penilaian Teknologi Kesihatan (HTA). Lawatan ini juga memberikan pandangan yang berharga dan langkah strategik kepada negara-negara di rantau Asia-Pasifik (APAC) untuk membangunkan dasar penetapan harga yang berkesan serta mengukuhkan sistem kesihatan masing-masing.

STUDY VISIT TO THAILAND ON MEDICINES PRICING, REIMBURSEMENT POLICY, AND BENEFIT PACKAGE FOR MEDICINES

The Western Pacific Regional Office (WPRO) of the World Health Organization (WHO) collaborated with the Health Intervention and Technology Assessment Program (HITAP) Ministry of Public Health, Thailand to organize a study visit to Thailand. Held from March 4th to 8th, 2024, in Nonthaburi, Thailand, the study visit aimed to share Thailand's approach to pricing medicines and facilitate cross-country learning. Participants from five countries which are from Mongolia, Philippines, Brunei, Bhutan and Malaysia engaged in discussions and presentations covering various aspects of medicine pricing policies, procurement mechanisms and Health Technology Assessment (HTA). The study visit provided valuable insights and strategic takeaways for countries in the Asia-Pacific (APAC) region to develop effective pricing policies and strengthen their healthcare systems.



Lawatan Sambil Belajar ke Thailand berkaitan Medicines Pricing, Reimbursement Policy, and Benefit Package for Medicines

Study Visit to Thailand on Medicines Pricing, Reimbursement Policy, and Benefit Package for Medicines



BAHAGIAN PENGUATKUASAAN FARMASI

PHARMACY ENFORCEMENT DIVISION

4,320

PREMIS | PREMISES

Bilangan Premis Farmasi
Komuniti Swasta
*Number of Private Community
Pharmacy Premises*

2,507

**AKTIVITI KESEDARAN
AWARENESS ACTIVITIES**

Jumlah Aktiviti Kesedaran
Penjual Dan Pemegang Taruh
*Total Number of Awareness
Activities for Sellers and
Stakeholders*

222

**PERANTI DIGITAL
DIGITAL DEVICES**

Bilangan Peranti Digital
Diterima Untuk Penganalisan
*Total Number of Digital Devices
Received for Analysis*



28,401

**IKLAN DISARING
ADVERTISEMENT SCREENED**

Jumlah Iklan Disaring Yang Berkaitan Dengan Farmasi/
Kesihatan/ Perubatan (Media cetak, Media Elektronik,
Media Baharu)
*Number of Advertisements Screened Related to Pharmacy/
Health/ Medicine (Print Media, Electronic Media, New Media)*



Bilangan Sekatan Akses/ Penurunan
Kandungan URL
*Number of Access Restrictions/
Content Removal URLs*

15,342

**SEKATAN AKSES
ACCESS RESTRICTIONS**

1,370

SERBUAN | RAIDS

RM37,491,206

NILAI RAMPASAN | VALUE OF SEIZURES

Jumlah Serbuan yang dijalankan & Nilai Rampasan
Total Raids Conducted & Value of Seizures



9,693


**PREMIS BERLESEN
LICENSED PREMISES**

2,762

**PREMIS BERDAFTAR
REGISTERED PREMISES**

Jumlah Pemeriksaan Premis Berlesen dan Premis Berdaftar
Total Inspections of Licensed and Registered Premises





BAHAGIAN PENGUATKUASAAN FARMASI **PHARMACY ENFORCEMENT DIVISION**

1.0 PENGENALAN | INTRODUCTION

Bahagian Penguatkuasaan Farmasi (BPF) berperanan untuk memastikan semua produk farmaseutikal, tradisional dan kosmetik dalam pasaran adalah sah daripada segi pendaftaran dan notifikasi. Ia juga berfungsi untuk memastikan bahawa pengendalian rangkaian bekalan dan pemasaran, pengiklanan produk-produk kesihatan dan perkhidmatan perubatan dikendalikan dengan mematuhi peruntukan undang-undang yang dikuatkuasakan iaitu di bawah Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956. Usaha ini dilaksanakan melalui aktiviti risikan dan operasi terancang, kawalan melalui sistem pelesenan, pemantauan berterusan dan bersepadu serta aktiviti seranta bersama agensi-agensi berkepentingan bagi menurunkan permintaan terhadap produk yang tidak selamat atau membahayakan. Berikut merupakan fungsi utama bagi cawangan dan seksyen di bawah BPF:

The Pharmacy Enforcement Division (PED) plays a pivotal role to ensure that all pharmaceutical products, traditional medicines and cosmetics available in the market are genuine in terms of registration and notification. It also acts to ensure that the link between supply and marketing, advertising of healthcare products and medical services is conducted in compliance with the provisions of the existing legislations in Poisons Act 1952, Sale of Drugs Act 1952 and Medicines (Advertisement and Sale) Act 1956. This effort is carried out through intelligence activities and planned operations, control via a licensing system, continuous and integrated monitoring, as well as engagement activities with relevant stakeholders to reduce the demand for unsafe or harmful products. Below are the main functions of branches and section under the PED:

CAWANGAN PERISIKAN DAN OPERASI | INTELLIGENCE AND OPERATION BRANCH

- Menyelaras aktiviti pengendalian aduan di peringkat ibu pejabat dan Cawangan Penguatkuasaan Farmasi (CPF) berkaitan aduan produk.
- Merancang dan memantau aktiviti pembasmian produk tidak berdaftar, produk tiruan dan produk campur racun di pasaran.
- *To coordinate complaints handling activities at the headquarters and Pharmacy Enforcement Branch (PEB) related to product complaints.*
- *To plan and monitor the eradication activities of unregistered products, counterfeit products and adulterated products in the market.*

CAWANGAN PELESENAN | LICENSING BRANCH

- Mengeluarkan Lesen/ Kebenaran Import/ Kebenaran Eksport/ Permit Import/ Permit Eksport/ Syarat Lesen Khas/ Kebenaran Khas untuk aktiviti pengimportan, pekeksportan, pengedaran substans berjadual bagi dadah berbahaya, bahan psikotropik, serta prekursor (*pseudoephedrine* dan *ephedrine*) dan penetapan kuota bagi bahan-bahan tersebut serta kelulusan pengedaran bahan terkawal.
- Merancang, menyelaras, mengkoordinasi dan memantau aktiviti pelesenan dan pemeriksaan yang dijalankan oleh CPF Negeri serta aktiviti saringan dan pemeriksaan pengimportan di pintu-pintu masuk Kastam bagi produk dan bahan yang dikawal bagi memastikan kepatuhan terhadap peruntukan undang-undang yang dikuatkuasakan.
- Menguruskan perkara-perkara berkaitan konvensyen-konvensyen dadah antarabangsa di mana BPF merupakan Pihak Berkuasa Berwibawa (*Competent Authority*) yang melibatkan substans terkawal seperti dadah berbahaya (narkotik), bahan psikotropik dan prekursor serta menyelaras tindakan dengan agensi/ jabatan/ pihak berkuasa lain yang berkaitan dengan aktiviti pelesenan, pemeriksaan, kawalan pintu masuk dan kawalan substans terkawal selaras dengan konvensyen antarabangsa.
- *Issuing of Licence / Import Authorization / Export Authorization/ Import Permit/ Export Permit/ Special Licence Conditions/ Special Authorization for importation, exportation, distribution activities of scheduled substances for dangerous drugs, psychotropic substances and precursors (pseudoephedrine and ephedrine), and quotas setting for such substances as well as approval for controlled substances distribution.*
- *Plan, coordinate and monitor the activities of licensing and inspection carried out by the State PEB and inspection activities at Customs entry points on the importation of products and substances which are regulated under the Acts enforced to ensure compliance with the provisions of the law enforced.*
- *Manage related matters pertaining International Drug Conventions involving dangerous drugs (narcotics), psychotropic substances and precursors where PED as the Competent Authority for the Conventions and coordinate actions with other agencies/ departments/ authorities related to the activities such as licensing, inspection, entry points control and substance control as in accordance with international conventions.*

CAWANGAN PERUNDANGAN | LEGISLATIVE BRANCH

- Menganalisis dan mengkaji undang-undang sedia ada untuk memastikan relevan dengan keperluan dan cabaran semasa serta meminda dan jika perlu, menggubal undang-undang untuk memantapkan dan memperkukuh kawalan dan penguatkuasaan.
- Mengkoordinasikan proses siasatan dan pendakwaan di semua CPF.
- *To conduct research and review on the existing laws to ensure their relevance to the current needs and challenges as well as to amend current laws or to enact new laws to strengthen the governance and regulatory control*
- *To coordinate investigation and prosecution activities in all PEB.*

CAWANGAN KAWALAN IKLAN | ADVERTISEMENT CONTROL BRANCH

- Memproses kelulusan iklan produk ubat dan perkhidmatan kesihatan serta memproses pindaan/ pembatalan/ tarik balik kelulusan iklan produk ubat dan perkhidmatan kesihatan; sebagai Sekretariat kepada Lembaga Iklan Ubat; serta menyediakan dan mengemas kini polisi Lembaga Iklan Ubat, garis panduan pengiklanan dan panduan berkaitan permohonan kelulusan iklan.
- Menjalankan saringan dan pemantauan ke atas iklan produk dan perkhidmatan perubatan dalam media cetak, media elektronik dan media baharu bagi memastikan peruntukan undang-undang sedia ada dipatuhi
- Merancang dan melaksanakan aktiviti kesedaran dan libat urus kepada pemegang taruh dan pihak yang berkepentingan bagi meningkatkan kefahaman dan kepatuhan kepada peruntukan undang-undang yang dikuatkuasakan.
- *Process approval/ amendments/ cancellations of advertisements for medicinal products and healthcare services and revocation of medicinal products and healthcare services advertisement; Secretariat for the Medicine Advertisement Board; prepare and update the Medicine Advertisement Board policy, advertising guidelines and guides relating to advertisement approval applications.*
- *Conduct screening and monitoring of medicinal products and healthcare services advertisements in print media, electronic media and new media to ensure compliance with existing legal provisions.*
- *Plan and implement awareness activities and engagement with various stakeholders and relevant parties to increase understanding and compliance with the currently enforced legal provisions.*

CAWANGAN FARMASI FORENSIK | FORENSIC PHARMACY BRANCH

- Menyaring dan memantau penjualan produk farmaseutikal di media baru serta menyediakan laporan pemprofilan bagi aduan yang diterima berhubung dengan pembekalan atau penjualan produk dalam Internet serta menjalankan forensik digital dan pemulihan data bagi membolehkan bukti dibawa ke mahkamah
- Mengurus dan mengendalikan makmal forensik siber dan makmal forensik kimia untuk membantu tugas pemantauan dan risikan pasaran serta mewujudkan pangkalan data bagi sampel yang diuji
- *Screen and monitor the sale of pharmaceutical products in the new media and prepare profiling reports based on complaints in relation to the supply or sale of pharmaceutical products on the Internet as well as conduct digital forensics and data recovery to enable evidence to be brought to court*
- *Manage and operate cyber forensic laboratory and chemical forensic laboratory to assist in market monitoring and intelligence activities as well as creating database of tested samples*

SEKSYEN PERKEMBANGAN PENGUATKUASAAN FARMASI | PHARMACY ENFORCEMENT DEVELOPMENT SECTION

- Memantau dan menyelaras peruntukan kewangan Aktiviti Penguatkuasaan Farmasi Ibu Pejabat dan Negeri, urusan sumber manusia, urusan latihan dan kompetensi pegawai di bawah Aktiviti Penguatkuasaan Farmasi
- Memantau dan menyelaras pelaksanaan Aktiviti Penguatkuasaan Farmasi supaya mencapai indikator dan objektif kualiti serta Dasar dan Pelan Tindakan yang ditetapkan
- Memantau dan menyelaras maklum balas dari Ibu Pejabat dan CPF Negeri kepada pihak yang berkepentingan dan pembangunan sistem sedia ada/ baru di BPF.
- *Monitor and coordinate budget allocation for pharmacy enforcement activities at the headquarters and state level; monitor and coordinate human resource matters, training matters and competencies for officers under Pharmacy Enforcement Activities*
- *Monitor and coordinate the implementation of Pharmacy Enforcement Activities to achieve quality indicators and objectives as well as set Policies and Action Plans.*
- *Monitor and coordinate feedback from the headquarters and the states to stakeholders as well as the development of existing/ new systems in the PED.*

2.0 AKTIVITI DAN SOROTAN | ACTIVITIES AND HIGHLIGHTS

LEMBAGA RACUN

Lembaga Racun telah bersidang sebanyak dua kali dalam tahun 2024 melalui mesyuarat kali ke-99 dan ke-100. Mesyuarat Lembaga Racun yang ke-99 telah diadakan pada 30 Januari 2024 dan memutuskan perkara-perkara berikut:

- i. Mengelaskan 17 bahan kimia sebagai racun baru di bawah Akta Racun 1952 [Akta 366]
- ii. Menyenaraikan sodium hyaluronate dalam sediaan parenteral sebagai racun Kumpulan C
- iii. Mengekalkan kawalan nikotin dalam sediaan lozeng sebagai racun Kumpulan C
- iv. Membenarkan penggunaan ubat-ubat yang diperlukan dan dibenarkan oleh Majlis Optik Malaysia dalam perkhidmatan optometri seperti cyclopentolate, tropicamide dan proparacaine. Kebenaran penggunaan ini hanya dibenarkan kepada optometris berdaftar sahaja
- v. Mengekalkan kawalan ibuprofen 200mg atau kurang, sebagai racun Kumpulan C

Seterusnya, pada 22 Ogos 2024, Ketua Pengarah Kesihatan telah menyempurnakan Majlis Sambutan dan mempengerusikan Mesyuarat Lembaga Racun yang ke-100 bertempat di KKM, Putrajaya. Mesyuarat kali ke-100 ini telah memutuskan perkara-perkara berikut:

- i. Mengelaskan 14 bahan kimia sebagai racun baru di bawah Akta Racun 1952 [Akta 366]
- ii. Menyenaraikan 22 bahan kimia/ psikoaktif daripada keputusan Mesyuarat *Commission on Narcotics Drugs* sebagai racun, bahan psikotropik atau dadah berbahaya
- iii. Tidak mengawal *cell gene and therapy products* (CGTP) di bawah Akta 366, sebaliknya dikawal oleh Akta Jualan Dadah 1952 sama ada melalui pindaan kepada Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984 atau penggubalan Peraturan-Peraturan baharu
- iv. Mengelaskan semula aceclofenac daripada racun Kumpulan B kepada C bagi semua sediaan selain daripada sediaan parenteral
- v. Mengecualikan kawalan di bawah Akta Racun 1952 ke atas cysteamine; *its salts* dalam kosmetik bertonifikasi di bawah Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984

POISONS BOARD

The Poisons Board met twice in 2024 through the 99th and 100th meetings. The 99th Poisons Board Meeting was held on 30 January 2024 and decided the following matters:

- i. Classification of 17 chemicals as new poisons under the Poisons Act 1952 [Act 366]*
- ii. Listing of sodium hyaluronate in parenteral preparation as group C poison*
- iii. Maintaining the control of nicotine in lozeng preparations as a Group C poison*
- iv. Allowing the use of medications that are required and permitted in optometry services by the Malaysian Optical Council such as cyclopentolate, tropicamide, and proparacaine. This is only granted to registered optometrists*
- v. Maintaining the control of ibuprofen 200mg or less, as a Group C poison*

On 22 August 2024, the Director-General of Health officiated the ceremony and subsequently chaired the 100th Poison Board Meeting at the MOH, Putrajaya. During this milestone of the 100th meeting, the following decisions were made:

- i. Classification of 14 chemicals as new poisons under the Poisons Act 1952 [Act 366]*
- ii. Listing of 22 chemicals/ psychoactive substances from the decisions of the Commission on Narcotic Drugs Meeting as poisons, psychotropic substances, or dangerous drugs*
- iii. Not regulating cell gene and therapy products (CGTP) under the Act 366, but instead regulating it under the Sale of Drugs Act 1952 either through amending the Control of Drugs and Cosmetics and Regulations 1984 or gazetting a new Regulations*
- iv. Reclassifying aceclofenac in all preparations except in parenteral, from Group B poison to Group C*
- v. Exempting cysteamine; its salts in cosmetics which are notified under Control of Drugs and Cosmetics and Regulations 1984 from control under the Poisons Act 1952*



Mesyuarat Lembaga Racun ke-100
 100th Poisons Board Meeting

LEMBAGA IKLAN UBAT

Lembaga Iklan Ubat (LIU) dalam mesyuaratnya yang pertama bagi sesi tahun 2024 pada 12 Mac 2024, telah memutuskan perkara-perkara berikut:

- Sijil ISO 15189 merupakan dokumen utama bagi tujuan pengesahan status makmal perubatan swasta. Hanya perkhidmatan atau ujian yang telah mendapat akreditasi melalui pensijilan ISO 15189 dibenarkan untuk ditawarkan atau diiklankan.
- LIU telah menetapkan polisi bahawa paparan harga ubat yang mengandungi maklumat seperti harga jualan, nama generik, nama dagangan, dan bahan aktif di fasiliti penjagaan kesihatan swasta tidak tertakluk di bawah Seksyen 4B Akta Ubat (Iklan dan Penjualan) 1956. Oleh itu, kelulusan LIU tidak diperlukan.
- Panduan baru akan diwujudkan sebagai rujukan kepada industri untuk iklan produk dan perkhidmatan kesihatan yang tidak memerlukan kelulusan LIU.

Manakala Lembaga Iklan Ubat dalam sesi mesyuaratnya yang ke-2 bagi tahun 2024 iaitu pada 12 November 2024 telah memutuskan perkara-perkara berikut:

- Pengiklanan perkhidmatan konsultasi dan rawatan pesakit secara dalam talian/ *telemedicine/ teleconsultation* tidak boleh diiklankan sehingga mekanisme pendaftaran perkhidmatan ini diwujudkan.
- LIU tidak meluluskan iklan promosi peranti perubatan dengan paparan jenama serta spesifikasi yang jelas.
- Iklan perkhidmatan di *billboard* fasiliti kesihatan yang memenuhi peruntukan di bawah Seksyen 4A Akta Ubat (Iklan & Penjualan) 1956 memerlukan kelulusan daripada LIU.

MEDICINE ADVERTISEMENTS BOARD

The Medicine Advertisements Board (MAB) on its first meeting for the 2024 session that was conducted on 12 March 2024 has decided the following matter:

- The ISO 15189 certificate is the primary document for verifying the status of private medical laboratories. Only services or tests that have been accredited through ISO 15189 certification are permitted to be offered or advertised.
- MAB has established a policy stating that the display of medicine prices containing information such as the selling price, generic name, trade name, and active ingredients at private healthcare facilities is not subject to Section 4B of the Medicines (Advertisement and Sale) Act 1956. Therefore, MAB approval is not required.
- A new guideline will be established as a reference for advertisements of health products and services that do not require MAB approval.

While Medicine Advertisements Board in its second meeting for the 2024 session on 12 November 2024 has decided the following matters:

- The advertisement of online/ *telemedicine/ teleconsultation* patient consultation and treatment services remains prohibited until a registration mechanism for such services is established.
- MAB does not approve advertisements promoting medical devices with clear brand and specification displays.
- Advertisements for services on billboards at healthcare facilities that fall under the provisions of Section 4A of the Medicines (Advertisement and Sale) Act 1956 require approval from MAB.



Mesyuarat Lembaga Iklan Ubat Bil. 2/2024
Medicine Advertisements Board Meeting No. 2/2024

KEMPEN TOLAK UBAT TIDAK SAH (TOBATS)

Kempen Tolak Ubat Tidak Sah atau singkatan rasminya TOBaTS adalah inisiatif baru BPF dalam memerangi penjualan dan pengiklanan ubat-ubatan yang menyalahi undang-undang di Malaysia. Kempen ini telah dilancarkan secara rasmi oleh Yang Berhormat Menteri Kesihatan Malaysia pada 20 November 2024. Objektif utama kempen ini adalah untuk meningkatkan kesedaran awam khususnya pengguna dan pemegang taruh tentang bahaya dan risiko penggunaan ubat tidak sah, pengiklanan ubatan tanpa kelulusan KKM serta memastikan pengguna mendapatkan bekalan ubat mereka daripada sumber yang sah sahaja.

Seiring dengan kempen ini, sejumlah 1,819 aktiviti kesedaran telah dijalankan sepanjang tahun 2024 oleh BPF di seluruh negara. Aktiviti-aktiviti ini meliputi libat urus, ceramah, pameran dan dialog bersama pemegang taruh, temu bual di stesen radio dan televisyen serta hebahan di medium digital melibatkan portal rasmi PPF di <https://pharmacy.moh.gov.my/tobats> dan platform media sosial rasmi seperti Facebook, Instagram dan TikTok (@Penguatkuasaan Farmasi) selaras dengan trend dan perkembangan semasa.



Pelancaran Kempen Tolak Ubat Tidak Sah (TOBaTS)
The Launching of Say No to Illegal Medicines (TOBaTS) Campaign

SAY NO TO ILLEGAL MEDICINES (TOBATS) CAMPAIGN

The Say No to Illegal Medicines Campaign or its official abbreviation TOBaTS was the latest initiative of the PED in combating the sale and advertisement of medicinal products in contravention to the law being enforced. This campaign was officially launched by the Honourable Minister of Health, Malaysia, on 20 November 2024. The main objectives of this campaign are to raise public awareness, particularly among consumers and stakeholders, about the dangers and risks associated with the use of illegal medicines, the advertising of medicines without approval, and to ensure that consumers obtain their medications only from legitimate sources.

As part of this campaign, a total of 1,819 awareness activities were carried out throughout 2024 by PED nationwide. These activities included engagements, talks, exhibitions, and dialogues with stakeholders, interviews on radio and television stations, as well as dissemination through digital platforms, involving the official portal of the PSP at <https://pharmacy.moh.gov.my/tobats> and official social media platforms such as Facebook, Instagram, and TikTok (@Penguatkuasaan Farmasi), in line with current trends and developments.



MESYUARAT BAGI MEMBINCANGKAN PEMANTAPAN KAWAL SELIA KE ATAS PENGIKLANAN DAN PENJUALAN PRODUK UBAT DAN KOSMETIK DALAM PLATFORM E-DAGANG

BPF telah mengadakan mesyuarat bersama pelbagai pemegang taruh iaitu NPRA, Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup (KPDN), Forum Kandungan Komunikasi dan Multimedia Malaysia (CMCF), Persatuan Farmasi Malaysia (MPS), Persatuan Farmasi Komuniti Malaysia (MCPG), *Pharmaceutical Association of Malaysia (PhAMA)*, *Malaysian Organisation of Pharmaceutical Industries (MOPI)*, *Cosmetic, Toiletries And Fragrance Association (CTFA)* dan *Malaysian Cosmetics And Toiletries Industry Group (MCTIG)* pada 26 Mac 2024 bertempat di pejabat PPF. Seterusnya beberapa siri mesyuarat BPF bersama Shopee Malaysia dan Lazada Malaysia telah diadakan pada 11 Jun 2024, 25 November 2024 dan 12 Disember 2024.

Mesyuarat ini membincangkan inisiatif perkongsian awam-swasta secara sukarela bertujuan untuk meningkatkan kawal selia ke atas pengiklanan dan penjualan produk ubat-ubatan serta kosmetik di platform e-dagang dalam Malaysia. BPF merancang untuk mengadakan Deklarasi Komitmen Strategik Bersama Pengendali Platform e-Dagang iaitu Shopee Malaysia dan Lazada Malaysia.

MEETING TO DISCUSS ON STRENGTHENING CONTROL OF ADVERTISEMENT AND SALE OF DRUG AND COSMETIC PRODUCTS IN E-MARKETPLACE PLATFORMS

A meeting was successfully held on 26 March 2024 between the PED with various relevant stakeholders from the NPRA, Ministry of Domestic Trade and Costs of Living (KPDN), Malaysian Communications and Multimedia Content Forum (CMCF), Malaysian Pharmacists Society (MPS), Malaysian Community Pharmacy Guild (MCPG), Pharmaceutical Association of Malaysia (PhAMA), Malaysian Organisation of Pharmaceutical Industries (MOPI), Cosmetic, Toiletries And Fragrance Association (CTFA) and Malaysian Cosmetics And Toiletries Industry Group (MCTIG). The meeting was organized and convened at the office of PSP. Several series of meetings between PED with Shopee Malaysia and Lazada Malaysia were held on 11 June 2024, 25 November 2024 and 12 December 2024.

The meetings discussed voluntary public-private partnership initiatives aimed at enhancing the control of advertisement and sale of drug and cosmetic products in local e-marketplace platforms. PED plans to hold a Declaration of Strategic Commitment with the giant e-marketplace platform operators in Malaysia, namely Shopee Malaysia and Lazada Malaysia.



Mesyuarat BPF Bersama Pemegang Taruh Pada 26 Mac 2024
PED Meeting with Stakeholders on 26 March 2024



Mesyuarat BPF bersama Shopee Malaysia dan Lazada Malaysia pada 11 Jun 2024
PED Meeting with Shopee Malaysia and Lazada Malaysia on 11 June 2024



KURSUS PEMANTAPAN KAWALAN BAHAN TERKAWAL 2024

Kursus Pemantapan Kawalan Bahan Terkawal 2024 telah diadakan pada 2 September 2024 di Hotel Lexis, Port Dickson. Kursus ini memberi penekanan terhadap pelaksanaan aktiviti kawalan dan pemantauan bahan terkawal iaitu dadah berbahaya, bahan psikotropik, bahan kimia prekursor dan bahan terkawal lain oleh BPF, agensi kerajaan serta pihak berkepentingan yang lain.

BPF selaku Pihak Berkuasa Berwibawa bagi konvensyen antarabangsa yang mengawal bahan terkawal telah melaksanakan pelbagai kawalan bagi memastikan pembekalan bahan terkawal adalah untuk tujuan yang sah. Kawalan ini penting bagi mengelakkan pemesanan dan penyalahgunaan bahan terkawal bagi tujuan penghasilan dadah haram serta kegunaan tidak sah yang lain.

COURSE ON STRENGTHENING CONTROL OF CONTROLLED SUBSTANCE 2024

The Course on Strengthening Control of Controlled Substance 2024 was held on 2 September 2024, at Hotel Lexis, Port Dickson. This course emphasized the implementation of control and monitoring activities for controlled substances, including dangerous drugs, psychotropic substances, precursor chemicals, and other controlled substances by PED, government agencies, and other stakeholders.

PED, as the Competent Authority for international conventions regulating controlled substances, has implemented various controls to ensure that the supply of controlled substances is for legitimate purposes. These controls are crucial to prevent the diversion and misuse of controlled substances for the production of illicit drugs and other illegal uses.



Kursus Pemantapan Kawalan Bahan Terkawal 2024
Course on Strengthening Control of Controlled Substance 2024

KURSUS FORENSIK FARMASI

Kursus Forensik Farmasi telah berlangsung dengan jayanya pada 26-28 Ogos 2024. Kursus ini bertujuan untuk memberikan pendedahan yang lebih mendalam kepada Pegawai Penguat kuasa Farmasi mengenai pelbagai disiplin dalam bidang forensik. Sebagai agensi peneraju dalam memerangi jenayah farmaseutikal, penguatkuasaan farmasi memerlukan pemahaman yang meluas dan komprehensif terhadap elemen-elemen pembuktian yang kompleks dan rumit.

Selama ini, BPF telah memiliki kepakaran yang signifikan dalam bidang Forensik Kimia dan Forensik Siber. Namun, kursus ini menekankan keperluan untuk memperluas cakupan kepada disiplin forensik lain, seperti Forensik Toksikologi, DNA, Cap Jari, Biometrik, Kenderaan, Dokumen, dan Audio Visual, bagi memastikan kesiapsiagaan pegawai dalam menghadapi cabaran siasatan farmaseutikal yang semakin rumit.

PHARMACY FORENSIC COURSE

The Pharmacy Forensics Course was successfully held from 26-28 August 2024. This course aimed to provide deeper exposure to Pharmacy Enforcement Officers on various disciplines in the field of forensics. As the leading agency in combating pharmaceutical crimes, pharmacy enforcement requires a broad and comprehensive understanding of the complex and intricate elements of evidence.

To date, the PED has developed significant expertise in the fields of Chemical Forensics and Cyber Forensics. However, this course emphasized the need to expand the scope to include other forensic disciplines, such as Toxicology, DNA, Fingerprints, Biometrics, Vehicles, Documents, and Audio-Visual Forensics, to ensure the readiness of officers in tackling increasingly complex pharmaceutical investigations.



Kursus Forensik Farmasi
Pharmacy Forensic Course

SEMINAR PEMANTAPAN TINDAKAN OPERASI BERKAITAN LABEL KESELAMATAN HOLOGRAM

Seminar Pemantapan Tindakan Operasi Berkaitan Label Keselamatan Hologram telah dijalankan pada 21-23 Oktober di The Straits Hotel & Suites Melaka yang disertai pegawai penguat kuasa farmasi dari BPF dan CPF Negeri seluruh negara. Penganjuran seminar ini adalah hasil kerjasama antara BPF dan pembekal label keselamatan hologram Syarikat Techno Secure Print Sdn. Bhd.

Tujuan seminar ini diadakan adalah untuk memantapkan pengetahuan pegawai penguat kuasa farmasi berkenaan pemalsuan produk dan pelekat label keselamatan hologram. Pegawai penguat kuasa farmasi dapat mempelajari pengalaman serta cabaran yang dihadapi oleh agensi penguatkuasaan lain berkenaan pemalsuan produk dan pelekat label keselamatan hologram.

SEMINAR ON STRENGTHENING OPERATIONAL ACTIONS RELATED TO SECURITY HOLOGRAM LABELS

The Seminar on Strengthening Operational Actions Related to Security Hologram Labels was held from 21-23 October at The Straits Hotel & Suites Melaka, attended by enforcement officers from the PED and State PEB across the country. This seminar was organized through a collaboration between PED and the security hologram label vendor, Techno Secure Print Sdn. Bhd.

The seminar aimed to improve the knowledge of pharmacy enforcement officers on counterfeit products and security hologram labels. It allowed the officers to gain insights into the experiences and challenges encountered by other enforcement agencies in dealing with counterfeit products and security hologram labels.



Seminar Pemantapan Tindakan Operasi Berkaitan Label Keselamatan Hologram
Seminar on Strengthening Operational Actions Related to Security Hologram Labels

KURSUS PENGENALAN KEPADA KELULUSAN KHAS YANG DIKELUARKAN OLEH PPF

Kursus Pengenalan Kepada Kelulusan Khas Yang Dikeluarkan oleh PPF telah dianjurkan untuk julung-julung kali oleh Cawangan Perundangan, BPF dan telah berlangsung selama tiga (3) hari, iaitu dari 14-16 Mei 2024. Kursus ini bertujuan untuk memberi pemahaman kepada pegawai penguat kuasa farmasi terutama pegawai di negeri yang mempunyai pintu masuk terhadap kelulusan khas yang dikeluarkan oleh PPF. Selain itu, menerusi kursus ini, pihak penganjur berhasrat untuk mengetahui dan memahami isu-isu atau kesukaran yang dialami oleh pegawai penguat kuasa farmasi di lapangan supaya urusan penilaian dan pengeluaran kelulusan khas oleh PPF boleh ditambah baik. Kursus berjalan dengan lancar dan dihadiri oleh 45 pegawai penguat kuasa farmasi dari semua CPF negeri dan juga dari BPF.

Sebanyak lapan (8) slot ceramah melibatkan sesi penyampaian maklumat, perkongsian pengalaman, kajian kes dan juga kuiz telah dijalankan oleh tujuh (7) penceramah, termasuk penceramah jemputan dari BAPF, NPRA, CPF Negeri Johor dan CPF Negeri Sabah. Maklum balas daripada peserta di akhir kursus sangat positif di mana kebanyakan peserta menyarankan agar kursus ini diadakan secara berterusan untuk pegawai penguat kuasa farmasi yang bertugas di pintu masuk dan diperluaskan kepada semua pegawai penguat kuasa farmasi secara umum.

COURSE ON INTRODUCTION TO SPECIAL APPROVALS ISSUED BY THE PSP

Course on Introduction to Special Approvals Issued by the PSP was organized for the first time by the Legislation Branch of PED, and took place over three (3) days, from 14-16 May 2024. The aim of this course is to provide an understanding to pharmacy enforcement officers, particularly those in states with entry points, regarding the special approvals issued by the PSP. Additionally, through this course, the organizer intended to learn about and understand the issues or challenges faced by pharmacy enforcement officers in the field, so that the evaluation and issuance of special approvals by the PSP can be improved. The course proceeded smoothly and was attended by 45 pharmacy enforcement officers from all State PEB and the PED.

A total of eight (8) lecture slots were held, which included information sessions, experience sharing, case studies, and quizzes, delivered by seven (7) speakers, including invited speakers from the BAPF, NPRA, PEB of Johor, and PEB of Sabah. Feedback from participants at the end of the course was very positive, with most participants suggesting that this course be conducted continuously for pharmacy enforcement officers working at entry points and expanded to all pharmacy enforcement officers in general.



Kursus Pengenalan Kepada Kelulusan Khas Yang Dikeluarkan Oleh PPF
Course on Introduction to Special Approvals Issued by the PSP

LAIN-LAIN AKTIVITI OTHER ACTIVITIES

TAJUK TITLE	Bengkel Pemurnian Draf Rang Undang-Undang Jualan Dadah (Pindaan) 2024 <i>Workshop on the Refinement of the Draft Sale of Drugs (Amendment) Bill 2024</i>
TARIKH/ TEMPAT DATE/ VENUE	27-29 Mei 2024, Colmar Tropicale, Berjaya Hill, Bukit Tinggi, Pahang <i>27-29 May 2024, Colmar Tropicale, Berjaya Hills, Bukit Tinggi, Pahang</i>
PESERTA PARTICIPANT	41 pegawai dari setiap Bahagian di bawah PPF, CPF Negeri dan Pejabat Penasihat Undang-Undang, KKM <i>41 officers from each Division of the PSP, State PEB, and the Legal Advisor's Office, MOH</i>
OBJEKTIF OBJECTIVE	Bengkel ini diadakan untuk memurnikan draf Rang Undang-Undang Jualan Dadah (Pindaan) 2024. Draf tersebut akan dikemukakan kepada Pejabat Penasihat Undang-Undang, KKM untuk semakan dan seterusnya untuk kelulusan Jabatan Peguam Negara. Kehadiran wakil dari Pejabat Penasihat Undang-undang, KKM dalam bengkel ini telah dimanfaatkan sepenuhnya bagi mendapatkan pandangan dari aspek perundangan dalam memastikan draf tersebut selaras dengan dasar KKM dan juga undang-undang lain. <i>This workshop was held to refine the draft of the Sales of Drugs (Amendment) Bill 2024. The draft will be submitted to the Legal Advisor's Office, MOH for review and subsequently for the approval of the Attorney General's Chambers. The representatives from the Legal Adviser's Office, MOH attended this workshop to advise and give views on legal aspects to ensure that the proposed amendments are in line with MOH policy and also other laws.</i>
HASIL OUTCOME	Secara keseluruhan , objektif bengkel ini telah dicapai dengan jayanya. <i>The objectives of this workshop were successfully achieved.</i>



TAJUK TITLE	Sesi Libat Urus bersama Persatuan Farmasi Malaysia (MPS) dan <i>Malaysian Community Pharmacy Guild</i> (MCPG) berkenaan Isu Penjualan Racun oleh Ahli Farmasi <i>Engagement Session with the Malaysian Pharmacists Society (MPS) and Malaysian Community Pharmacy Guild (MCPG) on the Issue of Poison Sales by Pharmacists</i>
TARIKH/ TEMPAT DATE/ VENUE	3 September 2024, Hotel KSL Esplanade, Klang <i>3 September 2024, KSL Esplanade Hotel, Klang</i>
PESERTA PARTICIPANT	100 peserta dari MPS, MCPG, CPF negeri dan BPF <i>100 participants from MPS, MCPG, State PEB and PED</i>
OBJEKTIF OBJECTIVE	<ul style="list-style-type: none"> • Menyediakan cadangan langkah-langkah yang boleh diambil bersama untuk mengatasi masalah penjualan racun tanpa preskripsi. • Menyampaikan maklumat bagi meningkatkan kesedaran pemegang taruh (ahli persatuan) dalam memainkan peranan yang berkesan dalam mengatasi masalah penjualan racun tanpa preskripsi disamping mendorong pematuhan yang lebih baik terhadap peraturan farmasi. • <i>Propose joint measures that can be taken to address the issue of poison sales without a prescription.</i> • <i>Provide information to raise awareness among stakeholders (association members) about their role in effectively addressing the issue of poison sales without a prescription while encouraging greater compliance with pharmacy regulations.</i>
HASIL OUTCOME	Sesi libat urus telah berjaya dilaksanakan. <i>The engagement session was successfully conducted.</i>

TAJUK TITLE	Sesi Libat Urus bersama: <i>Engagement Session with:</i> KOTRA PHARMA 26 April 2024 – 7 peserta <i>26 April 2024 – 7 participants</i> BREGO LIFE SCIENCES SDN. BHD. 10 Mei 2024 – 12 peserta <i>10 May 2024 – 12 participants</i> ASTRAZENECA SDN. BHD. 13 Jun 2024 – 10 peserta <i>13 June 2024 – 10 participants</i> SANOFI-AVENTIS (MALAYSIA) SDN. BHD. 25 Julai 2024 – 10 peserta <i>25 July 2024 – 10 participants</i>
TARIKH DATE	26 April 2024; 10 Mei 2024; 13 Jun 2024; 25 Julai 2024 <i>26 April 2024; 10 May 2024; 13 June 2024; 25 July 2024</i>
TEMPAT VENUE	BPF <i>PED</i>
PESERTA PARTICIPANT	7; 12; 10; 10 orang <i>7; 12; 10; 10 persons</i>
OBJEKTIF OBJECTIVE	Mewujudkan kerjasama dan persefahaman berhubung isu pendaftaran produk terutamanya yang melihatkan isu produk <i>counterfeit</i> . <i>Creating cooperation and understanding regarding product registration issues, especially those involving counterfeit product issues.</i>
HASIL OUTCOME	Sesi libat urus ini meningkatkan pemahaman syarikat/ pengadu terhadap isu berkaitan produk <i>counterfeit</i> dan status pengelasan produk. <i>This engagement session enhanced the company's/ complainant's understanding of issues related to counterfeit products and product classification status.</i>

TAJUK TITLE	Mesyuarat BPF bersama Chemical Industries Council of Malaysia (CICM) <i>Meeting Between the PED and the Chemical Industries Council of Malaysia (CICM)</i>
TARIKH/ TEMPAT DATE/ VENUE	29 Julai 2024, BPF <i>29 July 2024, PED</i>
PESERTA PARTICIPANT	19 Peserta (14 daripada BPF dan 5 daripada CICM) <i>19 Participants (14 from PED and 5 from CICM)</i>
OBJEKTIF OBJECTIVE	Meningkatkan kawalan terhadap penggunaan bahan kimia di Malaysia melalui jalinan kerjasama antara agensi kerajaan dan swasta <i>Enhancing control over the use of chemicals in Malaysia through collaboration between government and private agencies</i>
HASIL OUTCOME	Perbincangan dua hala bagi menetapkan hala tuju kerjasama antara BPF dan CICM seperti: <ul style="list-style-type: none"> • Penetapan titik fokus dan medium sebaran maklumat bagi menyalurkan sebarang maklumat berkaitan kawalan bahan kimia. • Penglibatan bersama dalam program yang dijalankan oleh kedua-dua belah pihak. • Mengadakan sesi dialog secara berkala antara BPF dan ahli CICM. <i>Bilateral discussions to establish the direction of collaboration between PED and CICM, including:</i> <ul style="list-style-type: none"> • <i>Designation of focal points and information dissemination mediums for sharing updates related to chemical control.</i> • <i>Joint participation in programmes organized by both parties.</i> • <i>Regular dialogue sessions between PED and CICM members.</i>



TAJUK TITLE	Mesyuarat Pasukan Petugas Prekursor, Narkotik dan Psikotropik Bil. 1/2024 <i>Precursor, Narcotics, and Psychotropic Task Force Meeting No. 1/2024</i>
TARIKH/ TEMPAT DATE/ VENUE	24 September 2024, BPF <i>24 September 2024, PED</i>
PESERTA PARTICIPANT	23 peserta (15 peserta daripada BPF dan 8 Peserta daripada agensi luar) <i>23 participants (15 participants from PED and 8 participants from external agencies)</i>
OBJEKTIF OBJECTIVE	<ul style="list-style-type: none"> • Mewujudkan jalinan kerjasama di antara agensi-agensi penguatkuasaan yang lain dalam kawalan prekursor, psikotropik dan narkotik. • Medium untuk perkongsian maklumat, perbincangan isu-isu dan cabaran, merangka pelan tindakan serta menetapkan halatuju dalam mengukuhkan mekanisma kawalan prekursor, psikotropik dan narkotik. • <i>Establishing collaborative partnerships between enforcement agencies for the control of precursors, psychotropics, and narcotics.</i> • <i>Serving as a platform for information sharing, discussion of issues and challenges, development of action plans, and setting the direction to strengthen control mechanisms for precursors, psychotropics, and narcotics.</i>
HASIL OUTCOME	Pembentangan daripada agensi-agensi (BPF, Polis Diraja Malaysia, Kastam Diraja Malaysia, Agensi Penguatkuasaan Maritim Malaysia, Jabatan Kimia dan Agensi Anti Dadah Kebangsaan) berkaitan kes-kes rampasan dadah terkini. <i>Presentations by agencies (PED, Royal Malaysia Police, Royal Malaysian Customs Department, Malaysian Maritime Enforcement Agency, Department of Chemistry, and the National Anti-Drug Agency) regarding recent drug seizure cases.</i>



TAJUK <i>TITLE</i>	Sesi Libat Urus bersama Ahli Farmasi bagi Pengukuhan Kawalan Penjualan Compounded Preparation yang Disediakan melalui Aktiviti Compounding di Premis Farmasi Komuniti <i>Engagement Session with Pharmacists for Strengthening the Control of Compounded Preparations Sold Through Compounding Activities at Community Pharmacy Premises</i>
TARIKH/ TEMPAT <i>DATE/ VENUE</i>	19 Julai 2024, Jabatan Perdana Menteri <i>19 July 2024, Prime Minister's Department</i>
PESERTA <i>PARTICIPANT</i>	<p>45 peserta: 26 ahli farmasi komuniti 1 wakil Persatuan Ahli Farmasi Malaysia (MPS) 2 wakil Persatuan Farmasi Komuniti Malaysia (MCPG) 2 wakil Persatuan Farmasi Bumiputera 6 peserta dari BPF 2 peserta dari BAPF 2 peserta dari NPRA 4 peserta dari CPF negeri</p> <p>45 participants: <i>26 community pharmacists</i> <i>1 representative from the MPS</i> <i>2 representatives from the MCPG</i> <i>2 representatives from the Malaysian Bumiputera Pharmacy Association</i> <i>6 participants from PED</i> <i>2 participants from BAPF</i> <i>2 participants from NPRA</i> <i>4 participants from State PEB</i></p>
OBJEKTIF <i>OBJECTIVE</i>	Menerangkan kepada ahli farmasi berdaftar/ berlesen yang menjalankan penjualan <i>compounded preparation</i> yang disediakan melalui aktiviti <i>compounding</i> di premis farmasi komuniti berkenaan pelaksanaan bagi pengukuhan kawalan terhadap aktiviti <i>compounding</i> di premis farmasi komuniti. <i>Explain to registered/ licensed pharmacists who are involved in the sale of compounded preparations prepared through compounding activities at community pharmacy premises regarding the implementation of strengthened control over compounding activities at community pharmacy premises.</i>
HASIL <i>OUTCOME</i>	<ul style="list-style-type: none"> • Pelaksanaan pengukuhan kawalan terhadap aktiviti <i>compounding</i> di premis farmasi komuniti melalui proses notifikasi melibatkan semua <i>compounded preparation</i> oleh ahli farmasi berdaftar/ berlesen kepada Pengarah BPF. • Proses notifikasi ini adalah bagi memenuhi keperluan syarat lesen pemegang lesen Jenis A di di premis farmasi komuniti yang menjalankan aktiviti <i>compounding</i> mulai tahun 2025. • <i>The implementation of strengthened control over compounding activities at community pharmacy premises through a notification process to the Director of the PED involving all compounded preparations by registered/ licensed pharmacists.</i> • <i>This notification process is to fulfil the requirements of the Type A license holder at community pharmacy premises that engage in compounding activities starting from the year 2025.</i>



TAJUK TITLE	Hari Kesedaran Farmasi – Tolak Ubat Tidak Sah (TOBaTS) <i>Pharmacy Awareness Day – Say No To Illegal Medicine (TOBaTS)</i>
TARIKH/ TEMPAT DATE/ VENUE	21 Mei 2024, Hotel Everly, Putrajaya <i>21 May 2024, Everly Hotel, Putrajaya</i>
PESERTA PARTICIPANT	300 peserta daripada Ibu Pejabat KKM, Putrajaya dan Agensi-agensi kerajaan di sekitar Putrajaya <i>300 participants from the MOH headquarters in Putrajaya and other government agencies within the vicinity</i>
OBJEKTIF OBJECTIVE	Meningkatkan kesedaran berhubung Kempen TOBaTS dan pembelian ubat yang selamat. <i>Increase awareness toward the TOBaTS Campaign and the safe purchasing of medicine.</i>
HASIL OUTCOME	Peserta dapat memahami cara menyemak status sesuatu produk ubat sebelum membuat pembelian. <i>Participant is able to check and verify status of the medicinal product before purchasing it.</i>



TAJUK TITLE	Latihan Sistem <i>Enterprise Resource Planning (ERP)</i> Label Keselamatan Hologram FarmaTag™ kepada Industri <i>Training on the Enterprise Resource Planning (ERP) System for FarmaTag™ Hologram Security Label to the Industry</i>
TARIKH/ TEMPAT DATE/ VENUE	12 November 2024, Hotel Grand Dorsett, Subang <i>12 November 2024, Grand Dorsett Hotel, Subang</i>
PESERTA PARTICIPANT	197 peserta yang mewakili 118 syarikat <i>197 participants representing 118 companies</i>
OBJEKTIF OBJECTIVE	Memberikan pendedahan kepada pihak industri mengenai pelaksanaan dan pengurusan sistem ERP label keselamatan hologram FarmaTag™, serta memberi galakan dan meningkatkan kesedaran tentang kepentingan modul <i>label assignment</i> . <i>Provide exposure to the industry regarding the implementation and management of FarmaTag™ hologram security label ERP system, as well as to encourage and increase awareness of the importance of the label assignment module.</i>



3.0 PENCAPAIAN DAN PENGIKTIRAFAN | ACHIEVEMENT AND RECOGNITION

PERSIDANGAN PENYELIDIKAN DAN PEMBANGUNAN (R&D) FARMASI KE-12 TAHUN 2024

Secara keseluruhannya sebanyak 16 kajian R&D oleh Pegawai Penguat kuasa Farmasi dari seluruh negara telah terpilih untuk dibentangkan dalam persidangan ini termasuk empat (4) kajian daripada BPF. Jumlah ini melibatkan sepuluh (10) kajian dalam kategori poster (3 kajian daripada BPF) dan enam (6) kajian dalam kategori oral (1 kajian daripada BPF).

Kajian oleh Cik Hii Lu Yien daripada Cawangan Penguatkuasaan Farmasi Negeri Sabah bertajuk 'Exploring the Issues and Challenges of Prosecution Faced by Pharmacy Enforcement Division in Malaysia' telah memenangi kategori Oral – Trek 1 manakala 1 kajian daripada BPF bertajuk 'Retrospective Study of Illegal Medicines Advertisements in Local e-Marketplace Platforms' oleh Cik Yap Fei Ting telah memenangi hadiah saguhati bagi kategori poster.

PENGHARGAAN KEPADA BAHAGIAN PENGUATKUASAAN FARMASI

React merupakan sebuah organisasi global yang mempunyai 30 tahun pengalaman dalam memerangi barangan palsu (*counterfeit*) dengan keahlian sebanyak 350 perniagaan. Organisasi ini mempunyai dua fungsi utama iaitu:

- i. Memberi sokongan kepada ahli dalam strategi anti-pemalsuan dengan menyediakan perkhidmatan 'kastam-dalam talian-dan penguatkuasaan' dengan bayaran bukan komersial
- ii. Memberi sokongan terhadap aktiviti untuk melindungi semua pemegang hak, pengguna dan kerajaan daripada kesan negatif perdagangan barangan tiruan

Setiap tahun, React akan mengadakan Latihan Serantau dan Bengkel Pengenalan Produk kepada agensi penguatkuasaan dan ahli-ahlinya. BPF telah dijemput sebagai ahli panel perbincangan bagi sesi latihan ini semenjak 2022.

Pada tahun ini, BPF telah diberi penghargaan oleh React dalam sesi Latihan Serantau dan Bengkel Pengenalan Produk yang diadakan di Luang Prabang, Laos. Penghargaan ini diberikan kerana usaha BPF dalam memerangi produk farmaseutikal haram. Ini termasuk bukan sahaja usaha menjalankan siasatan dan aktiviti penguatkuasaan, malah usaha dalam menangani produk farmaseutikal *counterfeit* dalam talian melalui sekatan akses, pemantauan platform e-dagang, menangani pemasangan produk-produk farmaseutikal tersebut serta menjalankan program kesedaran.

Penghargaan yang diberikan ini adalah bertepatan dengan slogan dan komitmen BPF iaitu Penguatkuasaan Farmasi: Agensi Peneraju dalam Memerangi Jenayah Farmaseutikal.

12TH NATIONAL PHARMACY RESEARCH AND DEVELOPMENT (R&D) CONFERENCE 2024

A total of 16 R&D research by Pharmacy Enforcement Officers from across the country were selected to be presented at this conference, including four (4) research from the PED. This number includes ten (10) research in the poster category (3 from PED) and six (6) research in the oral category (1 from PED).

A research by Ms. Hii Lu Yien from the Sabah State Pharmacy Enforcement Branch entitled 'Exploring the Issues and Challenges of Prosecution Faced by Pharmacy Enforcement Division in Malaysia' won the Oral – Track 1 category while a research from PED entitled 'Retrospective Study of Illegal Medicines Advertisements in Local e-Marketplace Platforms' by Ms. Yap Fei Ting won the consolation prize for the poster category.

APPRECIATION TO THE PHARMACY ENFORCEMENT DIVISION


React is a not-for-profit global organization with over 30 years of experience in combating counterfeit goods with 350 business members across all industry sectors. This organization has two main functions:

- i. Supporting members in their anti-counterfeiting strategies by providing customs-online-market enforcement services at non-commercial fees
- ii. To support activities to protect all rights holders, consumers and governments against the negative consequences of the trade in counterfeit goods

Each year, React conducts Regional Training and Product Introduction Workshops for enforcement agencies and their members. Since 2022, the PED has been invited to participate as a member of the discussion panel for these training sessions.

This year, the PED was recognized by React during the Regional Training Session and Product Identification Workshop held in Luang Prabang, Laos. This recognition was awarded for the division's efforts in combating illegal pharmaceutical products. These efforts include not only conducting investigations and enforcement activities but also addressing counterfeit pharmaceutical products online through access restrictions, e-commerce platforms monitoring, tackling product diversion, and conducting awareness programmes.

This award aligns with the slogan and commitment of the PED, namely Pharmacy Enforcement: A Leading Agency in Combating Pharmaceutical Crimes.



Penghargaan kepada BPF dalam Memerangi Produk Farmaseutikal Haram oleh Organisasi React di Laos
Appreciation to the PED for Combating Illegal Pharmaceutical Products by the React Organization in Laos

4.0 PENERBITAN DAN KAJIAN | PUBLICATION AND RESEARCH

CODE OF PRACTICE FOR TRADE AND INDUSTRY 2024

Code of Practice for Trade and Industry 2024 – To Prevent Diversion of Chemicals for the Illicit Manufacture of Narcotic Drugs telah diterbitkan buat pertama kali dalam bentuk PDF dan dimuat naik di laman sesawang www.pharmacy.gov.my untuk memudahkan rujukan oleh industri.

Kod Amalan ini adalah secara sukarela, dengan jangkaan bahawa akan wujud pengaturan sendiri antara industri, agensi penguatkuasaan undang-undang, dan komuniti.

Konvensyen Pertubuhan Bangsa-Bangsa Bersatu Menentang Permerdagangan Haram Dadah Narkotik dan Bahan Psikotropik, 1988 (Konvensyen 1988) menghendaki Negara Ahli mengambil langkah yang sesuai untuk mencegah pemerosongan bahan kimia prekursor dan bekerjasama antara satu sama lain dalam perkara ini. Malaysia, sebagai Negara Ahli, dikehendaki untuk menubuhkan dan mengekalkan sistem bagi memantau perdagangan antarabangsa bahan-bahan dalam Jadual I dan Jadual II Konvensyen 1988, untuk memudahkan pengenalan transaksi yang mencurigakan. Kod ini digunakan sebagai pelengkap kepada perundangan kebangsaan sedia ada selaras dengan Artikel 12 Konvensyen 1988.

CODE OF PRACTICE FOR TRADE AND INDUSTRY 2024

Code of Practice for Trade and Industry 2024 – To Prevent Diversion of Chemicals for the Illicit Manufacture of Narcotic Drugs has been published for the first time in PDF format and uploaded to the website www.pharmacy.gov.my to facilitate reference for industries.

The Code of Practice is voluntary, with the expectation of self-regulatory arrangements between the industry, law enforcement agencies and the community.

The United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988 (1988 Convention) requires States Parties to take appropriate measures to prevent diversion of precursor chemicals and to cooperate with one another in this matter. Malaysia as a State Party is required to establish and maintain a system to monitor the international trade of substances in Table I and Table II of the 1988 Convention, in order to facilitate the identification of suspicious transactions. The Code is used as a supplement to existing national legislation in line with the spirit of Article 12 of the 1988 Convention.

PENERBITAN E-BULETIN KKKLIU EDISI 01/2024, 02/2024 DAN 03/2024

Penerbitan E-Buletin KKKLIU ini merupakan medium untuk Sekretariat Lembaga Iklan Ubat menyampaikan maklumat terkini dan juga berkongsi sebarang pindaan yang dibuat kepada polisi atau garis panduan sedia ada yang telah diputuskan dalam Mesyuarat Lembaga Iklan Ubat. Maklumat yang dikongsikan dalam E-Buletin ini adalah dalam bentuk penjelasan grafik dan ringkas untuk memudahkan rujukan dan pemahaman semua.

Sekretariat Lembaga Iklan Ubat telah berjaya menerbitkan E-buletin KKKLIU Edisi 01/2024 pada 9 Februari 2024, E-Buletin KKKLIU Edisi 02/2024 pada 16 Julai 2024 dan E-Buletin KKKLIU Edisi 03/2024 pada 22 Januari 2025. E-Buletin KKKLIU ini boleh dimuat turun di Portal Farmasi www.pharmacy.gov.my.

PUBLICATION OF E-BULLETIN KKKLIU EDITION 01/2024, 02/2024 AND 03/2024

The publication of this E-Bulletin KKKLIU serves as a medium for the Secretariat of Medicine Advertisements Board to convey the latest information and share any amendments made to existing policies or guidelines decided during the Medicine Advertisements Board Meeting. The information shared in this E-Bulletin is presented in the form of concise and graphical explanations for easy reference and understanding by all.

The Secretariat of Medicine Advertisements Board has successfully published E-Bulletin KKKLIU Edition 01/2024 on 9 February 2024, E-Bulletin KKKLIU Edition 02/2024 on 16 July 2024 and E-Bulletin KKKLIU Edition 03/2024 on 22 January 2025. These E-Bulletins can be downloaded from Pharmacy Portal www.pharmacy.gov.my.



Penerbitan E-Buletin KKKLIU Edisi 01/2024, 02/2024 dan 03/2024
Publishing of E-Bulletin KKKLIU Edition 01/2024, 02/2024 and 03/2024



5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA INTERNATIONAL COLLABORATION AND PARTICIPATION

67TH COMMISSION ON NARCOTIC DRUGS (CND)

Mesyuarat telah diadakan pada 18-22 Mac 2024 di Vienna, Austria yang bertujuan untuk membincangkan hala tuju serta dasar-dasar berkaitan permasalahan dadah, mempertingkatkan peranan CND dan memperkasakan program-program antidadah di peringkat antarabangsa yang menumpukan kepada pengurangan bekalan dadah, pengurangan permintaan dadah dan kerjasama antarabangsa. CND bertanggungjawab untuk mengawal selia pelaksanaan Konvensyen Dadah Antarabangsa, iaitu:

- i. *Single Convention on Narcotic Drugs, 1961*
- ii. *Convention on Psychotropic Substances, 1971*
- iii. *Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988*

Mesyuarat selama lima hari ini tertumpu kepada sesi plenari yang terbahagi kepada *operational segment* yang membincangkan perkara-perkara mengenai pengurusan dan bajet manakala *normative segment* membincangkan mengenai pelaksanaan komitmen negara serta perbincangan resolusi.

67TH COMMISSION ON NARCOTIC DRUGS (CND)

The meeting was held from 18-22 March 2024 in Vienna, Austria, with the aim of discussing the direction and policies related to drug issues, enhancing the role of the CND, and strengthening international anti-drug programmes that focus on reducing the supply of drugs, reducing drug demand, and fostering international cooperation. The CND is responsible for overseeing the implementation of the International Drug Conventions, namely:

- i. *Single Convention on Narcotic Drugs, 1961*
- ii. *Convention on Psychotropic Substances, 1971*
- iii. *Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988*

These five days meeting focuses on a plenary session divided into an operational segment, discussing matters related to management and budget, and a normative segment discussing the implementation of countries' commitments and resolution discussions.



67th Commission on Narcotic Drugs
67th Commission on Narcotic Drugs

REGIONAL TRAINING ON PRECURSOR CONTROL TOOLS

Kursus ini dianjurkan oleh *United Nations Office on Drugs and Crimes (UNODC) Regional Southeast Asia and the Pacific* dengan kerjasama *International Narcotics Control Board (INCB)* pada 26-28 Mac 2024 di Bangkok, Thailand.

Kursus ini dapat mengukuhkan komunikasi dan mekanisme maklum balas dalam kalangan pihak berkuasa berwibawa negara di seluruh dunia untuk meningkatkan kecekapan sistem pemantauan antarabangsa terhadap kawalan bahan kimia prekursor serta memastikan ketersediaan bahan kimia prekursor untuk kegunaan yang sah sama ada untuk tujuan perubatan, kajian saintifik atau industri, serta mengelakkan pemesongan bahan kimia prekursor bagi penghasilan dadah secara haram.

REGIONAL TRAINING ON PRECURSOR CONTROL TOOLS

This training is organized by the United Nations Office on Drugs and Crimes (UNODC) Regional Southeast Asia and the Pacific, in collaboration with the International Narcotics Control Board (INCB) from 26-28 March 2024 in Bangkok, Thailand.

The course aims to strengthen communication and feedback mechanisms among competent national authorities worldwide to enhance the efficiency of the international monitoring system for precursor chemical control. It also seeks to ensure the availability of precursor chemicals for legitimate purposes, such as medical use, scientific research, or industry, while preventing the diversion of precursor chemicals for illicit drug production.



Regional Training on Precursor Control Tools
Regional Training on Precursor Control Tools

KUNJUNGAN HORMAT US DRUG ENFORCEMENT ADMINISTRATION (US DEA)

Satu kunjungan hormat daripada *United States Drug Enforcement Administration* (US DEA) telah diadakan pada 8 Mac 2024 bertempat di PPF. Tujuan kunjungan hormat ini adalah untuk mengetahui dengan lebih mendalam fungsi DEA dan peluang kerjasama yang lebih luas antara DEA dan BPF.

Penerangan ringkas telah diberikan mengenai fungsi jabatan, aktiviti-aktiviti penguatkuasaan yang dijalankan termasuk akta-akta yang dikuatkuasakan oleh BPF. Pihak DEA menyatakan kesudian untuk membantu siasatan yang dilakukan oleh pihak BPF yang memerlukan bantuan dan kepakaran daripada mereka. Kunjungan hormat ini diharapkan dapat membuka lebih banyak peluang jalinan kerjasama antara DEA dan BPF dalam aktiviti penguatkuasaan farmasi.



Kunjungan Hormat US DEA
Courtesy Call from US DEA

SAMBUTAN HARI AKADEMI PENGUATKUASAAN UNDANG-UNDANG ANTARABANGSA RANTAU ASIA (ILEA) 2024

Akademi Penguatkuasaan Undang-Undang Antarabangsa (ILEA) telah mengadakan Hari ILEA 2024 julung kalinya pada 15-16 Mei 2024 di kampus utama Bangkok, Thailand untuk menggalakkan alumni ILEA berkongsi "*Successful Story*" berkaitan dengan aktiviti penguatkuasaan di peringkat domestik dan antarabangsa. Objektif teras ILEA adalah untuk meningkatkan kapasiti, mengukuhkan perkongsian, dan memupuk hubungan agensi penguatkuasaan di serantau Asia.

Puan Diana Tan Ai Hsin, sebagai Alumni ILEA telah dijemput untuk menghadiri Hari ILEA 2024 ini dan beliau telah berkongsi kes serbuan Ops Pharma 1.0 & 2.0, Ops Runner dan Ops Gaukar-Maria Kim Network yang melibatkan kolaborasi antara BPF dengan agensi penguatkuasaan lain di peringkat nasional dan antarabangsa. Pada 16 Mei 2024, satu lawatan sambil belajar telah diadakan di *Real Time Crime Centre, Central Investigation Bureau, Bangkok Thailand*.

COURTESY CALL FROM US DRUG ENFORCEMENT ADMINISTRATION (US DEA)

A courtesy visit from the United States Drug Enforcement Administration (US DEA) was held on 8 March 2024 at the PSP. The purpose of this courtesy visit was to learn more about the functions of the DEA and opportunities for broader cooperation between the DEA and PED.

A brief explanation was given about the functions of the department, enforcement activities carried out including acts enforced by the PED. The DEA expressed its willingness to assist in investigations carried out by the PED that require their assistance and expertise. It is hoped that this courtesy visit will open up more opportunities for cooperation between the DEA and PED in pharmacy enforcement activities.



REGIONAL CELEBRATION OF INTERNATIONAL LAW ENFORCEMENT ACADEMY (ILEA) DAY 2024

The International Law Enforcement Academy (ILEA) held the first ILEA Day 2024 on 15-16 May 2024 at the main campus in Bangkok, Thailand to encourage ILEA alumni to share "Successful Stories" related to enforcement activities at the domestic and international level. ILEA's core objective is to increase capacity, strengthen partnerships, and foster relationships among enforcement agencies in the Asian region.

Madam Diana Tan Ai Hsin, as an ILEA Alumni, was invited to attend ILEA Day 2024 and she shared the case of Ops Pharma 1.0 & 2.0, Ops Runner and Ops Gaukar-Maria Kim Network raids involving collaboration between the PED and other enforcement agencies in national and international level. On 16 May 2024, a study tour was held at the Real Time Crime Centre, Central Investigation Bureau, Bangkok Thailand.



Sambutan Hari ILEA 2024
Regional Celebration of ILEA Day 2024

KURSUS TREND TERKINI DADAH SINTETIK HARAM DAN TEKNIK PENGHASILAN DI *INTERNATIONAL LAW ENFORCEMENT ACADEMY* (ILEA) BANGKOK

Kursus Trend Terkini dalam Dadah Sintetik Haram dan Teknik Penghasilan telah dikendalikan oleh Akademi Penguatkuasaan Undang-undang Antarabangsa di Bangkok dan Pentadbiran Penguatkuasaan Dadah (DEA) dari 13-17 Mei 2024. Kursus ini telah diadakan di *International Law Enforcement Academy* (ILEA) Bangkok, Thailand. Kursus ini telah dihadiri oleh dua (2) pegawai penguat kuasa farmasi iaitu En. Mohd Helmi bin Mohd Yunos dan En. Mohammad Firdaus bin Abidin.

Objektif utama kursus ini adalah untuk menyediakan maklumat forensik teknikal mengenai trend terkini dalam dadah sintetik haram dan teknik penghasilannya di seluruh dunia. Ini termasuk penghasilan dadah menggunakan makmal dadah rahsia dengan menggunakan kaedah penghasilan terkini dan precursor baru. Peserta membincangkan mengenai pengenalan, penghasilan, analisis, dan pendekatan undang-undang yang terkini untuk mengawal dadah baru dan analognya seperti fentanyl, methamphetamine dan sebagainya.

EMERGING TRENDS IN ILLICIT SYNTHETIC DRUG AND PRODUCTION TECHNIQUES COURSE AT INTERNATIONAL LAW ENFORCEMENT ACADEMY (ILEA) BANGKOK

The Emerging Trends in Illicit Synthetic Drug and Production Techniques course was conducted by the International Law Enforcement Academy (ILEA) in Bangkok and the Drug Enforcement Administration (DEA) from 13-17 May 2024. The course was held at International Law Enforcement Academy Bangkok, Thailand. This course was attended by two (2) pharmacy enforcement officers, Mr. Mohd Helmi bin Mohd Yunos and Mr. Mohammad Firdaus bin Abidin.

The main objective of this course is to provide technical forensic information on the most current trends in synthetic drugs and emerging illicit drug production techniques being encountered around the world. This includes drug production using clandestine drug laboratories utilising new production methods and novel precursors. The participants discussed the identification, production, analysis, and legal approaches to control newer drugs and their analogues such as fentanyl, methamphetamine etc.



Kursus Trend Terkini Dadah Sintetik Haram Dan Teknik Penghasilan
Emerging Trends in Illicit Synthetic Drug and Production Techniques Course

MESYUARAT KE-13 MEKANISMA NEGARA ANGGOTA WORLD HEALTH ORGANIZATION (WHO) BAGI PRODUK PERUBATAN SUBSTANDARD DAN PALSU

Wakil daripada BPF telah menghadiri Mesyuarat ke-13 Mekanisme Negara Anggota WHO bagi Produk Perubatan Substandard dan Palsu, di Geneva, Switzerland pada 20-22 November 2024.

Mesyuarat ini mengumpulkan pakar, pihak berkepentingan, dan pihak berkuasa regulatori untuk memberi tumpuan kepada bidang utama seperti:

- Meningkatkan sistem pengesanan dan pelaporan bagi produk perubatan substandard dan palsu
- Memperbaiki rangka kerja dan dasar regulatori untuk menghalang peredaran produk perubatan yang tidak selamat dan tidak berkesan
- Menguatkan kerjasama antarabangsa dan perkongsian maklumat antara negara, organisasi, dan industri
- Membangunkan strategi untuk meningkatkan kesedaran mengenai bahaya produk perubatan substandard dan palsu dalam kalangan profesional kesihatan dan orang awam
- Menyokong negara dalam melaksanakan amalan terbaik untuk memerangi produk substandard dan palsu dan meningkatkan kapasiti regulatori

Matlamat keseluruhan adalah untuk memastikan semua produk perubatan yang tersedia di seluruh dunia adalah selamat, berkesan, dan berkualiti tinggi, seterusnya melindungi kesihatan awam dan menyokong usaha global untuk memerangi kemudaratan yang disebabkan oleh ubat-ubatan substandard dan palsu.

WORLD HEALTH ORGANIZATION (WHO) 13TH MEETING OF THE MEMBER STATE MECHANISM ON SUBSTANDARD AND FALSIFIED (SF) MEDICAL PRODUCTS

A representative from the PED attended the WHO Thirteenth Meeting of the Member State Mechanism on Substandard and Falsified (SF) Medical Products in Geneva, Switzerland, from 20-22 November 2024.

The meeting brought together experts, stakeholders, and regulatory authorities to focus on key areas such as:

- *Enhancing systems for the detection and reporting of substandard and counterfeit medical products*
- *Improving regulatory frameworks and policies to prevent the circulation of unsafe and ineffective medical products*
- *Strengthening international cooperation and information sharing between countries, organizations, and industries*
- *Developing strategies to raise awareness of the dangers of substandard and counterfeit medical products among healthcare professionals and the public*
- *Supporting countries in implementing best practices to combat substandard and counterfeit products and strengthen regulatory capacity*

The overall goal is to ensure that all medical products available worldwide are safe, effective, and of high quality, thereby protecting public health and supporting global efforts to combat the harm caused by substandard and counterfeit medicines.



Mesyuarat Ke-13 Mekanisme Negara Anggota WHO Bagi Produk Perubatan Substandard Dan Palsu
WHO 13th Meeting of The Member State Mechanism on Substandard and Falsified (SF) Medical Products

BENGGEL UJIAN POTENSI DAN KAWALAN KUALITI MINYAK KANABIS PERUBATAN DAN PRODUK KRATOM

Bengkel bagi Ujian Potensi dan Kawalan Kualiti Minyak Kanabis Perubatan dan Produk Kratom telah diadakan di *National Science and Technology Development Agency Characterization and Testing Service Centre (NSTDA)*, Pathum Thani, Thailand pada 16-19 September 2024. Objektif bengkel adalah:

- Mendedahkan peserta dengan perspektif kawal selia produk berasaskan kanabis dan kratom di Thailand
- Memberikan gambaran keseluruhan ujian standard bagi kanabis dan kratom, serta garis panduan berkenaan kawalan kualiti
- Menyediakan sesi praktikal untuk ujian kanabinoid dan mitragynine dengan menggunakan instrumen *High-Performance Liquid Chromatography (HPLC)*

WORKSHOP ON POTENCY TESTING AND QUALITY CONTROL OF MEDICAL CANNABIS OIL AND KRATOMS PRODUCT

The Workshop on Potency Testing and Quality Control of Medical Cannabis Oil and Kratoms Products was conducted at National Science and Technology Development Agency (NSTDA) Characterization and Testing Service Centre, Pathum Thani, Thailand from 16-19 September 2024. The objectives of the workshop are:

- *To provide the participants with the regulatory perspective in cannabis and kratom based products in Thailand*
- *To provide an overview of standard cannabis and kratom testing and quality control guideline*
- *To provide hands-on practical session for cannabinoids and mitragynine testing using High-Performance Liquid Chromatography (HPLC) instrument*



Bengkel Ujian Potensi Dan Kawalan Kualiti Minyak Kanabis Perubatan Dan Produk Kratom
Workshop on Potency Testing and Quality Control of Medical Cannabis Oil and Kratoms Product



BAHAGIAN REGULATORI FARMASI NEGARA

***NATIONAL PHARMACEUTICAL
REGULATORY AGENCY***

BILANGAN PERMOHONAN PENDAFTARAN PRODUK
NUMBER OF PRODUCT REGISTRATION APPLICATION RECEIVED

298

PRESKRIPSI
PRESCRIPTION

101

BUKAN PRESKRIPSI
NON-PRESCRIPTION

641

SEMULAJADI
NATURAL

543

SUPPLEMEN KESIHATAN
HEALTH SUPPLEMENT

38

VETERINAR
VETERINARY

BILANGAN PRODUK YANG DIDAFTARKAN
NUMBER OF PRODUCT REGISTERED

432

PRESKRIPSI
PRESCRIPTION

80

BUKAN PRESKRIPSI
NON-PRESCRIPTION

713

SEMULAJADI
NATURAL

526

SUPPLEMEN KESIHATAN
HEALTH SUPPLEMENT

60

VETERINAR
VETERINARY

118,504

BILANGAN PERMOHONAN NOTIFIKASI KOSMETIK

NUMBER OF NEW COSMETIC PRODUCT NOTIFICATION APPLICATION



34,035

BILANGAN LAPORAN ADR DAN AEFI YANG DITERIMA

NUMBER OF ADR AND AEFI REPORT RECEIVED



BILANGAN LESEN / SIJIL YANG DIKELUARKAN
NUMBER OF LICENSE / CERTIFICATE ISSUED

302

LESEN PENGILANG
MANUFACTURER LICENSE



505

LESEN PENGIMPOR
IMPORTER LICENSE



1,291

LESEN PEMBORONG
WHOLESALE LICENSE



2,528

SIJIL PRODUK FARMASEUTIKAL
CERTIFICATE OF PHARMACEUTICAL PRODUCTS

58

SIJIL PENJUALAN BEBAS PRODUK VETERINAR
CFS Veterinary Products

2,066

SIJIL PENJUALAN BEBAS PRODUK KOSMETIK
CFS Cosmetic Products

190

SIJIL LOT RELEASE VAKSIN
LOT RELEASE VACCINE CERTIFICATE

174

SIJIL LOT RELEASE PRODUK PLASMA
PLASMA-DERIVED MEDICINAL PRODUCT (PDMP) LOT RELEASE CERTIFICATE

482

SIJIL AMALAN PERKILANGAN BAIK
GOOD MANUFACTURING PRACTICE (GMP) CERTIFICATE

2,306

BILANGAN SAMPEL YANG DIAMBIL UNTUK AKTIVITI PEMANTAUAN KUALITI PRODUK BERDAFTAR DAN KOSMETIK BERNOTIFIKASI
NUMBER OF SAMPLES TAKEN FOR QUALITY MONITORING ACTIVITY FOR REGISTERED PRODUCTS AND NOTIFIED COSMETICS

429

LESEN IMPORT PERCUBAAN KLINIKAL
CLINICAL TRIAL IMPORT LICENSE (CTIL)

25

KEBENARAN MENGIKILANG UNTUK PERCUBAAN KLINIKAL
CLINICAL TRIAL EXEMPTION (CTX)

58,576 | **PENGUJIAN MAKMAL YANG DIJALANKAN**
LABORATORY TESTS PERFORMED



10 | **PEMERIKSAAN AMALAN KLINIKAL BAIK (GCP)**
GOOD CLINICAL PRACTICE (GCP) INSPECTIONS



321

**BILANGAN PEMERIKSAAN AMALAN
PERKILANGAN BAIK (APB)**
*NUMBER OF GOOD MANUFACTURING
PRACTICE (GMP) INSPECTIONS*

637 | **BILANGAN PEMERIKSAAN AMALAN EDARAN BAIK (AEB) YANG DIJALANKAN**
NUMBER OF GOOD DISTRIBUTION PRACTICE (GDP) INSPECTIONS CONDUCTED

6 | **BILANGAN PEMERIKSAAN AMALAN
MAKMAL BAIK YANG DIJALANKAN**
*NUMBER OF GOOD LABORATORY PRACTICE
(GLP) INSPECTIONS CONDUCTED*

3 | **BILANGAN PEMERIKSAAN
JAWATANKUASA ETIKA YANG DIJALANKAN**
*NUMBER OF ETHIC COMMITTEE (EC)
INSPECTIONS CONDUCTED*

23 | **BILANGAN PEMERIKSAAN PUSAT KAJIAN BIOEKUIVALENS (BE)**
NUMBER OF INSPECTIONS ON BIOEQUIVALENCE CENTRES (BE)





BAHAGIAN REGULATORI FARMASI NEGARA NATIONAL PHARMACEUTICAL REGULATORY AGENCY

1.0 PENGENALAN | INTRODUCTION

Bahagian Regulatori Farmasi Negara (NPRA) merupakan sebuah badan regulatori kerajaan di bawah Program Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia yang bertanggungjawab dalam memastikan kualiti, keselamatan dan keberkesanan produk farmaseutikal serta kualiti dan keselamatan produk semulajadi dan kosmetik yang dipasarkan di Malaysia.

NPRA yang dahulunya dikenali sebagai Makmal Kawalan Kimia Ubat Kebangsaan (MKKUK), telah ditubuhkan pada bulan Oktober 1978. Makmal ini telah ditubuhkan untuk melaksanakan kawalan kualiti ke atas ubat-ubatan di negara ini. Nama MKKUK kemudiannya ditukar kepada Biro Pengawalan Farmaseutikal Kebangsaan (BPFK) pada tahun 1993 selaras dengan perkembangan fungsinya sebagai badan regulatori farmaseutikal dan sekretariat kepada Pihak Berkuasa Kawalan Dadah (PBKD). BPFK menjalankan fungsi regulatori seperti pendaftaran produk, notifikasi kosmetik, analisis sampel, pemeriksaan dan pelesenan, aktiviti pasca pendaftaran dan pemantauan kesan advers ubat.

Pada 18 Julai 2016, nama BPFK secara rasminya ditukar kepada NPRA. Selain daripada aktiviti pengawalseliaan ke atas produk generik, produk semula jadi, kosmetik dan produk veterinar, NPRA telah memperluaskan kawalan regulatori ke atas kualiti dan keselamatan Bahan Aktif Farmaseutikal (API) serta kawalan kualiti produk vaksin dan plasma melalui aktiviti *Lot Release*.

Sejajar dengan perkembangan serta keperluan semasa, NPRA telah melaksanakan perubahan struktur organisasi melalui proses penstrukturan semula pada 2 Disember 2019. Dengan pelaksanaan pengstrukturkan semula ini, NPRA dapat menambah baik kualiti perkhidmatan yang diberikan bagi mencapai misi untuk menjamin kesihatan rakyat melalui kawalan regulatori ubat-ubatan dan kosmetik.

NPRA telah membangunkan laman sesawang khusus untuk industri dan orang awam. Platform ini menyediakan maklumat mengenai peranan, fungsi, dan aktiviti NPRA bagi memastikan ketelusan dan akses mudah. Untuk maklumat lanjut, sila layari laman sesawang melalui pautan berikut: www.npra.gov.my

National Pharmaceutical Regulatory Agency (NPRA) is a government agency under the Pharmaceutical Services Programme, Ministry of Health Malaysia which is responsible in ensuring the quality, safety and efficacy of pharmaceutical products as well as the quality and safety of natural products and cosmetics marketed in Malaysia.

NPRA, formerly known as the National Pharmaceutical Control Laboratory (MKKUK), was set up in October 1978. This institution was established to implement quality control on pharmaceutical products. MKKUK's name was later changed to National Pharmaceutical Control Bureau (NPCB) in 1993 in line with the expansion of its functions as a pharmaceutical regulatory agency and secretariat to the Drug Control Authority (DCA). NPCB carries out regulatory functions such as product registration, cosmetic notification, sample analysis, inspection and licensing, post-registration activities and adverse drug reaction monitoring.

On 18 July 2016, the name of NPCB was officially changed to NPRA. Apart from regulatory control of generics (scheduled poison and non-scheduled poison), natural products, cosmetics and veterinary products, NPRA has extended regulatory control of the quality and safety of Active Pharmaceutical Ingredients (API) as well as the quality control of vaccine and plasma products through Lot Release activities.

In line with current developments, NPRA underwent a major restructuring process which came into effect on 2 December 2019. Through this restructuring exercise, NPRA will continuously strive to improve the services provided as we seek to achieve our mission to safeguard the nation's health through scientific excellence in the regulatory control of medicinal products and cosmetics.

NPRA has developed a dedicated website to provide valuable information to both the industry and the public. This platform offers insights into NPRA's role, functions and activities ensuring transparency and accessibility. For more details, please visit the website using the following link: www.npra.gov.my

Berikut merupakan empat pusat di NPRA dengan fungsi masing-masing:
Below are the four centres in NPRA with respective functions:



2.0 AKTIVITI DAN SOROTAN | ACTIVITIES AND HIGHLIGHTS

PENGANJURAN 27TH PIC/S EXPERT CIRCLE MEETING ON HUMAN BLOOD, TISSUES, CELLS AND ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs)

27th PIC/S Expert Circle Meeting on Human Blood, Tissues, Cells and Advanced Therapy Medicinal Products (ATMPs) telah diadakan pada 20-22 Ogos 2024 di Kuala Lumpur. Acara penting ini menghimpunkan pemeriksa Amalan Perkilangan Baik (APB) dari pelbagai negara ahli Pharmaceutical Inspection Co-operation Scheme (PIC/S) untuk membincangkan isu-isu semasa serta berkongsi pengalaman berkaitan pemeriksaan dan pengawalseliaan komponen darah, tisu, sel dan ATMP.

Topik utama yang dibincangkan termasuk perkembangan terkini garis panduan untuk institusi darah dan tapak pembuatan ATMP. Para peserta turut terlibat dalam perbincangan mendalam mengenai cabaran semasa dalam bidang ini, dengan memberi tumpuan kepada pendekatan pemeriksaan untuk pengeluar produk darah dan tisu manusia. Mesyuarat ini juga memudahkan perkongsian pengetahuan mengenai pendekatan moden terhadap pemeriksaan, agar sejajar dengan kemajuan teknologi perubatan.

Salah satu agenda mesyuarat ini ialah latihan mengenai PIC/S Annex 2A of the Good Manufacturing Practice (GMP) Guide, yang khusus membincangkan pembuatan ATMP. Latihan ini amat penting untuk memastikan pemeriksa dilengkapi dengan maklumat terkini dan amalan terbaik bagi menilai pematuhan dalam sektor yang berkembang pesat ini.

Acara ini menekankan kepentingan pendekatan yang selaras dalam pengawalseliaan dan pemeriksaan di kalangan pihak berkuasa ahli PIC/S. Dengan berkongsi pengalaman dan amalan terbaik, para peserta berusaha untuk memperbaiki hasil pengawalseliaan dan memastikan kesihatan awam dilindungi melalui pengawasan yang berkesan terhadap produk darah dan tisu. Perbincangan yang diadakan semasa mesyuarat ini akan menyumbang kepada usaha berterusan untuk memperkukuhkan kerangka pengawalseliaan di peringkat global, yang akhirnya memberi manfaat kepada pesakit yang bergantung pada produk perubatan kritikal ini.

Kesimpulannya, usaha kolaboratif yang dipamerkan semasa acara ini mencerminkan komitmen untuk meningkatkan standard dalam pengawalseliaan darah manusia, tisu, sel dan ATMP bagi memastikan ia memenuhi piawai keselamatan dan keberkesanan tertinggi demi perlindungan Kesihatan awam.

27TH PIC/S EXPERT CIRCLE MEETING ON HUMAN BLOOD, TISSUES, CELLS AND ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs)

The 27th PIC/S Expert Circle Meeting on Human Blood, Tissues, Cells and Advanced Therapy Medicinal Products (ATMPs) took place from 20-22 August 2024 in Kuala Lumpur. This significant event brought together regulatory authorities and inspectors from various countries to discuss contemporary issues and share experiences related to the inspection and regulation of blood components, tissues, cells and ATMPs. The meeting aimed to enhance collaboration among participating authorities and improve the consistency of inspections across different jurisdictions.

Key topics discussed during the meeting included the latest updates on guidelines for blood establishments and ATMP manufacturing sites. Participants engaged in in-depth discussions about current challenges in the field, particularly focusing on the inspection approaches for manufacturers of human blood and tissue products. The meeting also facilitated knowledge exchange regarding modern approaches to inspections, emphasizing the importance of adapting regulatory practices to keep pace with advancements in medical technologies.

A highlight of the meeting was the training on PIC/S Annex 2A of the Good Manufacturing Practice (GMP) Guide, which specifically addresses the manufacture of ATMPs. This training is crucial for ensuring that inspectors are well-equipped with the latest information and best practices for evaluating compliance in this rapidly evolving sector. Additionally, participants shared insights on research and development trends in ATMPs, fostering a collaborative environment that encourages innovation while maintaining high safety standards.

The event underscored the importance of harmonized approach to regulation and inspection among PIC/S member authorities. By sharing experiences and best practices, attendees aimed to improve regulatory outcomes and ensure that public health is safeguarded through effective oversight of blood and tissue products. The discussions held during this meeting will contribute to ongoing efforts to enhance regulatory frameworks globally, ultimately benefiting patients who rely on these critical medical products.

In conclusion, the PIC/S Expert Circle Meeting served as a pivotal platform for dialogue among global regulatory bodies. The collaborative efforts showcased during this event reflect a commitment to advancing standards in the regulation of human blood, tissues, cells and ATMPs ensuring that they meet the highest safety and efficacy benchmarks for public health protection.



Majlis Perasmian oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi)
Opening Ceremony by Deputy Director General Health (Pharmaceutical Services)

SESI LIBAT URUS BERSAMA PIHAK BERKEPENTINGAN (STAKEHOLDERS) BAGI PROGRAM PEMANTAUAN KUALITI PRODUK BERASASKAN RISIKO

Satu sesi libat urus telah diadakan pada 15 November 2024 bagi memaklumkan pihak berkepentingan mengenai aktiviti regulatori baharu yang akan dilaksanakan pada tahun 2025 iaitu program pemantauan kualiti produk berasaskan risiko (RB PQM). Perkongsian maklumat dengan pihak berkepentingan berkenaan:

- i. Peranan NPRA dalam mengawalselia kualiti produk berdaftar di pasaran Malaysia melalui aktiviti pemantauan kualiti produk yang telah dan sedang dilaksanakan.
- ii. Penambahbaikan yang akan dijalankan terhadap aktiviti pemantauan di bawah Program RB PQM dan kepentingan pelaksanaan aktiviti ini bagi memastikan program pemantauan kualiti produk berdaftar adalah mampan (*sustainable*), dapat dilaksanakan secara lebih sistematik dan efektif disamping mengoptimumkan penggunaan sumber yang terhad.

Proses/ aktiviti yang terlibat dalam pelaksanaan Program RB PQM dan tanggungjawab, komitmen serta kerjasama yang diperlukan daripada pihak industri dalam menjayakan program ini.

STAKEHOLDER'S ENGAGEMENT ON RISK BASED PRODUCT QUALITY MONITORING (RB PQM)

A stakeholder's engagement was held on 15 November 2024 to inform the stakeholders regarding a new regulatory activity that will be implemented in 2025, namely the Risk Based Product Quality Monitoring (RB PQM). Information shared with the stakeholders regarding:

- i. *The role of NPRA in regulating the quality of registered products in the Malaysian market through product quality monitoring activities that have been implemented and are currently being carried out.*

- ii. *Improvements to be made in monitoring activities under the Risk-Based Product Quality Monitoring Programme (RB PQM) and the importance of implementing this programme to ensure that the monitoring of registered product quality remains sustainable, can be conducted more systematically and effectively, and optimizes the use of limited resources.*

Processes/ activities involved in the implementation of the RB PQM Program, as well as the responsibilities, commitments, and collaboration required from the industry to ensure the success of this programme.



Sesi Libat Urus bersama Pihak Berkepentingan (Stakeholders) bagi Program RB PQM
Stakeholder's Engagement for RB PQM

SEMINAR PHARMACOVIGILANCE IN THE PHARMACEUTICAL INDUSTRY

Satu seminar telah diadakan secara dalam talian pada 23 Oktober 2024 untuk semua pemegang pendaftaran produk di Malaysia. Objektif seminar ini adalah seperti berikut:

- i. Memberikan pendedahan kepada peserta mengenai aktiviti yang berkaitan farmakovigilans
- ii. Menekankan impak aktiviti farmakovigilans terhadap pemantauan keselamatan dan keberkesanan ubat-ubatan berdaftar di Malaysia
- iii. Memperkukuhkan aktiviti farmakovigilans yang dijalankan oleh pihak PRH

PHARMACOVIGILANCE IN THE PHARMACEUTICAL INDUSTRY

An online seminar was held on 23 October 2024 for all product registration holders in Malaysia. The objectives of this seminar were as follows:

- i. To provide participants with exposure to activities related to pharmacovigilance
- ii. To emphasize the impact of pharmacovigilance activities on the monitoring of the safety and efficacy of registered medicines in Malaysia
- iii. To strengthen pharmacovigilance activities conducted by PRH

SESI LAWATAN SAMBIL BELAJAR KE NPRA

NPRA telah menerima kunjungan daripada pelajar Sarjana Muda Farmasi, Sarjana Muda Teknologi Farmaseutikal dan Diploma Farmasi dari tiga (3) institusi pengajian tinggi dan satu (1) badan kerajaan sepanjang tahun 2024 seperti dalam jadual di bawah. Sesi lawatan sambil belajar tersebut bertujuan untuk memberi pendedahan dan maklumat kepada para pelajar universiti mengenai proses pendaftaran produk serta aspek kawalan regulatori produk farmaseutikal di Malaysia. Agenda lawatan melibatkan pembentangan daripada anggota NPRA yang merangkumi topik seperti pengenalan kepada NPRA, pendaftaran produk dan notifikasi kosmetik di Malaysia, prinsip Amalan Perkilangan Baik (APB) serta aktiviti kawalan kualiti.

EDUCATIONAL VISIT TO NPRA

NPRA received study visits from Bachelor of Pharmacy and Bachelor of Pharmaceutical Technology university students from three (3) higher education institutions and one (1) government body throughout the year 2024 as listed in the table below. These study visits aim to provide information and exposure to the university students on the product registration process as well as aspects of regulatory control of pharmaceutical products in Malaysia. The agenda of the visit includes presentations from NPRA covering topics such as introduction to NPRA, product registration and notification of cosmetics in Malaysia, Good Manufacturing Practice (GMP) principles and quality control activities.

Senarai institusi yang telah membuat lawatan ke NPRA
List of institutions involved in visits to NPRA

Bil. No.	Institusi Institution	Program Programme	Bilangan peserta Number of participants	Tarikh Date
1	Universiti Putra Malaysia (UPM) <i>University of Putra Malaysia (UPM)</i>	Sarjana Muda Sains Perubatan <i>Bachelor of Medical and Health Sciences</i>	58	15 Januari 2024 <i>15 January 2024</i>
2	Pusat Keselamatan Makanan Negara (NCFS) <i>National Centre for Food Safety (NCFS)</i>		15	21 Mei 2024 <i>21 May 2024</i>
3	Management and Science University (MSU) <i>Management and Science University (MSU)</i>	Sarjana Muda Farmasi dan Sarjana Muda Teknologi Farmaseutikal <i>Bachelor in Pharmacy and Bachelor in Pharmaceutical Technology</i>	40	28 Jun 2024 <i>28 June 2024</i>
4	Kolej Institut Jantung Negara (IJN) <i>IJN College</i>	Diploma Farmasi <i>Diploma in Pharmacy</i>	34	2 September 2024 <i>2 September 2024</i>



Lawatan daripada UPM
Visit from UPM



Lawatan daripada NCFS
Visit from NCFS

SENARAI PAMERAN YANG DISERTAI OLEH NPRA

Aktiviti pameran merupakan salah satu inisiatif untuk mempromosikan perkhidmatan NPRA melalui perkongsian maklumat secara dua hala berkaitan berkaitan fungsi, peranan dan aktiviti regulatori farmaseutikal kepada pihak-pihak berkepentingan (*stakeholders*) termasuk masyarakat umum dan pihak industri.

LIST OF EXHIBITIONS PARTICIPATED BY NPRA

Exhibition are one of the initiatives to promote NPRA through the two-way sharing of information related to the functions, roles, and regulatory activities of pharmaceuticals to stakeholders, including the general public and the industry.

Senarai Pameran yang Disertai NPRA
List of Exhibitions Participated by NPRA

Bil. No.	Nama Pameran <i>Name of Exhibition</i>	Penganjur <i>Organiser</i>	Tarikh <i>Date</i>
1.	Hari Kesedaran Farmasi – ‘Tolak Ubat Tidak Sah’	Bahagian Penguatkuasaan Farmasi, KKM	21 Mei 2024 <i>21 May 2024</i>
2.	<i>UM Pharmily Day/Career Fair/Public Health Campaign 2024</i>	Fakulti Farmasi, Universiti Malaya	25 Mei 2024 <i>25 May 2024</i>
3.	Program Kesedaran Farmasi 2024	Fakulti Farmasi, Universiti Kebangsaan Malaysia	25 Mei 2024 <i>25 May 2024</i>
4.	<i>ISPE Annual Conference & Exhibition 2024</i>	<i>International Society for Pharmaceutical Engineering (ISPE)</i>	26-27 Jun 2024 <i>26-27 June 2024</i>
5.	<i>National Training Week 2024</i>	Kementerian Kesihatan Malaysia	29-30 Jun 2024 <i>29-30 Jun 2024</i>
6.	<i>Convention Pharmaceutical Ingredients (CPI)</i>	CPHI	10-12 Julai 2024 <i>10-12 July 2024</i>
7.	<i>R&D Conference</i>	Program Perkhidmatan Farmasi	20 Ogos 2024 <i>20 August 2024</i>
8.	Hari Kesedaran Farmasi – ‘Tolak Ubat Tidak Sah’	Bahagian Penguatkuasaan Farmasi, KKM	24 Oktober 2024 <i>24 October 2024</i>
9.	Program Dua (2) Tahun Kerajaan Madani (2TM)	Unit Penyelarasan Lonjakan Prestasi (PACU), Jabatan Perdana Menteri	22 November 2024 <i>22 November 2024</i>
10.	<i>Healthtech Innovation Connect (‘HTIC’)</i>	<i>Malaysian Research Accelerator for Technology and Innovation (‘MRANTI’)</i>	3-4 Disember 2024 <i>3-4 December 2024</i>



Convention Pharmaceutical Ingredients (CPI), Bangkok, Thailand
Convention Pharmaceutical Ingredients (CPI), Bangkok, Thailand



Program Dua (2) Tahun Kerajaan Madani (2TM)
Program Dua (2) Tahun Kerajaan Madani (2TM)

SESI DIALOG YANG DIADAKAN OLEH NPRA DENGAN INDUSTRI *DIALOGUE SESSIONS WITH THE INDUSTRY*

Bil. No.	Nama Dialog <i>Name of Dialogue</i>	Bilangan Peserta <i>No. of Participant</i>	Tarikh <i>Date</i>
1.	Dialog Industri NPRA-Malaysia Association of Cell & Gene Therapy (MACGT), Tissue Engineering & Regenerative Medicine Society of Malaysia (TESMA) & Malaysia Stem Cell Research & Therapy (MSCRT) Bil. 1/2024	46	25 Mac 2024 <i>25 March 2024</i>
2.	Dialog Industri NPRA-Malaysian Dietary Supplement Association (MADSA) Bil. 1/2024	43	3 Mei 2024 <i>3 May 2024</i>
3.	Dialog Industri NPRA-Malaysia Medical Device Association (MMDA) Bil. 1/2024	36	12 Jun 2024 <i>12 June 2024</i>
4.	Dialog Industri NPRA-Malaysia Association of Pharmaceutical Suppliers (MAPS) Bil.1/2024	41	31 Julai 2024 <i>31 July 2024</i>
5.	Dialog Industri NPRA-Malaysian Organization of Pharmaceutical Industries (MOPI) Bil.1/2024	108	26 Ogos 2024 <i>26 August 2024</i>
6.	Dialog Industri NPRA-Pharmaceutical Association of Malaysia (PHAMA) Bil. 1/2024	42	9 September 2024 <i>9 September 2024</i>
7.	Dialog Industri NPRA-The Cosmetic, Toiletry and Fragrance Association of Malaysia (CTFA) Bil.1/2024	35	11 September 2024 <i>11 September 2024</i>



Dialog Industri NPRA - Malaysia Association of Pharmaceutical Suppliers (MAPS) Bil. 1/2024
Dialog Industri NPRA - Malaysia Association of Pharmaceutical Suppliers (MAPS) Bil. 1/2024



Dialog Industri NPRA - Pharmaceutical Association of Malaysia (PHAMA) Bil.1/2024
Dialog Industri NPRA - Pharmaceutical Association of Malaysia (PHAMA) Bil.1/2024

PENGLIBATAN MAKMAL DALAM PROFICIENCY TESTING 2024

Makmal memainkan peranan penting dalam memastikan ketepatan dan kebolehpercayaan keputusan ujian yang dijalankan. Penyertaan dalam *Proficiency Testing* membolehkan makmal menilai prestasi analisis mereka dengan membandingkan hasil ujian dengan makmal lain serta standard yang ditetapkan. *Proficiency Testing* ini adalah untuk menentukan kompetensi penganalisis yang bertugas di makmal dan memenuhi keperluan MS ISO/IEC 17025:2017.

LABORATORY INVOLVEMENT IN PROFICIENCY TESTING 2024

The laboratory plays an important role in ensuring the accuracy and reliability of test results. Participation in Proficiency Testing (PT) allows laboratories to assess their analytical performance by comparing test results with other laboratories and established standards. This Proficiency Testing is conducted to determine the competency of analysts working in the laboratory and to meet requirements of MS ISO/IEC 17025:2017.

Penglibatan Makmal dalam Proficiency Testing 2024 *Laboratory Involvement in Proficiency Testing 2024*

Bil. No.	Nama Pengujian <i>Name of Test</i>	Bilangan Peserta <i>No. of Participant</i>	Penganjur <i>Organiser</i>
1.	<i>Identification of Hydroquinone in Cosmetic Products (CM 04/2024)</i>	1	<i>Bureau of Cosmetics and Hazardous Substances, Department of Medical Sciences, Ministry of Public Health, Thailand</i>
2.	<i>Microbial Contamination Test in Cosmetics Products (Lotion)</i>	6	<i>IFM Quality Services, Australia</i>
3.	<i>Microbial Contamination Test in Traditional Products</i>	4	<i>IFM Quality Services, Australia</i>

PENGLIBATAN MAKMAL DALAM INTER LABORATORY COMPARISON 2024

Perbandingan Antara Makmal (*Inter-Laboratory Comparison*, ILC) ialah proses jaminan kualiti di mana beberapa makmal menganalisis sampel yang sama dan membandingkan keputusan ujian mereka. Ini membantu menilai ketepatan, kebolehpercayaan, dan konsistensi prestasi makmal serta mengenal pasti sebarang perbezaan atau aspek yang perlu diperbaiki. ILC adalah penting untuk mengekalkan standard ujian yang tinggi, memastikan patuhan kepada keperluan akreditasi seperti MS ISO/IEC 17025 dan meningkatkan keyakinan terhadap Keputusan makmal.

LABORATORY INVOLVEMENT IN INTER LABORATORY COMPARISON 2024


Inter Laboratory Comparison (ILC) is a quality assurance process where multiple laboratories analyze the same sample and compare their test results. This helps assess the accuracy, reliability, and consistency of laboratory performance while identifying any discrepancies or areas for improvement. ILC is essential for maintaining high testing standards, ensuring compliance with accreditation requirements such as MS ISO/IEC 17025 and enhancing confidence in laboratory results.

Penglibatan Makmal Dalam Inter Laboratory Comparison 2024 *Laboratory Involvement in Inter Laboratory Comparison 2024*

Bil. No.	Nama Pengujian <i>Name of Test</i>	Bilangan Peserta <i>No. of Participant</i>	Penganjur <i>Organiser</i>
1.	Ujian kandungan aluminium dalam vaksin Hepatitis B menggunakan <i>UV-Spectrophotometer (UV-VIS)</i>	8	Unit Perkhidmatan Analisis, Seksyen Perkhidmatan dan Bekalan, NPRA
2.	Ujian Pengecaian (<i>Disintegration</i>) dan ujian keseragaman berat (<i>Uniformity of Weight</i>)	8	Unit Perkhidmatan Analisis, Seksyen Perkhidmatan dan Bekalan, NPRA
3.	<i>Paracetamol</i>	8	Unit Perkhidmatan Analisis, Seksyen Perkhidmatan dan Bekalan, NPRA

3.0 PENCAPAIAN DAN PENGIKTIRAFAN | ACHIEVEMENT AND RECOGNITION

 <p>World Health Organization</p>	<p>NPRA telah mendapat pengiktirafan antarabangsa oleh <i>World Health Organization (WHO)</i> sebagai <i>WHO Collaborating Centre for Regulatory Control of Pharmaceuticals</i> pada tahun 1996 atas sumbangan NPRA dalam bidang regulatori farmasi.</p> <p><i>NPRA received international recognition by the World Health Organization (WHO) as a WHO Collaborating Centre for Regulatory Control of Pharmaceuticals in 1996 for NPRA's contributions in the field of pharmaceutical regulation.</i></p>
	<p>Melalui NPRA, negara Malaysia telah menjadi negara anggota <i>Pharmaceutical Inspection Cooperation Scheme (PIC/S)</i> sejak tahun 2002. NPRA terlibat secara aktif dalam program berkaitan Amalan Perkilangan Baik (APB) dan <i>Quality Assurance Programme</i>.</p> <p><i>Through NPRA, Malaysia has been a member of the Pharmaceutical Inspection Cooperation Scheme (PIC/S) since 2002. NPRA is actively involved in programs related to Good Manufacturing Practices (GMP) and the Quality Assurance Programme.</i></p>
 <p>OECD BETTER POLICIES FOR BETTER LIVES</p>	<p>Melalui NPRA, negara Malaysia telah diterima sebagai ahli <i>Organisation for Economic Cooperation and Development Good Laboratory Practice Mutual Acceptance of Data System (OECD MAD)</i> sejak 29 Mac 2013. Data dari kajian bukan klinikal yang dijalankan di bawah fasiliti yang tersenarai di bawah Program Pemantauan Komplians GLP NPRA akan diterima untuk penilaian selanjutnya oleh semua negara OECD dan negara bukan OECD yang mematuhi sistem MAD.</p> <p><i>Through NPRA, Malaysia has been accepted as a member of the Organisation for Economic Cooperation and Development Good Laboratory Practice Mutual Acceptance of Data System (OECD MAD) since March 29, 2013. Data from non-clinical studies conducted under facilities listed under the NPRA GLP Compliance Monitoring Programme will be accepted for further evaluation by all OECD countries and non-OECD countries that adhere to the MAD system.</i></p>
 <p>ICH harmonisation for better health</p>	<p>Malaysia merupakan pemerhati (<i>Observer</i>) kepada <i>International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)</i> sejak bulan Jun 2018. ICH merupakan platform bagi badan regulatori dan industri farmaseutikal membincangkan keperluan pendaftaran ubat-ubatan dari aspek saintifik dan teknikal.</p> <p><i>Malaysia has been an observer to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) since June 2018. ICH is a platform for regulatory bodies and the pharmaceutical industry to discuss the scientific and technical aspects of drug registration requirements.</i></p> <p>Malaysia juga telah diterima sebagai ahli <i>International Pharmaceutical Regulator's Programme (IPRP)</i> pada bulan November 2019. IPRP merupakan platform bagi badan regulatori membincangkan dan melaksanakan garis panduan yang diterbitkan oleh ICH dalam mengawalselia produk farmaseutikal untuk kegunaan manusia.</p> <p><i>Malaysia was also accepted as a member of the International Pharmaceutical Regulators Programme (IPRP) in November 2019. IPRP is a platform for regulatory bodies to discuss and implement guidelines published by ICH in regulating pharmaceutical products for human use.</i></p>
 <p>QUALITY SYSTEM SIRIM Certified to: MS ISO 9001:2015 Cert No.: QMS 00894</p>	<p>NPRA telah memperolehi pensijilan MS ISO 9001 dari pihak SIRIM QAS Sdn. Bhd. pada tahun 2001. Bermula dengan pensijilan MS ISO 9002:1994, disusuli dengan MS ISO 9001:2000 dan MS ISO 9001:2008. Pensijilan terkini MS ISO 9001:2015 telah diperolehi pada tahun 2017 dengan nombor sijil QMS 00894 dan sah sehingga 24 Mei 2025.</p> <p><i>NPRA obtained MS ISO 9001 certification from SIRIM QAS Sdn. Bhd. in 2001. Starting with MS ISO 9002:1994 certification, followed by MS ISO 9001:2000 and MS ISO 9001:2008. The latest certification, MS ISO 9001:2015, was obtained in 2017 with certificate number QMS 00894 and is valid until May 24, 2025.</i></p>
 <p>STANDARDS MALAYSIA ACCREDITED</p>	<p>Makmal NPRA telah memperolehi akreditasi MS ISO/IEC 17025:2005 dari Jabatan Standard Malaysia pada tahun 2010 dan MS ISO/IEC 17025:2017 pada bulan Oktober 2020 bagi pengujian produk tradisional dan kosmetik. Pada tahun 2022, makmal NPRA telah menambah skop akreditasi bagi pengujian produk vaksin Hepatitis B dengan no. SAMM 450 dan sah sehingga 14 Januari 2025.</p> <p><i>The NPRA laboratory obtained MS ISO/IEC 17025:2005 accreditation from the Department of Standards Malaysia in 2010 and MS ISO/IEC 17025:2017 in October 2020 for the testing of traditional products and cosmetics. In 2022, the NPRA laboratory expanded its accreditation scope to include testing of Hepatitis B vaccine products with the accreditation number SAMM 450, valid until January 14, 2025.</i></p>

	<p>NPRA telah diberi Anugerah Pengawal Selia Aktif / <i>Unified Public Consultation (UPC)</i> oleh <i>Malaysian Productivity Corporation (MPC)</i> di Persidangan Amalan Baik Peraturan 2021 bagi pencapaian sepanjang tahun 2020 dan 2021.</p> <p><i>NPRA was awarded the Active Regulator / Unified Public Consultation (UPC) Award by the Malaysian Productivity Corporation (MPC) at the Regulatory Good Practice Conference 2021 for achievements throughout 2020 and 2021.</i></p>
	<p>Menerima pengiktirafan 3-bintang EMGS yang telah dilaksanakan oleh Malaysian Green Technology & Climate Change Corporation (MGTC) dan penerimaan sijil secara rasmi pada 21 Mei 2024 bertempat di EQ Hotel Kuala Lumpur</p> <p><i>Received 3-star EMGS recognition, awarded by the Malaysian Green Technology & Climate Change Corporation (MGTC), with the official certificate presentation took place on 21 May 2024 at EQ Hotel Kuala Lumpur</i></p>
	<p>NPRA telah diberikan Anugerah MyGovUC 2.0 Tahun 2023 bagi kategori Penggunaan Perkhidmatan Utama Tertinggi di kalangan agensi.</p> <p><i>NPRA was awarded the MyGovUC 2.0 Award for the year 2023 in the category of Highest Use of Key Services among agencies.</i></p>
	<p>Telah mendapat pengiktirafan 2-diamond bagi Sustainable Energy Low Carbon Building Assessment pada 27 Mac 2024. Pengiktirafan ini berdasarkan keupayaan NPRA untuk menjimatkan tenaga dan seterusnya mengurangkan pelepasan karbon dioksida sebanyak 887.39 tan sepanjang tahun 2023. Ini merupakan inisiatif jangka panjang ke arah kelestarian alam sekitar.</p> <p><i>Received 2-diamond recognition for the Sustainable Energy Low Carbon Building Assessment on 27 March 2024. This recognition is based on NPRA's ability to save energy, resulting in a reduction of 887.39 tons of carbon dioxide emissions throughout 2023. This initiative is part of a long-term commitment to environmental sustainability.</i></p>
	<p>Mendapat pengiktirafan 4-bintang bagi Pelabelan Prestasi Intensiti Tenaga Bangunan (Building Intensity - BEI) oleh Suruhanjaya Tenaga pada 1 Mac 2024 untuk pencapaian penjimatan tenaga sepanjang tahun 2023. Ini merupakan inisiatif oleh Kementerian Sumber Asli, Alam Sekitar dan Perubahan Iklim (NRECC) dan dikelola oleh Suruhanjaya Tenaga.</p> <p><i>Received 4-star recognition for Building Energy Intensity (BEI) Performance Labelling by the Energy Commission on 1 March 2024, in recognition of energy-saving achievements throughout 2023. This initiative is led by the Ministry of Natural Resources, Environment, and Climate Change (NRECC) and managed by the Energy Commission.</i></p>
	<p>Menerima penarafan 4-bintang di dalam penilaian pensijilan Bangunan Hijau MyCREST yang telah dilaksanakan oleh pihak Construction Research Institute of Malaysia (CREAM) selaku coordinator pensijilan tersebut pada 23 Oktober 2024.</p> <p><i>Received a 4-star rating in the MyCREST Green Building certification assessment, conducted by the Construction Research Institute of Malaysia (CREAM) as the certification coordinator on 23 October 2024.</i></p>

5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA INTERNATIONAL COLLABORATION AND PARTICIPATION

PENGLIBATAN NPRA DALAM KUMPULAN KERJA ASEAN

Malaysia, melalui NPRA giat mengambil bahagian dalam aktiviti tiga (3) kumpulan kerja yang ditubuhkan di bawah ASEAN Consultative Committee for Standards and Quality (ACCSQ) untuk membangunkan skim pengharmonian produk farmaseutikal, produk semulajadi dan suplemen Kesihatan serta peraturan-peraturan kosmetik di negara-negara ASEAN.

Kumpulan kerja tersebut termasuk *Pharmaceutical Product Working Group (PPWG)*, *Traditional Medicines and Health Supplements Product Working Group (TMHS PWG)* dan *ASEAN Cosmetic Committee (ACC)*.

NPRA'S PARTICIPATION IN ASEAN WORKING GROUPS

Through NPRA, Malaysia actively participates in three (3) product-working groups established under the ASEAN Consultative Committee for Standards and Quality (ACCSQ) which aim to develop harmonization schemes of pharmaceuticals, natural products and health supplements as well as cosmetics regulations in ASEAN countries.

These working groups include the Pharmaceutical Product Working Group (PPWG), Traditional Medicines and Health Supplements Product Working Group (TMHS PWG) and ASEAN Cosmetic Committee (ACC).

Senarai mesyuarat di peringkat ASEAN yang telah dihadiri oleh pegawai NPRA sepanjang tahun 2024

List of ASEAN meetings attended by NPRA officers in the year 2024

Bil. No.	Mesyuarat Meeting	Tarikh Date
1.	<i>38th ASEAN Cosmetic Committee Meeting (ACC)</i>	<i>24-25 May 2024 24-25 May 2024</i>
2.	<i>26th Implementation Working Group (IWG) Meeting</i>	<i>5-6 June 2024 5-6 June 2024</i>
3.	<i>37th ASEAN Consultative Committee on Standards and Quality Pharmaceutical Product Working Group (ACCSQ PPWG) Meeting</i>	<i>6-7 June 2024 6-7 June 2024</i>
4.	<i>3rd Task Force ASEAN Pharmaceutical Regulatory Framework Meeting</i>	<i>27-28 June 2024 27-28 June 2024</i>
5.	<i>33rd Meeting of the ASEAN TMHS Good Manufacturing Practice Task Force (GMP TF)</i>	<i>4-6 July 2024 4-6 July 2024</i>
6.	<i>40th Meeting of the ASEAN TMHS Scientific Committee (ATSC)</i>	<i>4-6 July 2024 4-6 July 2024</i>
7.	<i>4th Task Force ASEAN Pharmaceutical Regulatory Framework Meeting</i>	<i>23-24 August 2024 23-24 August 2024</i>
8.	<i>7th Joint Sectoral Committee on the Mutual Recognition Arrangement on BE Meeting (JSC MRA BE)</i>	<i>25-26 November 2024 25-26 November 2024</i>
9.	<i>13th Joint Sectoral Committee on the Mutual Recognition Arrangement on Good Manufacturing Practice Meeting (JSC MRA GMP)</i>	<i>25-26 November 2024 25-26 November 2024</i>
10.	<i>5th ASEAN Pharmaceutical Testing Laboratory Committee Meeting (APTLC)</i>	<i>26-27 November 2024 26-27 November 2024</i>
11.	<i>9th Joint Assessment Committee Group Meeting (JACG)</i>	<i>26-27 November 2024 26-27 November 2024</i>
12.	<i>38th ASEAN Consultative Committee on Standards and Quality Pharmaceutical Product working Group (ACCSQ PPWG) Meeting</i>	<i>28-29 November 2024 28-29 November 2024</i>
13.	<i>40th ASEAN Cosmetic Committee Meeting (ACC)</i>	<i>21-22 November 2024 21-22 November 2024</i>
14.	<i>32nd Meeting of the ASEAN TMHS Good Manufacturing Practice Task Force (GMP TF)</i>	<i>27 November 2024 27 November 2024</i>
15.	<i>41st Meeting of the ASEAN TMHS Scientific Committee (ATSC)</i>	<i>28 November 2024 28 November 2024</i>
16.	<i>36th Meeting of the ASEAN Consultative Committee on Standards and Quality Traditional Medicines & Health Supplement Product Working Group (TMHS PWG)</i>	<i>12-13 December 2024 12-13 December 2024</i>
17.	<i>37th ASEAN Cosmetic Scientific Body (ACSB) Meeting</i>	<i>24-25 Mei 2024 24-25 May 2024</i>
18.	<i>38th ASEAN Cosmetic Scientific Body (ACSB) Meeting</i>	<i>20-23 November 2024 20-23 November 2024</i>

MAJLIS MENANDATANGANI SEMULA MEMORANDUM PERSEFAHAMAN ANTARA KERAJAAN MALAYSIA DAN THE HEALTH SCIENCES AUTHORITY (HSA) OF SINGAPORE BAGI KERJASAMA DALAM BIDANG REGULATORI FARMASEUTIKAL

Majlis Menandatangani Semula Memorandum Persefahaman antara Kerajaan Malaysia yang diwakili oleh KKM dan *The Health Sciences Authority (HSA) of Singapore* bagi kerjasama dalam bidang regulatori farmaseutikal telah berlangsung pada 6 Mei 2024 di HSA, Singapura.

Majlis tersebut telah disempurnakan oleh YBrs. Puan Norhaliza A. Halim selaku Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi) dan YBrs. Dr. Mimi Choong May Ling selaku Ketua Pengarah Eksekutif HSA. Pemeteraian kerjasama ini merupakan kesinambungan kerjasama antara NPRA bersama pihak HSA selaku badan regulatori produk farmaseutikal negara masing-masing.

Memorandum Persefahaman yang ditandatangani buat pertama kalinya pada 28 Mac 2012 telah berkuatkuasa selama lima (5) tahun dan secara automatik dilanjutkan secara automatik lima (5) tahun lagi sebelum tamat secara rasminya pada 28 Mac 2022. Pemeteraian semula memorandum ini dapat memudahkan proses pertukaran maklumat regulatori farmaseutikal antara kedua-dua agensi bagi memperkasakan Amalan Regulatori Baik (*Good Regulatory Practice*) dan seterusnya meningkatkan kecekapan kedua-dua agensi.

Antara bidang kerjasama yang telah dikenalpasti dan akan diteruskan adalah kawalan regulatori produk farmaseutikal (termasuk isu-isu pendaftaran, pasca pendaftaran dan penguatkuasaan) serta aktiviti kajian klinikal. Pemeteraian kerjasama antara KKM dan HSA dilihat akan menjadi pemangkin kepada peningkatan kecekapan kawalan regulatori produk farmaseutikal di Malaysia.

SIGNING CEREMONY FOR THE RENEWAL OF THE MEMORANDUM OF UNDERSTANDING (MoU) BETWEEN MINISTRY OF HEALTH (MOH) AND THE HEALTH SCIENCES AUTHORITY (HSA) OF SINGAPORE FOR COOPERATION IN THE PHARMACEUTICAL REGULATORY FIELD

The signing ceremony for the Renewal of the Memorandum of Understanding (MoU) between the Government of Malaysia, represented by the MOH, and the Health Sciences Authority (HSA) of Singapore for cooperation in the pharmaceutical regulatory field took place on 6 May 2024 at HSA, Singapore.

The ceremony was officiated by Madam Norhaliza A. Halim, Senior Director of Pharmaceutical Services, and Dr. Mimi Choong May Ling, Chief Executive Officer of HSA. This renewal of cooperation represents a continuation of the collaboration between the NPRA and HSA, as the regulatory bodies for pharmaceutical products in their respective countries.

The Memorandum of Understanding, initially signed on 28 March 2012, was effective for five (5) years and automatically extended for another five (5) years before officially ending on 28 March 2022. The renewal of this memorandum facilitates the exchange of pharmaceutical regulatory

information between the two agencies, empowering Good Regulatory Practices (GRP) and enhancing the efficiency of both agencies.

Among the identified areas of cooperation to be continued are regulatory control of pharmaceutical products (including issues related to registration, post-registration and enforcement) as well as clinical research activities. This cooperation between MOH and HSA is seen as a catalyst for improving the efficiency of pharmaceutical regulatory control in Malaysia.



Majlis Perasmian Tandatangani Memorandum of Understanding (MoU) di antara Kerajaan Malaysia dan Health Sciences Authority (HSA)

HSA Signed Memorandum of Understanding (MoU) with the Ministry of Health, Malaysia

PIC/S ON-SITE REASSESSMENT MINISTRY OF FOOD AND DRUG SAFETY (MFDS), SOUTH KOREA

Seramai lima (5) assessor yang terdiri daripada pihak berkuasa PIC/s pelbagai negara seperti Malaysia, Singapura, Amerika Syarikat, Switzerland dan Netherlands menjalankan penilaian ke atas sistem inspektorat yang diamalkan oleh MFDS, South Korea pada 2-6 September 2024.

Wakil assessor daripada NPRA telah menjalankan penilaian ke atas beberapa komponen seperti keperluan perundangan, direktif dan polisi, sumber manusia, prosedur dan strategi pemeriksaan, program surveilan dan pengurusan kualiti. Selain daripada penilaian dokumen, *observed inspection* turut dijalankan di mana wakil NPRA bertindak sebagai pemerhati dan penilai dalam pemeriksaan yang dijalankan oleh MFDS.

PIC/S ON-SITE REASSESSMENT MINISTRY OF FOOD AND DRUG SAFETY (MFDS), SOUTH KOREA

A total of five (5) assessors from PIC/S regulatory authorities of various countries, including Malaysia, Singapore, the United States, Switzerland and the Netherlands, conducted an assessment of the inspectorate system implemented by MFDS, South Korea from 2-6 September 2024.

A representative assessor from NPRA evaluated several components, such as legal requirements, directives and policies, human resources, inspection procedures and strategies, surveillance programs, and quality management. In addition to document assessments, an observed inspection was also conducted, where the NPRA representative acted as an observer and assessor in the inspection carried out by MFDS.



PIC/S On-Site Reassessment Ministry of Food and Drug Safety (MFDS), South Korea

PIC/S On-Site Reassessment Ministry of Food and Drug Safety (MFDS), South Korea

INTERNATIONAL PARTNERSHIP REFERENCE STANDARD & REFERENCE STANDARD PRODUCTION

Program ASEAN Reference Substance (ARS) merupakan sebahagian daripada usaha ASEAN untuk memperkukuhkan Kerjasama serantau dalam bidang sains dan teknologi, khususnya dalam bidang kesihatan, farmaseutikal dan keselamatan makanan. ARS atau bahan rujukan ASEAN dihasilkan secara bersama-sama oleh negara ahli ASEAN. Ia digunakan untuk memastikan bahawa kaedah pengujian yang digunakan di makmal-makmal di seluruh Rantau ASEAN memberikan Keputusan yang tepat, konsisten dan diyakini.

NPRA yang mewakili Malaysia dalam *ARS Working Group* terlibat secara aktif dalam penghasilan ARS. Pada tahun 2024, Malaysia telah menyumbang kepada penghasilan dua ARS iaitu Ascorbic Acid dan Omeprazole. Selain itu, Malaysia juga telah menghadiri *16th Meeting on the Production of ASEAN Reference Substances (ARS)* dengan tema "*Strengthening ASEAN Collaboration in Producing Reference Substance that Comply with International Standards*" pada 19-20 Mac 2024 di Bali, Indonesia. Mesyuarat ini telah diadakan untuk membincangkan perkembangan terkini tentang ARS, termasuk aspek pengurusan dan pengedarannya.

INTERNATIONAL PARTNERSHIP REFERENCE STANDARD & REFERENCE STANDARD PRODUCTION

The ASEAN Reference Substance (ARS) Programme is part of ASEAN's efforts to strengthen regional cooperation in science and technology, particularly in health, pharmaceuticals and food safety. ARS is jointly produced by ASEAN member countries. It is used to ensure that the testing methods applied in laboratories across the ASEAN region provide accurate, consistent and reliable results.

NPRA representing Malaysia in the ARS Working Group, is actively involved in the production of ARS. In 2024, Malaysia contributed to the production of two ARS which are Ascorbic Acid and Omeprazole. Additionally, Malaysia participated in the '16th Meeting on the Production of ASEAN Reference Substances (ARS), with the theme "Strengthening ASEAN Collaboration in Producing Reference Substances that Comply with International Standards", held on 19-20 March 2024 in Bali, Indonesia. The meeting was conducted to discuss the latest developments on ARS, including aspects of its management and distribution.



International Partnership Reference Standard & Reference Standard Production

International Partnership Reference Standard & Reference Standard Production

38TH OECD WORKING PARTY MEETING ON GOOD LABORATORY PRACTICE (GLP), PARIS

OECD Working Party Meeting dijalankan secara tahunan dan bertujuan untuk:

- Membincangkan isu-isu teknikal berkaitan amalan dan pemeriksaan GLP dikalangan negara OECD dan MAD adherents.
- Koordinasi dan pengharmonian polisi serta penetapan polisi-polisi baharu berkaitan amalan dan pemeriksaan GLP negara OECD dan MAD adherents.
- Menjalankan penilaian berkala (on-site assessment) ke atas negara OECD dan MAD adherents setiap sepuluh tahun serta membentangkan hasil penilaian tersebut kepada semua ahli.

Semasa mesyuarat kali ke-38 yang diadakan pada 16-18 April 2024, hasil penilaian (OSE) oleh pasukan penilai OECD ke atas NPRA, KKM dan Jabatan Standard Malaysia, MITI pada Mei 2023 lepas telah dibentangkan untuk pandangan mesyuarat. Wakil dari NPRA iaitu Cik Fadhillah binti Hasbullah serta dua (2) wakil dari JSM telah hadir ke mesyuarat ini untuk menjawab semua persoalan yang dibangkitkan oleh ahli mesyuarat berkaitan penilaian OSE Malaysia 2023. Mesyuarat bersetuju untuk memutuskan Malaysia kekal sebagai negara OECD MAD *adherent* berikutan hasil penilaian yang positif terhadap kepatuhan Malaysia bagi sistem MAD dalam *Assessment of Chemicals*.

38TH OECD WORKING PARTY MEETING ON GOOD LABORATORY PRACTICE (GLP), PARIS

The OECD Working Party Meeting is held annually with the aim of:

- *Discussing technical issues related to GLP practices and inspections among OECD countries and Mutual Acceptance of Data (MAD) adherents.*
- *Coordinating and harmonizing policies as well as establishing new policies related to GLP practices and inspections among OECD countries and MAD adherents.*
- *Conducting periodic on-site assessments (OSE) of OECD countries and MAD adherents every ten years and presenting the results of these assessments to all members.*

During the 38th meeting held on 16-18 April 2024, the OSE evaluation results from the OECD assessment team on NPRA, MOH and the Department of Standards Malaysia, MITI conducted in May 2023 were presented for discussion. Representatives from NPRA, namely Ms. Fadhillah binti Hasbullah, along with two (2) representatives from JSM, attended the meeting to respond to any queries raised by the meeting members regarding the Malaysia OSE 2023 evaluation. The meeting agreed to maintain Malaysia's status as an OECD MAD adherent following the positive assessment results on Malaysia's compliance with the MAD system in the Assessment of Chemicals.



38th OECD Working Party Meeting on Good Laboratory Practice (GLP)

38th OECD Working Party Meeting on Good Laboratory Practice (GLP)

LATIHAN SANGKUTAN BERKAITAN *RISK-BASED APPROACH IN PRODUCT QUALITY MONITORING INCLUDING PRODUCT SELECTION, SAMPLING AND TESTING DI THERAPEUTIC GOODS ADMINISTRATION (TGA), AUSTRALIA*

Matlamat program ini adalah bagi mengukuhkan kapasiti pihak berkuasa kebangsaan dalam meningkatkan ketersediaan ubat-ubatan dan peranti perubatan yang selamat dan berkesan melalui penambahbaikan amalan regulatori dan jalinan kerjasama serantau.

Latihan ini telah dikendalikan oleh pasukan RSP dengan kerjasama pegawai-pegawai di TGA daripada pelbagai latar belakang dan mempunyai pengalaman serta pengetahuan yang luas dalam bidang masing-masing. Latihan ini memberi tumpuan dalam meningkatkan pengetahuan dan mendedahkan pegawai NPRA kepada *legal framework*, *regulatory framework*, polisi regulatori, keperluan regulatori dan proses kerja di TGA terutamanya yang melibatkan pemantauan kualiti produk-produk yang dipasarkan di Australia berdasarkan pendekatan berasaskan risiko. Latihan ini turut menitikberatkan pemahaman terhadap keseluruhan *regulatory framework* yang melibatkan aktiviti pre dan post marketing dalam memastikan akses kepada produk (therapeutic goods) yang berkesan, berkualiti dan selamat secara berterusan. Struktur latihan adalah dalam bentuk penyampaian ceramah beserta pendedahan kepada situasi dan contoh sebenar yang berlaku sepanjang pelaksanaan dan penambahbaikan *legal framework*, *regulatory framework*, polisi regulatori, keperluan regulatori dan proses kerja di TGA, terutama yang melibatkan pelaksanaan pemantauan kualiti produk menggunakan pendekatan berasaskan risiko.

ATTACHMENT TRAINING TO LEARN ABOUT *RISK-BASED APPROACH IN PRODUCT QUALITY MONITORING INCLUDING PRODUCT SELECTION, SAMPLING AND TESTING AT THERAPEUTIC GOODS ADMINISTRATION (TGA), AUSTRALIA*

The objective of this programme is to strengthen the capacity of national regulatory authorities in enhancing the availability of safe and effective medicines and medical devices through improvements in regulatory practices and regional cooperation.

The training was conducted by the RSP team in collaboration with TGA officers from various backgrounds, each possessing extensive experience and knowledge in their respective fields. This training focused on enhancing the knowledge and exposure of NPRA officers to the legal framework, regulatory framework, regulatory policies, regulatory requirements and work processes at TGA, particularly in relation to product quality monitoring in the Australian market using a risk-based approach. Additionally, the training emphasized a comprehensive understanding of the entire regulatory framework, covering pre-and post-marketing activities to ensure continuous access to effective, high quality and safe therapeutic goods. The training structure consisted of lectures along with real-life case studies and practical examples illustrating the implementation and improvement of the legal framework, regulatory framework, regulatory policies, regulatory requirements and work processes at TGA, with a strong focus on risk-based quality monitoring of products.



Latihan Sangkutan *Risk-Based Approach in Product Quality Monitoring*
Training on Risk-Based Approach in Product Quality Monitoring

PMDA-ATC PHARMACEUTICALS REVIEW SEMINAR 2024 FOR PPWG MEMBER STATES

Seminar *PMDA-ATC Pharmaceuticals Review 2024* untuk negara anggota PPWG, yang diadakan pada 11-14 Jun 2024, memberi tumpuan kepada konsep *reliance* dalam membuat keputusan regulatori bagi meningkatkan kecekapan dan keberkesanan proses semakan farmaseutikal. Dianjurkan oleh *Pharmaceuticals and Medical Devices Agency (PMDA)* Jepun, seminar ini menjadi platform bagi pihak berkuasa regulatori untuk berkongsi pengetahuan dan amalan terbaik dalam menggunakan penilaian yang dijalankan oleh pihak berkuasa regulatori yang dipercayai.

Sepanjang seminar, para peserta mengambil bahagian dalam perbincangan, kajian kes, dan sesi praktikal yang menekankan bagaimana *reliance* dapat mempercepat kelulusan regulatori, mengoptimalkan sumber dan memastikan akses kepada ubat-ubatan secara lebih cepat tanpa menjejaskan keselamatan, keberkesanan atau kualiti. Sesi ini juga menekankan kepentingan kepercayaan bersama, ketelusan dan kerjasama antarabangsa dalam memperkukuh sistem regulatori. Wakil NPRA turut serta secara aktif dalam perbincangan ini, memperoleh pandangan berharga mengenai pelaksanaan pendekatan *reliance* dalam rangka kerja regulatori Malaysia serta mengukuhkan kerjasama dengan rakan serantau dan antarabangsa.

PMDA-ATC PHARMACEUTICALS REVIEW SEMINAR 2024 FOR PPWG MEMBER STATES

The PMDA-ATC Pharmaceuticals Review Seminar 2024 for PPWG member states, held from 11-14 June 2024, focused on the concept of reliance in regulatory decision making to enhance the efficiency and effectiveness of pharmaceutical review processes. Organised by the Pharmaceutical and Medical Devices Agency (PMDA) Japan, the seminar provided a platform for regulators to exchange knowledge and best practices on leveraging assessments conducted by trusted regulatory authorities.

Throughout the seminar, participants engaged in discussions, case studies and practical sessions that highlighted how reliance can streamline regulatory approvals, optimize resources and improve timely access to medicines without compromising safety, efficacy, or quality. The sessions also emphasized the importance of mutual trust, transparency and international collaboration in strengthening regulatory systems. NPRA representatives actively contributed to the discussions, gaining valuable insights into implementing reliance approaches in Malaysia's regulatory framework while reinforcing partnerships with regional and global counterparts.

13TH MEETING OF THE REGIONAL ALLIANCE OF NATIONAL REGULATORY AUTHORITIES FOR MEDICAL PRODUCTS IN THE WESTERN PACIFIC

Mesyuarat ke-13 Perikatan Serantau Pihak Berkuasa Kawal Selia Kebangsaan (NRA) di Rantau Pasifik Barat telah diadakan pada 14-15 Ogos 2024. Sebelum itu, Jawatankuasa Pemandu Perikatan Serantau (RASC) telah bersidang pada 13 Ogos 2024 untuk membincangkan keutamaan kawal selia utama dan inisiatif strategik.

Perikatan Serantau ini terdiri daripada NRA dari seluruh Rantau Pasifik Barat yang komited untuk bekerjasama dan memperkukuh sistem kawal selia bagi memastikan keselamatan, kualiti dan keberkesanan produk perubatan. Melalui kerjasama, kebergantungan dan peraturan yang berkesan, Perikatan ini berusaha untuk meningkatkan kesihatan awam dengan menyelaraskan dan memperbaiki amalan kawal selia.

Perbincangan dalam mesyuarat ini memberi tumpuan kepada usaha memperkukuh kapasiti makmal bagi mencegah isu pencemaran seperti pencemaran *diethylene glycol* (DEG) dan *ethylene glycol* (EG), meningkatkan pengawasan pasca pemasaran, memperbaiki ujian kualiti ubat-ubatan serta memperkukuh sistem farmakovigilans. Selain itu, peserta turut membincangkan rancangan untuk membangunkan pendekatan kawal selia yang disesuaikan dengan cabaran unik yang dihadapi oleh negara kecil, serta strategi untuk meningkatkan kebergantungan dan penyesuaian kawal selia bagi memperbaiki akses kepada produk perubatan berkualiti tinggi.

NPRA telah menjadi peserta aktif dalam mesyuarat ini. Penglibatan berterusan dengan Perikatan Serantau ini mengukuhkan komitmen Malaysia terhadap amalan terbaik global dalam kawal selia farmaseutikal dan perlindungan kesihatan awam.

13TH MEETING OF THE REGIONAL ALLIANCE OF NATIONAL REGULATORY AUTHORITIES FOR MEDICAL PRODUCTS IN THE WESTERN PACIFIC

The Thirteenth Meeting of the Regional Alliance of National Regulatory Authorities (NRAs) in the Western Pacific Region was held on 14-15 August 2024. Preceding this, the Regional Alliance Steering Committee (RASC) convened on 13 August 2024 to discuss key regulatory priorities and strategic initiatives.

The Regional Alliance comprises of NRAs from across the Western Pacific Region committed to collaborating and strengthening regulatory system to ensure the safety, quality and efficacy of medical products. Through cooperation, reliance and effective regulation, the Alliance seeks to enhance public health by harmonizing and improving regulatory practices.

Discussions during the meeting focused on strengthening laboratory capacities to prevent contamination issues such as diethylene glycol (DEG) and ethylene glycol (EG) contamination, enhancing post-market surveillance, improving medicines quality testing, and reinforcing pharmacovigilance systems. Additionally, participants explored the plan to develop a customized regulatory approach tailored to the unique challenges faced by small countries, as well as strategies to enhance reliance and regulatory convergence to improve access to high-quality medical products.

NPRA has been an active participant in this meeting. The continued engagement with the Regional Alliance reinforces Malaysia's commitment to global best practices in pharmaceutical regulation and public health protection.



13th Meeting of the Regional Alliance of National Regulatory Authorities for Medical Products in the Western Pacific
13th Meeting of the Regional Alliance of National Regulatory Authorities for Medical Products in the Western Pacific

LAWATAN WHO COUNTRY OFFICE MALAYSIA KE NPRA

Pada 22 November 2024, dua pegawai dari Pejabat Negara WHO di Malaysia telah mengunjungi NPRA. Dr. Paul Soo, Pegawai Teknikal dari Jabatan Pengukuhan Sistem Kesihatan, telah mengiringi Ketua Pasukan yang baru dilantik, Puan Debbie Muirhead, untuk sesi perbincangan bersama pegawai NPRA.

Puan Muirhead, yang baru sahaja memegang jawatan di Pejabat Negara WHO Malaysia, menegaskan komitmen organisasi tersebut dalam memberikan bantuan teknikal dan sokongan dasar kepada NPRA. Kerjasama ini bertujuan untuk memperkukuh lagi sistem kawal selia serta memudahkan pelaksanaan Pelan Pembangunan Institusi (IDP) WHO bagi membolehkan Malaysia mencapai Tahap Kematangan 3 (ML3).

Sesi perbincangan ini dipimpin oleh Dr. Azuana binti Ramli, yang memberikan Gambaran keseluruhan mengenai struktur dan operasi NPRA sebagai pengenalan kepada Puan Muirhead. Mesyuarat ini memberi tumpuan kepada strategi untuk mencapai akreditasi ML3, khususnya dalam bidang keutamaan Malaysia seperti Pembangunan rangka kerja perundangan yang komprehensif dan memperkukuh aktiviti pengawasan pasca pemasaran.

Pejabat Negara WHO Malaysia akan terus menyokong NPRA dengan menyediakan kepakaran teknikal, inisiatif Pembangunan kapasiti dan panduan strategik bagi memperkukuh fungsi kawal selia. Kerjasama berterusan ini mencerminkan komitmen WHO dalam mempertingkatkan kesihatan awam melalui kawal selia farmaseutikal yang kukuh di Malaysia.

WHO COUNTRY OFFICE MALAYSIA'S VISIT TO NPRA

On 22 November 2024, two officers from the WHO Country Office in Malaysia visited NPRA. Dr. Paul Soo, Technical Officer from the Health System Strengthening Department, accompanied the newly appointed Team Lead, Ms. Debbie Muirhead, for a discussion session with NPRA officers.

Ms. Muirhead, who recently assumed her role at the WHO Country Office Malaysia, reaffirmed the organisation's commitment to providing technical assistance and policy support to NPRA. This collaboration aims to further strengthen the regulatory system and facilitate the implementation of WHO's Institutional Development Plan (IDP) to enable Malaysia to achieve Maturity Level (ML3) status.

The discussion session was led by Dr. Azuana binti Ramli, who provided an overview of NPRA's structure and operations as an introduction for Ms. Muirhead. The meeting focused on strategies to advance towards ML3 accreditation, particularly in Malaysia's priority areas, such as the development of a comprehensive legal framework and enhancing post-marketing surveillance activities.

Moving forward, the WHO Country Office Malaysia will continue to support NPRA by providing technical expertise, capacity building initiatives and strategic guidance to strengthen the regulatory functions. This ongoing collaboration underscores WHO's commitment to enhancing public health through a robust pharmaceutical regulation in Malaysia.



Lawatan WHO Country Office Malaysia ke NPRA
WHO Country Office Malaysia visit to NPRA



BAHAGIAN LEMBAGA FARMASI MALAYSIA

PHARMACY BOARD MALAYSIA DIVISION



BAHAGIAN LEMBAGA FARMASI MALAYSIA **PHARMACY BOARD MALAYSIA DIVISION**

1.0 PENGENALAN | INTRODUCTION

Bahagian Lembaga Farmasi Malaysia (BLFM) berperanan dalam memastikan pendaftaran Ahli Farmasi dan Pertubuhan Perbadanan memenuhi keperluan Akta Pendaftaran Ahli Farmasi 1951 dan Peraturan-peraturan di bawahnya. Dalam memastikan standard bagi pendidikan, latihan dan etika ahli farmasi dipatuhi, BLFM juga bertindak sebagai sekretariat kepada Lembaga Farmasi Malaysia yang ditubuhkan mengikut peruntukan Seksyen 3(1) Akta Pendaftaran Ahli Farmasi 1951.

Pharmacy Board Malaysia Division (PBMD) has a role to ensure registration of pharmacists and bodies corporate is in accordance to the Registration of Pharmacists Act 1951 and its regulations. In ensuring that the standard for education, training and ethics for pharmacists are met, PBMD functions as a secretariat for Pharmacy Board Malaysia which was established according with Section 3(1), Registration of Pharmacists Act 1951.

Terdapat dua (2) Cawangan di bawah BLFM iaitu Cawangan Pendaftaran dan Cawangan Pengiktirafan & Etika. Fungsi dan peranan kedua-dua Cawangan adalah seperti berikut:

There are two (2) subdivision under the PBMD, namely Registration Subdivision and Recognition & Ethics Subdivision. The functions and activities of both subdivisions are as follows:



SENARAI IJAZAH FARMASI DIKTIRAF OLEH LEMBAGA FARMASI MALAYSIA**LIST OF RECOGNIZED PHARMACY DEGREE BY PHARMACY BOARD OF MALAYSIA**

Negara <i>Country</i>	Nama Institusi <i>Name of Institution</i>	Nama Program <i>Programme Name</i>
Malaysia	Universiti Sains Malaysia (USM)	Sarjana Muda Farmasi (Kepujian)
	Universiti Malaya (UM)	Sarjana Muda Farmasi (Kepujian)
	Universiti Kebangsaan Malaysia (UKM)	Sarjana Muda Farmasi (Kepujian)
		Sarjana Muda Farmasi dengan Kepujian/ <i>Bachelor of Pharmacy with Honours</i> (Recognised on 8 September 2022)
	Universiti Teknologi MARA (UiTM)	Sarjana Muda Farmasi (Kepujian)
		Sarjana Muda Farmasi dengan Kepujian/ <i>Bachelor of Pharmacy with Honours</i> (Recognised on 31 October 2023)
	Universiti Islam Antarabangsa	Sarjana Muda Farmasi (Kepujian)
	AIMST University	<i>Bachelor of Pharmacy (Hons)</i>
	UCSI University	<i>Bachelor of Pharmacy (Hons)</i>
	<i>International Medical University (IMU)</i>	<i>Bachelor of Pharmacy (Hons)</i>
	<i>International Medical University (IMU)</i> (twinning with University of Strathclyde)	<i>Master of Pharmacy</i>
	<i>University of Nottingham Malaysia Campus</i>	<i>Master of Pharmacy</i>
	<i>University of Cyberjaya (Formerly known as Cyberjaya University College of Medical Sciences)</i>	<i>Bachelor of Pharmacy (Hons)</i>
	MAHSA University	<i>Bachelor of Pharmacy (Hons)</i>
	SEGI University	<i>Bachelor of Pharmacy (Hons)</i>
	<i>Lincoln University College</i>	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 1 June 2017)
	<i>Monash University Malaysia</i>	<i>Bachelor of Pharmacy (Recognised on 1 January 2013)</i>
		<i>Bachelor of Pharmacy (Hons) (Recognised on 1 January 2013)</i>
	<i>Management & Science University</i>	<i>Bachelor of Pharmacy (Hons) (Recognised on 24 October 2012))</i>
	<i>Taylor's University</i>	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 7 July 2015)
	<i>Asia Metropolitan University (AMU)</i>	<i>Bachelor of Pharmacy (Hons) (Recognised on 10 July 2017)</i>
	<i>University Kuala Lumpur – Royal College of Medicine Perak</i>	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 8 September 2017)
	<i>KPJ Healthcare University (Formerly known as KPJ Healthcare University College)</i>	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 19 July 2017)
<i>QUEST International University [Formerly known as QUEST International University Perak (QIUP)]</i>	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 8 February 2019)	
Universiti Sultan Zainal Abidin	<i>Bachelor of Pharmacy (Hons)</i> (Recognised on 27 January 2023)	

Arab Saudi <i>Saudi Arabia</i>	<i>University of Riyadh / King Saud University</i>	<i>Bachelor of Pharmacy</i>
Australia	<i>University of Adelaide</i>	<i>Bachelor of Pharmacy</i>
	<i>Monash University, Victorian College of Pharmacy</i>	<i>Bachelor of Pharmacy</i>
	<i>University of Sydney</i>	<i>Bachelor of Pharmacy</i>
	<i>University of Queensland</i>	<i>Bachelor of Pharmacy</i>
		<i>Bachelor of Pharmacy (Honours) (Recognised on 2 April 2015)</i>
	<i>The University of South Australia</i>	<i>Bachelor of Pharmacy</i>
	<i>The University of Tasmania</i>	<i>Bachelor of Pharmacy</i>
	<i>Curtin University of Technology</i>	<i>Bachelor of Pharmacy (Recognised on 10 July 2017)</i>
	<i>Griffith University Gold Coast</i>	<i>Bachelor of Pharmacy (Recognition takes effect from 1 December 2023)</i>
<i>Bachelor of Pharmacy (Hons) (Recognition takes effect from 1 December 2023)</i>		
Kanada <i>Canada</i>	<i>University of British Columbia</i>	<i>Bachelor of Science (Pharmacy)</i>
	<i>University of Alberta</i>	<i>Bachelor of Science (Pharmacy)</i>
	<i>Dalhousie University</i>	<i>Bachelor of Science (Pharmacy)</i>
United Kingdom	<i>University of Bath</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Aston in Birmingham</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Bradford</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Brighton</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Wales' College of Cardiff Cardiff University</i>	<i>Bachelor of Pharmacy / Master of Pharmacy</i>
	<i>De Montfort University Leicester</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>Liverpool John Moores University</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of London</i> ● <i>King's College of London</i> ● <i>The School of Pharmacy</i> ● <i>Chelsea College</i>	<i>Bachelor of Pharmacy / Master of Pharmacy</i>
	<i>University of Manchester</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Nottingham</i>	<i>Bachelor of Pharmacy / Master of Pharmacy</i>
<i>Master of Pharmacy with Honours in Pharmacy (with Integrated Foundation Training) (Recognition takes effect on 1 January 2027)</i>		

United Kingdom	<i>University of Portsmouth</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Sunderland</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Strathclyde</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>Robert Gordon's Institute of Technology, Aberdeen</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>Heriot-Watt University of Edinburgh</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Reading</i>	<i>Master of Pharmacy (Recognised on 12 December 2015)</i>
	<i>University College London</i>	<i>Master of Pharmacy (Recognised on 17 October 2017)</i>
	<i>University of East Anglia (UEA)</i>	<i>Master of Pharmacy (MPharm) (Recognised on 1 January 2022)</i> <i>Master of Pharmacy with Placement (MPharm) (Recognised on 1 January 2023)</i>
Ireland	<i>The Queen's University of Belfast, Northern Ireland</i>	<i>Bachelor of Science (Pharmacy) / Master of Pharmacy</i>
	<i>University of Dublin</i>	<i>Bachelor of Science (Pharmacy)</i>
	<i>Royal College of Surgeons of Ireland (RCSI)</i>	<i>Master of Pharmacy (Recognised on 12 December 2015)</i>
Indonesia	<i>Bandung Institute of Technology</i>	Sarjana Sains Farmasi
		<i>Sarjana Muda Farmasi (Pharmaceutical Science and Technology Programme) (Recognised from 17 April 2014 until 31 December 2018)</i>
		<i>Sarjana Muda Farmasi (Clinical and Community Pharmacy Programme) (Recognised on 1 January 2018)</i>
	<i>Gadjah Mada University</i>	Sarjana Sains Farmasi / Sarjana Farmasi
	<i>Airlangga Surabaya University</i>	Sarjana Sains Farmasi
		<i>Sarjana Farmasi (Recognised on 16 April 2018)</i>
	<i>Padjadjaran University</i>	Sarjana Sains Farmasi
		<i>Sarjana Farmasi (Recognised on 16 April 2018)</i>
	<i>Universiti Sumatera Utara (USU)</i>	<i>Sarjana Muda Farmasi (Pharmaceutical Science and Technology Programme) (Recognised on 30 May 2014)</i>
		<i>Sarjana Muda Farmasi (Clinical and Community Pharmacy Programme) (Recognised on 30 May 2014)</i>
<i>Sarjana Farmasi (Recognised on 11 February 2019)</i>		

Indonesia	<i>Hasanuddin University (UNHAS)</i>	Sarjana Sains (Recognised on 8 November 2011)
Iraq	<i>University of Baghdad</i>	<i>Bachelor of Pharmacy</i>
Jepun <i>Japan</i>	<i>Kyoto University</i>	<i>Bachelor of Pharmaceutical Science</i>
	<i>Nagoya City University</i>	<i>Bachelor of Science (Pharmacy)</i>
	<i>Kumamoto University</i>	<i>Bachelor of Pharmaceutical Science</i>
	<i>Tohoku University</i>	<i>Bachelor of Pharmacy</i>
	<i>Hokkaido University</i>	<i>Bachelor of Pharmacy</i>
	<i>Tokyo University of Science</i>	<i>Bachelor of Pharmacy</i>
New Zealand	<i>University of Otago</i>	<i>Bachelor of Pharmacy</i>
Mesir <i>Egypt</i>	<i>Cairo University</i>	<i>Bachelor of Pharmaceutical Science</i>
	<i>Alexandria University</i>	<i>Bachelor of Pharmaceutical Science</i>
		<i>Bachelor of Pharmacy (Clinical Pharmacy) (Recognised on 19 May 2015)</i>
	<i>Mansoura University</i>	<i>Bachelor of Pharmaceutical Science</i>
		<i>Bachelor of Pharmacy (Clinical Pharmacy) (Recognised on 19 May 2015)</i>
	<i>Zagazig University</i>	<i>Bachelor of Pharmaceutical Science</i>
<i>Bachelor of Pharmaceutical Science (Clinical Pharmacy) (Recognised on 19 May 2015)</i>		
<i>Bachelor of Pharmacy (Clinical Pharmacy) (Recognised on 10 July 2017)</i>		
Singapura <i>Singapore</i>	<i>National University of Singapore</i>	<i>Bachelor of Science (Pharmacy)</i>
Turki <i>Turkey</i>	<i>University of Ankara</i>	<i>Bachelor of Pharmacy</i>
	<i>Hacettepe University</i>	<i>Bachelor of Pharmacy</i>
	<i>University of Istanbul</i>	<i>Bachelor of Pharmacy</i>
USA	<i>University of Wisconsin</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>University of Iowa</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>University of Kansas</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>South Western Oklahoma State University</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>Ohio State University</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>Massachusetts College of Pharmacy and Allied Health Sciences</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>Northeast Louisiana University / University of Louisiana</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>Medical University of South Carolina</i>	<i>Bachelor of Science (Pharmacy) / Doctor of Pharmacy</i>
	<i>Idaho State University</i>	<i>Doctor of Pharmacy</i>

USA	<i>University of Toledo</i>	<i>Bachelor of Pharmacy / Doctor of Pharmacy</i>
	<i>Butler University, Indiana</i>	<i>Bachelor of Pharmacy / Doctor of Pharmacy</i>
	<i>University of North Carolina</i>	<i>Doctor of Pharmacy</i>
India	<i>Banaras Hindu University</i>	<i>Bachelor of Pharmacy</i>
	<i>Nagpur University</i>	<i>Bachelor of Pharmacy</i>
Pakistan	<i>Punjab University, Lahore / University of the Punjab Allama Iqbal Campus</i>	<i>Bachelor of Pharmacy / Doctor of Pharmacy</i>
Taiwan	<i>National Taiwan University</i>	<i>Bachelor of Science (Pharmacy) (before 4th July 1997, excluded from recognition)</i>
	<i>Kaohsiung Medical College / Kaohsiung Medical University</i>	<i>Bachelor of Science (Pharmacy) (before 30th November 1998, excluded from recognition)</i>
	<i>Taipei Medical College / Taipei Medical University</i>	<i>Bachelor of Science (Pharmacy) (before 4th November 1999, excluded from recognition)</i>
United Arab Emirates	<i>Gulf Medical University</i>	<i>Doctor of Pharmacy (Hons)</i>
<i>Jordan</i>	<i>Zarqa University</i>	<i>Bachelor of Pharmacy (Recognised on 14 May 2024)</i>

Kemaskini 20 Februari 2025

Updated 20 February 2025

2.0 AKTIVITI DAN SOROTAN | ACTIVITIES AND HIGHLIGHTS

DIALOG DI ANTARA PENGARAH KANAN PERKHIDMATAN FARMASI DENGAN DEKAN FAKULTI/ PUSAT PENGAJIAN FARMASI

Dialog di antara Pengarah Kanan Perkhidmatan Farmasi dengan Dekan Fakulti/ Pusat Pengajian Farmasi telah diadakan pada 12 Julai 2024 bertempat di Bilik Mesyuarat Delima, Program Perkhidmatan Farmasi. Sesi ini disertai oleh 32 peserta, termasuk juga Pengarah-pengarah dari Program Perkhidmatan Farmasi dan wakil dari Agensi Kelayakan Malaysia (MQA). Objektif dialog ini adalah seperti berikut:

- i. Menyampaikan maklumat terkini berhubung *Standard for Undergraduate Pharmacy Programme 2024*
- ii. Membincangkan isu-isu semasa berkaitan program farmasi

DIALOGUE BETWEEN THE SENIOR DIRECTOR OF PHARMACEUTICAL SERVICES AND THE DEAN OF THE FACULTY/ SCHOOL OF PHARMACY

A dialogue between the Senior Director of Pharmaceutical Services and the Deans of the Faculty/ School of Pharmacy took place on 12 July 2024, at the Delima Meeting Room, Pharmaceutical Services Programme. The session was attended by 32 participants, including also Directors of the Pharmaceutical Services Programme and a representative from the Malaysian Qualifications Agency (MQA). The objectives of the dialogue were:

- i. Provide the latest updates on the *Standard for Undergraduate Pharmacy Programme 2024*
- ii. As a platform to discuss on the current issues related to the pharmacy programme



Dialog di Antara Pengarah Kanan Perkhidmatan Farmasi Dengan Dekan Fakulti/ Pusat Pengajian Farmasi

Dialogue between the Senior Director of Pharmaceutical Services and the Deans of the Faculty/ School of Pharmacy

BENGKEL PENGEMASKINIAN 'COMMUNITY PHARMACY BENCHMARKING GUIDELINE' 2024

Pada tahun 2024, Bahagian Lembaga Farmasi Malaysia telah mengadakan Bengkel Pengemaskinian *Community Pharmacy Benchmarking Guideline*. Objektif bengkel adalah untuk mengemaskini serta menambah elemen-elemen yang selari dengan perkembangan semasa di sektor Farmasi Komuniti di Malaysia sekiranya ada. Wakil dari Program Perkhidmatan Farmasi, Bahagian Regulatori Farmasi Negara, Bahagian Perkhidmatan Farmasi Jabatan Kesihatan Negeri, Persatuan Farmasi Malaysia, *Malaysian Community Pharmacy Guild* dan farmasi komuniti telah dijemput sebagai peserta dalam bengkel ini. Pengarah Bahagian Penguatkuasaan Farmasi, Pengarah Bahagian Lembaga Farmasi Malaysia dan Presiden Persatuan Farmasi Malaysia turut dijemput sebagai panel dalam bengkel ini.

UPDATING 'COMMUNITY PHARMACY BENCHMARKING GUIDELINE' WORKSHOP 2024

In 2024, the Pharmacy Board Malaysia Division has organized a workshop on updating the *Community Pharmacy Benchmarking Guideline*. The objective of the workshop was to update and incorporate elements aligned with the current developments in the community pharmacy sector in Malaysia, if applicable. Representatives from the Pharmaceutical Services Programme, National Pharmaceutical Regulatory Agency, Pharmaceutical Services Division of the State Health Departments, Malaysian Pharmacists Society (MPS), Malaysian Community Pharmacy Guild (MCPG) and community pharmacies sector were invited as participants in this workshop. The Director of Pharmacy Enforcement Division, the Director of Pharmacy Board Malaysia Division and the President of the Malaysian Pharmacists Society were also invited as panelists for this workshop.



Bengkel Pengemaskinian 'Community Pharmacy Benchmarking Guideline' 2024
Updating 'Community Pharmacy Benchmarking Guideline' Workshop 2024



KURSUS PENGENALAN SIASATAN KES DISIPLIN KE ATAS AHLI FARMASI BERDAFTAR DAN PERTUBUHAN PERBADANAN BERDAFTAR

Seksyen Etika Farmasi telah menganjurkan Kursus Pengenalan Siasatan Kes Disiplin ke atas Ahli Farmasi Berdaftar dan Pertubuhan Perbadanan Berdaftar pada 20 Mei 2024 dan dihadiri oleh seramai 40 orang peserta yang terdiri daripada ahli Jawatankuasa Siasatan yang baru dilantik oleh Lembaga Farmasi Malaysia di bawah Akta Pendaftaran Ahli Farmasi 1951 [Akta 371].

Kursus ini diadakan untuk memberi pendedahan kepada ahli Jawatankuasa Siasatan berkenaan tatacara pengendalian kes disiplin ke atas Ahli Farmasi Berdaftar & Pertubuhan Perbadanan Berdaftar dan untuk meningkatkan kefahaman ahli Jawatankuasa Siasatan dalam pemakaian Akta 371 dan Peraturannya serta *Code of Ethics for Pharmacists 2018*.

INTRODUCTION COURSE ON DISCIPLINARY CASE INVESTIGATION AGAINST REGISTERED PHARMACISTS AND REGISTERED BODIES CORPORATE

The Pharmacy Ethics Section has organized the Introduction Course on Disciplinary Case Investigation Against Registered Pharmacists and Registered Bodies Corporate on 20th May 2024 and attended by 40 participants, comprising newly appointed Committee of Inquiry (COI) members. The COI members are appointed by the Pharmacy Board in accordance with the Registration of Pharmacists Act 1951 [Act 371].

This course was conducted to provide exposure to the COI members regarding disciplinary case handling procedures involving Registered Pharmacists & Registered Bodies Corporate. It also aimed to enhance their understanding of the application of Act 371, its Regulations, and the Code of Ethics for Pharmacists 2018.



Kursus Pengenalan Siasatan Kes Disiplin ke atas Ahli Farmasi Berdaftar dan Pertubuhan Perbadanan Berdaftar
Introduction Course on Disciplinary Case Investigation against Registered Pharmacists and Registered Bodies Corporate

BENKEL PENYEDIAAN DAN PEMURNIAN GARIS PANDUAN CREDENTIALING AMALAN FARMASI BAGI AHLI FARMASI BERDAFTAR

Bengkel bagi menyediakan satu garis panduan berkaitan *credentialing* Ahli Farmasi Berdaftar di bawah aktiviti Jawatankuasa Induk Credentialing Amalan Farmasi (JICAF) telah diadakan seperti berikut:

- i. Bengkel Penyediaan Garis Panduan *Credentialing* Amalan Farmasi Bagi Ahli Farmasi Berdaftar telah diadakan pada 20-21 Jun 2024 yang dihadiri oleh 41 orang ahli dan wakil Jawatankuasa Pelaksana dan Teknikal (JKPT) di bawah JICAF. Ahli-ahli JKPT terdiri daripada Ahli Farmasi Berdaftar dari pelbagai sektor termasuk KKM, bukan KKM, akademia, industri farmaseutikal, hospital universiti dan farmasi komuniti.
- ii. Bengkel Pemurnian Garis Panduan *Credentialing* Amalan Farmasi Bagi Ahli Farmasi Berdaftar telah diadakan pada 26-27 Jun 2024 bagi memperhalusi draf garis panduan yang telah disediakan. Bengkel ini telah dihadiri oleh 29 orang ahli dan wakil JKPT.

WORKSHOP ON THE PREPARATION AND REFINEMENT OF PHARMACY PRACTICE CREDENTIALING GUIDELINES FOR REGISTERED PHARMACISTS

Workshop to develop credentialing guidelines for registered pharmacist have been carried out under JICAF activities as such:

- i. Workshop on The Preparation of Pharmacy Practice Credentialing Guidelines for Registered Pharmacists was conducted on 20-21 June 2024 which was attended by 41 members and representatives of the Jawatankuasa Pelaksana & Teknikal under JICAF. JKPT's members consists of registered pharmacists from various sectors including MOH, non-MOH, akademia, pharmaceutical industry, hospital university and community pharmacy.*
- ii. Workshop on The Refinement of Pharmacy Practice Credentialing Guidelines for Registered Pharmacists was conducted on 26-27 June 2024 to refine the draft guidelines that have been prepared. This workshop was attended by 29 JKPT members and representatives.*



Bengkel Penyediaan Garis Panduan *Credentialing* Amalan Farmasi bagi Ahli Farmasi Berdaftar
Workshop on The Preparation of Pharmacy Practice Credentialing Guidelines for Registered Pharmacists



3.0 PENCAPAIAN DAN PENGIKTIRAFAN | ACHIEVEMENT AND RECOGNITION

LAWATAN PENGIKTIRAFAN PROGRAM IJAZAH FARMASI

Program Ijazah Farmasi adalah program yang dikawal selia oleh Badan Profesional iaitu Lembaga Farmasi Malaysia (LFM). LFM memastikan keperluan seperti yang telah dinyatakan di dalam Standard dan Kelulusan Program Ijazah Farmasi dipatuhi oleh setiap Pemberi Pendidikan Tinggi (PPT) bagi membolehkan program ijazah farmasi yang ditawarkan oleh PPT tersebut diiktiraf.

Lawatan Pengiktirafan Semula program ijazah farmasi oleh Panel Penilai LFM akan diadakan apabila menghampiri tempoh pembaharuan akreditasi bagi menilai kepatuhan program ijazah farmasi kepada Standard dan Kelulusan Program Ijazah Farmasi sebelum membuat syor pengiktirafan diteruskan kepada LFM. Sepanjang tahun 2024, sebanyak lapan aktiviti berkaitan pengiktirafan program ijazah farmasi telah dilaksanakan.

PHARMACY DEGREE PROGRAMME RECOGNITION VISIT

The Pharmacy Degree Program is regulated by the Pharmacy Board Malaysia (PBM), the governing professional body for pharmacist in Malaysia. PBM ensures that all universities comply with the requirements outlined in the Standards on Approval and Recognition of Pharmacy Programme to allow the pharmacy degree program offered by each university is officially recognized.

Re-accreditation visits by the Panel of Assessors will be conducted when it is due for accreditation renewal. These visits assess the university's pharmacy program compliance to the required standards before a recommendation for recognition is submitted to PBM. In 2024, a total of eight activities related to the recognition of the pharmacy program were conducted.

Lawatan Pemantauan Pemberian Pengiktirafan Semula <i>Re-accreditation Monitoring Visit</i>		
1.	<i>Bachelor of Pharmacy (Hons)/ Lincoln University College</i>	29 Feb-1 Mac 2024 <i>29 February-1 March 2024</i>
2.	<i>Bachelor of Pharmacy (Hons)/ Universiti Sultan Zainal Abidin (UniSZA)</i>	14-15 Mei 2024 <i>14-15 May 2024</i>
3.	<i>Bachelor of Pharmacy (Hons)/ Universiti SEGi</i>	23-24 Mei 2024 <i>23-24 May 2024</i>
4.	<i>Bachelor of Pharmacy (Hons)/ Universiti Sains Malaysia (USM)</i>	18-19 September 2024 <i>18-19 September 2024</i>
5.	<i>Bachelor of Pharmacy (Hons)/ Universiti Islam Antarabangsa Malaysia (UIAM)</i>	16-17 Oktober 2024 <i>16-17 October 2024</i>
Lawatan Pemantauan Pemberian Pengiktirafan Semula <i>Re-accreditation Visit</i>		
6.	<i>Bachelor of Pharmacy (Hons)/ Universiti Teknologi MARA (UiTM)</i>	5-7 Jun 2024 <i>5-7 June 2024</i>
7.	<i>Bachelor of Pharmacy (Hons)/ KPJ Healthcare University</i>	10-12 Jun 2024 <i>10-12 June 2024</i>
8.	<i>Bachelor of Pharmacy (Hons)/ IMU University</i>	6-9 September 2024 <i>6-9 September 2024</i>



Lawatan Pemantauan Program *Bachelor of Pharmacy (Hons)*, Lincoln University College
Monitoring Visit for Bachelor of Pharmacy (Hons), Lincoln University College

29 Februari-1 Mac 2024
29 February - 1 March 2024



Lawatan Pemantauan Program *Bachelor of Pharmacy (Hons)*, Universiti Sultan Zainal Abidin (UniSZA)
Monitoring Visit for Bachelor of Pharmacy (Hons), Universiti Sultan Zainal Abidin (UniSZA)

14-15 Mei 2024
14 - 15 May 2024



Lawatan Pemantauan Program *Bachelor of Pharmacy (Hons)*, Universiti SEGi
Monitoring Visit for Bachelor of Pharmacy (Hons), SEGi University

23-24 Mei 2024
 23-24 May 2024



Lawatan Pengiktirafan Semula Program *Bachelor of Pharmacy (Hons)*, Universiti Teknologi MARA
Re-accreditation Visit for Bachelor of Pharmacy (Hons), Universiti Teknologi MARA

5-7 Jun 2024
 5-7 June 2024



Lawatan Pengiktirafan Semula Program *Bachelor of Pharmacy (Hons)*, KPJ Healthcare University
Re-accreditation Visit for Bachelor of Pharmacy (Hons), KPJ Healthcare University

10-12 Jun 2024
 10-12 June 2024



Lawatan Pengiktirafan Semula Program *Bachelor of Pharmacy (Hons)*, IMU University
Re-accreditation Visit for Bachelor of Pharmacy (Hons), IMU University

4-6 September 2024
 4-6 September 2024



Lawatan Pemantauan Program *Bachelor of Pharmacy (Hons)*, Universiti Sains Malaysia (USM)
Monitoring Visit for Bachelor of Pharmacy (Hons), Universiti Sains Malaysia (USM)

18-19 September 2024
 18-19 September 2024



Lawatan Pemantauan Program *Bachelor of Pharmacy (Hons)*, University Islam Antarabangsa Malaysia (UIAM)
Monitoring Visit for Bachelor of Pharmacy (Hons), International Islamic University Malaysia (IIUM)

16-17 Oktober 2024
 16-17 October 2024

PEPERIKSAAN KELAYAKAN UNTUK MENGAMAL FARMASI (PKUMF)

BLFM telah mengadakan tiga sesi Peperiksaan Kelayakan Untuk Mengamal Farmasi (PKUMF) sepanjang tahun 2024. Graduan Farmasi yang ingin berdaftar sebagai ahli farmasi di Malaysia perlu menduduki dan lulus peperiksaan ini. Peperiksaan ini telah diadakan secara serentak di 33 pusat peperiksaan yang telah ditetapkan oleh BLFM di seluruh negara.

QUALIFYING EXAMINATION TO PRACTICE PHARMACY

PBMD has held three sessions of Qualifying Examination to Practice Pharmacy in the year of 2024. The Qualifying Examination to Practice Pharmacy is pre requisite for registration with the PBM. The exam has been conducted concurrently in 33 examination centres selected by PBMD across the country.

Bilangan Calon Peperiksaan Kelayakan Untuk Mengamal Farmasi
Number of Candidates for Qualifying Examination To Practice Pharmacy

Sesi Peperiksaan <i>Exam Session</i>	Tarikh <i>Date</i>	Bilangan Calon <i>Number of Candidates</i>
Sesi 1 <i>Session 1</i>	27 Mac 2024 <i>27 March 2024</i>	753
Sesi 2 <i>Session 2</i>	31 Julai 2024 <i>31 July 2024</i>	530
Sesi 3 <i>Session 3</i>	27 November 2024 <i>27 November 2024</i>	780

BENGKEL TRAINING OF PRECEPTORS (TOP) BAGI PENGIKTIRAFAN PRINCIPAL PRECEPTOR DAN MASTER PRECEPTOR UNTUK MENGENDALI LATIHAN PROVISIONAL SECARA LIBERALISASI KEPADA AHLI FARMASI PROVISIONAL (PRP) 2024

Pada tahun 2024, Bahagian Lembaga Farmasi Malaysia telah mengadakan 2 kali Bengkel *Training of Preceptors (TOP)* yang melibatkan seramai 103 peserta dari sektor Farmasi komuniti, Hospital Swasta, Industri Farmaseutikal Mengilang, Industri Farmaseutikal Tidak Mengilang dan R&D Akademia. Objektif bengkel adalah untuk:

- Memberi panduan dan latihan kepada *Principal Preceptor* dan *Master Preceptor* untuk pengendalian latihan PRP secara liberalisasi di fasiliti latihan liberalisasi
- Memberi penerangan dan latihan secara terperinci tentang penggunaan dan pengisian buku log latihan PRP di sektor terbabit

TRAINING OF PERCEPTORS (TOP) WORKSHOP TO ACCREDIT PRINCIPAL AND MASTER PRECEPTORS TO CONDUCT LIBERALISED INTERN TRAINING FOR PROVISIONALLY REGISTERED PHARMACIST (PRP) 2024

In 2024 Pharmacy Board Malaysia Division has held 2 sessions of Training of Preceptors (TOP) workshops for 103 candidates from Community Pharmacy, Private Hospital, Manufacturing Pharmaceutical Industry, Non Manufacturing Pharmaceutical Industry and R&D Academia. The objectives of this workshop were:

- To provide guidance and training to the Principal and Master preceptors to conduct intern training in liberalised training facilities
- To provide detailed information and training for the usage and filling in of the training logbooks in the relevant sector

Bengkel 'Training of Preceptors (TOP)' bagi pengiktirafan *Principal Preceptor*' Dan '*Master Preceptor*' Bagi Latihan Provisional Secara Liberalisasi Kepada Ahli Farmasi Provisional (PRP) 2024
Training of Preceptors (TOP) Workshop to Accredite Principal And Master Preceptors to Conduct Liberalised Intern Training for Provisionally Registered Pharmacist (PRP) 2024

Sesi <i>Session</i>	Tarikh <i>Date</i>	Jenis Premis <i>Type of Premises</i>	Jumlah Peserta <i>No. of participants</i>
Pertama <i>First</i>	6 Mac 2024 <i>6 March 2024</i>	Penyelidikan dan Pembangunan (R&D) Akademia <i>Research and Development (R&D) Academia</i>	1
		Hospital Swasta <i>Private Hospital</i>	6
		Industri Farmaseutikal Mengilang <i>Manufacturing Pharmaceutical Industry</i>	4
		Industri Farmaseutikal Tidak Mengilang <i>Non-Manufacturing Pharmaceutical Industry</i>	4
		Farmasi Komuniti <i>Community Pharmacy</i>	26

Sesi <i>Session</i>	Tarikh <i>Date</i>	Jenis Premis <i>Type of Premises</i>	Jumlah Peserta <i>No. of participants</i>
Kedua <i>Second</i>	24–25 Julai 2024 <i>24-25 July 2024</i>	R&D Akademia <i>R&D Academia</i>	22
		Hospital Swasta <i>Private Hospital</i>	25
		Industri Farmaseutikal Mengilang <i>Manufacturing Pharmaceutical Industry</i>	3
		Industri Farmaseutikal Tidak Mengilang <i>Non-Manufacturing Pharmaceutical Industry</i>	6
		Farmasi Komuniti <i>Community Pharmacy</i>	6

BENKEL PEMANTAPAN PRESEPTOR DI FASILITI LATIHAN DI BAWAH KEMENTERIAN KESIHATAN MALAYSIA (KKM)

Pada 26-27 Februari 2024, BLFM telah menganjurkan satu Bengkel Pemantapan Preseptor bagi latihan PRP di fasiliti di bawah KKM. Seramai 44 orang preseptor dari seluruh negara telah menghadiri bengkel tersebut. Tujuan bengkel tersebut adalah untuk memberi lebih fokus kepada para preseptor agar mereka lebih mantap dan tersedia untuk menghadapi cabaran-cabaran yang kritikal di sepanjang servis mereka sebagai preseptor.

PRECEPTOR STRENGTHENING WORKSHOP AT THE TRAINING FACILITY UNDER THE MINISTRY OF HEALTH, MALAYSIA

On 26-27 February 2024, BLFM organized a Preceptor Strengthening Workshop for PRP training at facilities under the Ministry of Health. A total of 44 preceptors from all over the country attended the workshop. The purpose of the workshop was to give more focus to the preceptors so that they are more robust and available to face critical challenges along their service as preceptors.

DIALOG BERSAMA PRESEPTOR DAN PRP DI FASILITI LATIHAN KEMENTERIAN KESIHATAN BERHUBUNG LATIHAN AHLI FARMASI PROVISIONAL (PRP)

Dialog bersama preseptor dan PRP di fasiliti latihan KKM berhubung latihan PRP telah diadakan sebanyak tiga (3) sesi secara hibrid pada ketetapan seperti berikut:

DIALOGUE WITH THE PRECEPTORS AND PROVISIONALLY REGISTERED PHARMACIST (PRP) FROM THE MINISTRY OF HEALTH TRAINING FACILITIES REGARDING TRAINING OF THE PRP

Dialogue with the preceptors and PRP from the MOH training facilities has been conducted in hybrid three (3) times as below:

Sesi <i>Session</i>	Zon/ Negeri <i>Zone/ State</i>	Tarikh <i>Date</i>	Lokasi <i>Venue</i>	Jumlah Peserta <i>Participants</i>	
				Preseptor <i>Preceptor</i>	PRP <i>PRP</i>
1	Zon Selatan <i>Southern Zone</i> (Melaka, Negeri Sembilan dan Johor) Secara hibrid	29 April 2024 <i>29 April 2024</i>	Bahagian Perkhidmatan Farmasi Negeri Johor	146	97
2	Zon Tengah <i>Central Zone</i> (Selangor, WPKL, Hospital Kuala Lumpur & Institusi Kanser Negara)	12 Ogos 2024 <i>12 August 2024</i>	Institusi Kesihatan Negara, Setia Alam, Selangor	139	73
3	Zon Utara <i>Northern Zone</i> (Perlis, Kedah, Pulau Pinang & Perak)	3 Oktober 2024 <i>3 October 2024</i>	Hospital Seberang Jaya	179	103

Objektif dialog ini adalah seperti berikut:

- i. Menyampaikan maklumat terkini berhubung latihan PRP kepada preseptor
- ii. Membincangkan isu-isu berkaitan latihan PRP di fasiliti KKM

SESI TAKLIMAT BUKU LOG VERSI 2024 PERINGKAT KEBANGSAAN BAGI LATIHAN PRP DI KLINIK KESIHATAN DI BAWAH KKM

Sesi ini telah diadakan pada 17 April 2024 dan seramai 534 preseptor telah menghadiri sesi taklimat tersebut. Objektif sesi ini diadakan adalah untuk:

- i. Memberi panduan dan latihan kepada preseptor yang akan menyelia latihan PRP di Klinik Kesihatan di bawah KKM
- ii. Memberi penerangan secara terperinci tentang penggunaan dan pengisian buku versi 2024 bagi latihan PRP di sektor terbabit

LAWATAN PEMANTAUAN PERJALANAN LATIHAN PROVISIONAL DI PREMIS LATIHAN BAGI AHLI FARMASI BERDAFTAR PROVISIONAL (PRP)

BLFM telah mengadakan lawatan pemantauan perjalanan latihan provisional di kedua-dua premis kerajaan dan liberalisasi. Tujuan lawatan ini adalah untuk memastikan perjalanan latihan di premis latihan adalah berjalan mengikut keperluan buku log dan juga bagi mengenal pasti isu-isu yang dihadapi di premis latihan oleh preseptor dan juga PRP.

The objectives of the dialogue were as below:

- i. This dialogue served as a platform to disseminate updates and related information to the preceptors regarding PRP training*
- ii. As a sharing session for preceptors to discuss any issues related to PRP training*

BRIEFING SESSION FOR LOG BOOK VERSION 2024 FOR PROVISIONAL TRAINING IN HEALTH CLINIC UNDER MOH

The session was held on 17 April 2024 and about 534 preceptors has attended the session. The objectives of the session were:

- i. Provide guidance and training to preceptors who will supervise PRP training in Health Clinic under MOH*
- ii. Provide a detailed explanation on the use and filling of log book version 2024 for PRP training in the sector involved*

VISIT TO PROVISIONALLY REGISTERED PHARMACIST TRAINING PREMISES TO MONITOR TRAINING ACTIVITIES

PBMD has visited both training premises under MOH and also Liberalised premises. The objective of these visits are to ensure that the training being conducted in training facilities in accordance to log books and also to identify issues faced by the preceptors and also PRPs in training facilities.

Negeri <i>State</i>	Nama Premis <i>Premise Name</i>	Tarikh Lawatan <i>Visit Date</i>
Johor	Klinik Kesihatan Mahmoodiah	30 April 2024 <i>30 April 2024</i>
	Am Pm Pharmacy – Tampoi	30 April 2024 <i>30 April 2024</i>
Selangor	Hospital Tunku Azizah	13 Ogos 2024 <i>13 August 2024</i>
	Health Lane Family Pharmacy Sdn. Bhd.	13 Ogos 2024 <i>13 August 2024</i>
Pulau Pinang	Hospital Pulau Pinang	4 Oktober 2024 <i>4 October 2024</i>
	Fuji Acre Sdn. Bhd.	4 Oktober 2024 <i>4 October 2024</i>

4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*

GARIS PANDUAN CREDENTIALING AMALAN FARMASI BAGI AHLI FARMASI BERDAFTAR

GARIS PANDUAN CREDENTIALING AMALAN FARMASI BAGI AHLI FARMASI BERDAFTAR

Garis Panduan Credentialing Amalan Farmasi Bagi Ahli Farmasi Berdaftar telah dibentangkan dan dipersetujui dalam Mesyuarat JICAF ke-3 (Bil.2/2024) pada 29 Oktober 2024.

Garis Panduan Credentialing Amalan Farmasi Bagi Ahli Farmasi Berdaftar was presented and agreed at the 3rd JICAF meeting (Bil.2/2024) on 29 October 2024.




Garis Panduan *Credentialing* Amalan Farmasi Bagi Ahli Farmasi Berdaftar

Garis Panduan Credentialing Amalan Farmasi bagi Ahli Farmasi Berdaftar



GLOSARI TERMA, SINGKATAN DAN AKRONIM

***GLOSSARY OF TERMS, ABBREVIATIONS
AND ACRONYMS***



GLOSARI TERMA, SINGKATAN DAN AKRONIM

GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS

ACC	<i>ASEAN Cosmetic Committee</i>
ACCSQ	<i>ASEAN Consultative Committee for Standards and Quality</i>
ACSB	<i>ASEAN Cosmetic Scientific Body</i>
ADAF	Audit Dalam Amalan Farmasi
ADR	Kesan Advers Ubat <i>Adverse Drug Reaction</i>
AKB GCP	Amalan Klinikal Baik <i>Good Clinical Practice</i>
AMB GLP	Amalan Makmal Baik <i>Good Laboratory Practice</i>
AMR	Rintangan Antimikrob <i>Antimicrobial Resistance</i>
AMS	<i>Antimicrobial Stewardship</i>
APAC	<i>Asia Pacific</i>
APB GMP	Amalan Perkilangan Baik <i>Good Manufacturing Practice</i>
API	Bahan Aktif Farmaseutikal <i>Active Pharmaceutical Ingredient</i>
APTLC	<i>ASEAN Pharmaceutical Testing Laboratory Committee</i>
ARS	<i>ASEAN Reference Substance</i>
ASEAN	<i>Association of Southeast Asian Nations</i>
ATMPs	<i>Advanced Therapy Medicinal Products</i>
ATSC	<i>ASEAN TMHS Scientific Committee</i>
AVSSR	<i>ASEAN Vaccine Security and Self-Reliance</i>
BAPF	Bahagian Amalan dan Perkembangan Farmasi <i>Pharmacy Practice and Development Division</i>
BDPSF	Bahagian Dasar dan Perancangan Strategik Farmasi <i>Pharmacy Policy and Strategic Planning Division</i>
BE	Bioekuivalens <i>Bioequivalence</i>
BEI	Intensiti Tenaga Bangunan <i>Building Energy Intensity</i>
BIM	Bahasa Isyarat Malaysia
BLFM PBMD	Bahagian Lembaga Farmasi Malaysia <i>Pharmacy Board Malaysia Division</i>
BPF PED	Bahagian Penguatkuasaan Farmasi <i>Pharmacy Enforcement Division</i>

BPFK NPCB	Biro Pengawasan Farmaseutikal Kebangsaan <i>National Pharmaceutical Control Bureau</i>
CGTP	<i>Cell Gene and Therapy Products</i>
CICM	<i>Chemical Industries Council of Malaysia</i>
CMCF	Forum Kandungan Komunikasi dan Multimedia Malaysia <i>Malaysian Communications and Multimedia Content Forum</i>
CND	<i>Commission on Narcotic Drugs</i>
COVID-19	<i>Coronavirus Disease</i>
CPD	Pembangunan Profesional Berterusan <i>Continuous Professional Development</i>
CPF PEB	Cawangan Penguatkuasaan Farmasi <i>Pharmacy Enforcement Branch</i>
CPHI	<i>Convention Pharmaceutical Ingredients</i>
CPS	<i>Clinic Pharmacy System</i>
CRA	Penilaian Risiko Rasuah <i>Corruption Risk Assessment</i>
CREAM	<i>Construction Research Institute of Malaysia</i>
CTFA	<i>Toiletries And Fragrance Association</i>
CTIL	Lesen Import Percubaan Klinikal <i>Clinical Trial Import License</i>
CTX	Kebenaran Mengilang untuk Percubaan Klinikal <i>Clinical Trial Exemption</i>
DEA	Pentadbiran Penguatkuasaan Dadah <i>Drug Enforcement Administration</i>
DMTAC	<i>Diabetes Medication Therapy Adherence Clinic</i>
DOSM	Jabatan Perangkaan Malaysia <i>Department of Statistic Malaysia</i>
DUNas	Dasar Ubat Nasional <i>Malaysian National Medicines Policy</i>
EBM	<i>Evidence-based Medicine</i>
EMGS	<i>Energy Management Gold Standard</i>
ERP	<i>Enterprise Resource Planning</i>
FUKKM MOHMF	Formulari Ubat-ubatan Kementerian Kesihatan Malaysia <i>Ministry of Health Medicines Formulary</i>
GRP	Amalan Regulatori Baik <i>Good Regulatory Practices</i>
HITAP	<i>Health Intervention and Technology Assessment Programme</i>

HMR	Penilaian Ubat-ubatan di Rumah <i>Home Medication Review</i>
HPLC	<i>High Performance Liquid Chromatography</i>
HSA	<i>The Health Science Authority</i>
HTA	Penilaian Teknologi Kesihatan <i>Health Technology Assessment</i>
ICH	<i>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</i>
ICSR	<i>Individual Case Safety Reports</i>
ICT	Teknologi Maklumat dan Komunikasi <i>Information and Communication Technology</i>
IDP	Pelan Pembangunan Institusi <i>Institutional Development Plan</i>
ILC	<i>Inter Laboratory Comparison</i>
ILEA	Akademi Penguatkuasaan Undang-undang Antarabangsa <i>International Law Enforcement Academy</i>
INCB	<i>International Narcotics Control Board</i>
IPRP	<i>International Pharmaceutical Regulator's Programme</i>
ISCRs	<i>Individual Case Safety Reports</i>
ISO	<i>International Organization for Standardization</i>
ISO/IEC	<i>International Standard for Testing and Calibration Laboratories</i>
IVI	<i>International Vaccine Institute</i>
IWG	<i>Implementation Working Group</i>
JACG	<i>Joint Assessment Coordinating Group</i>
JICAF	Jawatankuasa Induk Credentialing Amalan Farmasi <i>Steering Committee of Pharmacy Practice Credentialing</i>
JKPT	Jawatankuasa Penilaian Teknikal <i>Technical Evaluation Committee</i>
JKUT	Jawatankuasa Ubat dan Terapeutik
JOPPP	<i>Journal of Pharmaceutical Policy and Practice</i>
JSC	<i>Joint Sectoral Committee</i>
JSM DSM	Jabatan Standard Malaysia <i>Department of Standards Malaysia</i>
KKLIU	Kementerian Kesihatan Lembaga Iklan Ubat
KKM MOH	Kementerian Kesihatan Malaysia <i>Ministry of Health</i>
KPDN	Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup <i>Ministry of Domestic Trade and Costs of Living</i>

KPHU	Kajian Pemantauan Harga Ubat <i>Medicine Prices Monitoring Survey</i>
LFM PBM	Lembaga Farmasi Malaysia <i>Pharmacy Board Malaysia</i>
LIU MAB	Lembaga Iklan Ubat <i>Medicine Advertisement Board</i>
LMIC	Negara Berpendapatan Rendah dan Sederhana <i>Low-Middle Income Countries</i>
MAD	<i>Mutual Acceptance of Data</i>
MADRAC	Jawatankuasa Penasihat Kesan Advers Malaysia <i>Malaysian Adverse Drug Reactions Advisory Committee</i>
MASc	<i>Medicines Access Scheme</i>
MCPG	Persatuan Farmasi Komuniti Malaysia <i>Malaysian Community Pharmacy Guild</i>
MCTIG	<i>Malaysian Cosmetics And Toiletries Industry Group</i>
MFDS	<i>Ministry of Food and Drug Safety</i>
MGTC	<i>Malaysian Green Technology and Climate Change Corporation</i>
MINDEF	Kementerian Pertahanan Malaysia <i>Ministry of Defence Malaysia</i>
MITI	Kementerian Perdagangan Antarabangsa dan Industri <i>Ministry of Investment, Trade and Industry</i>
MKHU	Mekanisme Ketelusan Harga Ubat <i>Medicine Price Transparency Mechanism</i>
MKKUK	Makmal Kawalan Kimia Ubat Kebangsaan <i>National Pharmaceutical Control Laboratory</i>
ML3	Tahap Kematangan 3 <i>Maturity Level 3</i>
MOPI	<i>Malaysian Organisation of Pharmaceutical Industries</i>
MOSTI	Kementerian Sains, Teknologi dan Inovasi <i>Ministry of Science, Technology and Innovation</i>
MPC	Perbadanan Produktiviti Malaysia <i>Malaysian Productivity Corporation</i>
MPS	Persatuan Farmasi Malaysia <i>Malaysian Pharmacist Society</i>
MQA	Agensi Kelayakan Malaysia <i>Malaysian Qualifications Agency</i>
MRA	<i>Mutual Recognition Arrangement</i>
MSOM	Statistik Penggunaan Ubat di Malaysia <i>Malaysian Statistics on Medicines</i>
MTAC	<i>Medication Therapy Adherence Clinic</i>
MVPO	Pejabat Projek Vaksin Malaysia <i>Malaysian Vaccine Project Office</i>

MyACCP	<i>Malaysia Advance Clinical Pharmacy Programme</i>
MyUBAT	Sistem Perkhidmatan Pembekalan Ubat Susulan Farmasi KKM <i>MOH Pharmacy Follow-up Drug Supply Service System</i>
NADI	<i>National Diabetes Institute</i>
NAG	Panduan Antimikrobial Kebangsaan <i>National Antimicrobial Guideline</i>
NCD	Penyakit Tidak Berjangkit <i>Non-Communicable Diseases</i>
NIH	Institut Kesihatan Negara <i>National Institutes of Health</i>
NPRA	Bahagian Regulatori Farmasi Negara <i>National Pharmaceutical Regulatory Agency</i>
NRA	Kawal Selia Kebangsaan <i>National Regulatory Authorities</i>
NRECC	Kementerian Sumber Asli, Alam Sekitar dan Perubahan Iklim <i>Ministry of Natural Resources, Environment and Climate Change</i>
NSTDA	<i>National Science and Technology Development Agency Characterization and Testing Service Centre</i>
NVI	<i>National Vaccine Institute</i>
OACP	Pelan Anti Rasuah Organisasi <i>Organizational Anti Corruption Plan</i>
OECD	<i>Organisation for Economic Co-Operation and Development</i>
OKU PWD	Orang Kurang Upaya <i>Person With Disabilities</i>
OSE	<i>On-Site Evaluation</i>
PBKD DCA	Pihak Berkuasa Kawalan Dadah <i>Drug Control Authority</i>
PDMP	Produk Plasma <i>Plasma-derived Medicinal Product</i>
PhAMA	Persatuan Farmaseutikal Malaysia <i>Pharmaceutical Association of Malaysia</i>
PharmQIs	<i>Pharmacy Quality Improvement Initiatives</i>
PhD	Doktor Falsafah <i>Doctor of Philosophy</i>
PhIS	<i>Pharmacy Information System</i>
PIC/S	<i>Pharmaceutical Inspection Co-operation Scheme</i>
PKD	Pejabat Kesihatan Daerah <i>District Health Office</i>
PKUMF	Peperiksaan Kelayakan untuk Mengamal Farmasi <i>Qualifying Examination to Practice Pharmacy</i>

PMDA	<i>Pharmaceutical and Medical Devices Agency</i>
POLI	<i>Pharmonline International</i>
PPF PSP	Program Perkhidmatan Farmasi <i>Pharmaceutical Services Programme</i>
PPT HEP	Pemberi Pendidikan Tinggi <i>Higher Education Providers</i>
PPWG	<i>Pharmaceutical Product Working Group</i>
PRH	Pemegang Pendaftaran Produk <i>Product Registration Holder</i>
PRP	Ahli Farmasi Berdaftar Provisional <i>Provisionally Registered Pharmacist</i>
PRPM	Keutamaan Penyelidikan Farmasi di Malaysia <i>Pharmacy Research Priorities in Malaysia</i>
PT	<i>Proficiency Testing</i>
R&D	Penyelidikan dan Pembangunan <i>Research and Development</i>
RaMTAC	<i>Rheumatoid Arthritis Medication Therapy Adherence Clinic</i>
RASC	Jawatankuasa Pemandu Perikatan Serantau <i>Regional Alliance Steering Committee</i>
RB PQM	Program Pemantauan Kualiti Produk Berasaskan Risiko <i>Risk-Based Product Quality Monitoring Programme</i>
SAMM	Skim Akreditasi Makmal Malaysia
SPK QMS	Sistem Pengurusan Kualiti <i>Quality Management System</i>
SPM	Skim Perubatan Madani
TF	<i>Task Force</i>
TGA	<i>Therapeutic Goods Administration</i>
TMHS PWG	<i>Traditional Medicines and Health Supplements Product Working Group</i>
TOBaTS	Tolak Ubat Tidak Sah <i>Say No to Illegal Medicines</i>
TOP	<i>Training of Preceptors</i>
TRM	<i>Training Road Map</i>
UKK SAM	Ubat Kelulusan Khas <i>Special Approval Medicines</i>
UKM	Universiti Kebangsaan Malaysia
UNODC	<i>United Nations Office on Drugs and Crime</i>
UPC	<i>Unified Public Consultation</i>
WHO	Pertubuhan Kesihatan Sedunia <i>World Health Organisation</i>
WPRO	Pejabat Wilayah Pasifik Barat <i>Western Pacific Regional Office</i>

CATATAN



KEMENTERIAN KESIHATAN MALAYSIA
PROGRAM PERKHIDMATAN FARMASI

*Lot 36, Jalan Profesor Diraja Ungku Aziz,
46200 Petaling Jaya, Selangor Darul Ehsan.*

 03-7841 3200

 www.pharmacy.gov.my

 Program Perkhidmatan
Farmasi KKM